
<html lang="en"     class="pb-page"  data-request-id="dd825c4e-474b-45db-9ee2-f096fc765622"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01694;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans" /></meta><meta name="dc.Creator" content="Atli  Thorarensen" /></meta><meta name="dc.Creator" content="Martin E.  Dowty" /></meta><meta name="dc.Creator" content="Mary Ellen  Banker" /></meta><meta name="dc.Creator" content="Brian  Juba" /></meta><meta name="dc.Creator" content="Jason  Jussif" /></meta><meta name="dc.Creator" content="Tsung  Lin" /></meta><meta name="dc.Creator" content="Fabien  Vincent" /></meta><meta name="dc.Creator" content="Robert M.  Czerwinski" /></meta><meta name="dc.Creator" content="Agustin  Casimiro-Garcia" /></meta><meta name="dc.Creator" content="Ray  Unwalla" /></meta><meta name="dc.Creator" content="John I.  Trujillo" /></meta><meta name="dc.Creator" content="Sidney  Liang" /></meta><meta name="dc.Creator" content="Paul  Balbo" /></meta><meta name="dc.Creator" content="Ye  Che" /></meta><meta name="dc.Creator" content="Adam M.  Gilbert" /></meta><meta name="dc.Creator" content="Matthew F.  Brown" /></meta><meta name="dc.Creator" content="Matthew  Hayward" /></meta><meta name="dc.Creator" content="Justin  Montgomery" /></meta><meta name="dc.Creator" content="Louis  Leung" /></meta><meta name="dc.Creator" content="Xin  Yang" /></meta><meta name="dc.Creator" content="Sarah  Soucy" /></meta><meta name="dc.Creator" content="Martin  Hegen" /></meta><meta name="dc.Creator" content="Jotham  Coe" /></meta><meta name="dc.Creator" content="Jonathan  Langille" /></meta><meta name="dc.Creator" content="Felix  Vajdos" /></meta><meta name="dc.Creator" content="Jill  Chrencik" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Telliez" /></meta><meta name="dc.Description" content="Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant ef..." /></meta><meta name="Description" content="Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant ef..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01694" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01694" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01694" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01694" /></link>
        
    
    

<title>Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01694" /></meta><meta property="og:title" content="Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0016.jpeg" /></meta><meta property="og:description" content="Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in several human clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01694"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01694">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01694&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01694&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01694&amp;href=/doi/10.1021/acs.jmedchem.6b01694" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1971-1993</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01685" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01733" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Atli++Thorarensen">Atli Thorarensen</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-6791-5809" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+E.++Dowty">Martin E. Dowty</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Banker">Mary Ellen Banker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Juba">Brian Juba</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Jussif">Jason Jussif</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tsung++Lin">Tsung Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabien++Vincent">Fabien Vincent</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+M.++Czerwinski">Robert M. Czerwinski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Agustin++Casimiro-Garcia">Agustin Casimiro-Garcia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ray++Unwalla">Ray Unwalla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+I.++Trujillo">John I. Trujillo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sidney++Liang">Sidney Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Balbo">Paul Balbo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Che">Ye Che</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adam+M.++Gilbert">Adam M. Gilbert</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+F.++Brown">Matthew F. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Hayward">Matthew Hayward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Justin++Montgomery">Justin Montgomery</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Leung">Louis Leung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Yang">Xin Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Soucy">Sarah Soucy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Hegen">Martin Hegen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jotham++Coe">Jotham Coe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Langille">Jonathan Langille</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Felix++Vajdos">Felix Vajdos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jill++Chrencik">Jill Chrencik</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Telliez">Jean-Baptiste Telliez</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1.0"><span class="aff-text"><sup>†</sup>Worldwide Medicinal Chemistry, and <sup>‡</sup>Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div><div class="aff-info" id="aff3.0"><span class="aff-text"><sup>∥</sup>Pharmacokinetics, Dynamics, and Metabolism, <sup>⊥</sup>Primary Pharmacology Group, and <sup>#</sup>Worldwide Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="corresp-info"><strong>*</strong>A.T.: phone, 617-674-7392; e-mail, <a href="/cdn-cgi/l/email-protection#ebaa9f8782c5bf8384998a998e85988e85ab9b8d82918e99c5888486"><span class="__cf_email__" data-cfemail="f3b2879f9adda79b9c819281969d80969db383959a899681dd909c9e">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>J.-B.T.: phone, 617-758-9430; e-mail, <a href="/cdn-cgi/l/email-protection#b8f2ddd9d695fad9c8ccd1cbccdd96ecddd4d4d1ddc2f8c8ded1c2ddca96dbd7d5"><span class="__cf_email__" data-cfemail="4c06292d22610e2d3c38253f382962182920202529360c3c2a2536293e622f2321">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01694&amp;href=/doi/10.1021%2Facs.jmedchem.6b01694" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1971–1993</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 31, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 November 2016</li><li><span class="item_label"><b>Published</b> online</span>16 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 March 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01694" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01694</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1971%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAtli%2BThorarensen%252C%2BMartin%2BE.%2BDowty%252C%2BMary%2BEllen%2BBanker%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D5%26contentID%3Dacs.jmedchem.6b01694%26title%3DDesign%2Bof%2Ba%2BJanus%2BKinase%2B3%2B%2528JAK3%2529%2BSpecific%2BInhibitor%2B1-%2528%25282S%252C5R%2529-5-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-2-methylpiperidin-1-yl%2529prop-2-en-1-one%2B%2528PF-06651600%2529%2BAllowing%2Bfor%2Bthe%2BInterrogation%2Bof%2BJAK3%2BSignaling%2Bin%2BHumans%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1993%26publicationDate%3DMarch%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01694"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4620</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">58</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01694" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Atli&quot;,&quot;last_name&quot;:&quot;Thorarensen&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;E. Dowty&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Banker&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Juba&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Jussif&quot;},{&quot;first_name&quot;:&quot;Tsung&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Fabien&quot;,&quot;last_name&quot;:&quot;Vincent&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;M. Czerwinski&quot;},{&quot;first_name&quot;:&quot;Agustin&quot;,&quot;last_name&quot;:&quot;Casimiro-Garcia&quot;},{&quot;first_name&quot;:&quot;Ray&quot;,&quot;last_name&quot;:&quot;Unwalla&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;I. Trujillo&quot;},{&quot;first_name&quot;:&quot;Sidney&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Balbo&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Che&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;M. Gilbert&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;F. Brown&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Hayward&quot;},{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;Montgomery&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Leung&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Soucy&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Hegen&quot;},{&quot;first_name&quot;:&quot;Jotham&quot;,&quot;last_name&quot;:&quot;Coe&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Langille&quot;},{&quot;first_name&quot;:&quot;Felix&quot;,&quot;last_name&quot;:&quot;Vajdos&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;Chrencik&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Telliez&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1971-1993&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01694&quot;},&quot;abstract&quot;:&quot;Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in sev&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01694&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01694" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01694&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01694" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01694&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01694" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01694&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01694&amp;href=/doi/10.1021/acs.jmedchem.6b01694" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01694" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01694" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01694%26sid%3Dliteratum%253Aachs%26pmid%3D28139931%26genre%3Darticle%26aulast%3DThorarensen%26date%3D2017%26atitle%3DDesign%2Bof%2Ba%2BJanus%2BKinase%2B3%2B%2528JAK3%2529%2BSpecific%2BInhibitor%2B1-%2528%25282S%252C5R%2529-5-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-2-methylpiperidin-1-yl%2529prop-2-en-1-one%2B%2528PF-06651600%2529%2BAllowing%2Bfor%2Bthe%2BInterrogation%2Bof%2BJAK3%2BSignaling%2Bin%2BHumans%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D5%26spage%3D1971%26epage%3D1993%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/jmcmar.2017.60.issue-5/20170309/jmcmar.2017.60.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of <b>11</b> (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor <b>11</b> led to its evaluation in several human clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85348" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85348" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Janus kinases (JAK) are non-receptor tyrosine kinases required for signaling through type I/II cytokine receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> There are four JAK family members: JAK1, JAK2, JAK3, and TYK2. JAK1, JAK2, and TYK2 are ubiquitously expressed, while JAK3 expression is largely restricted to leukocytes. All four isoforms are involved in immune related functions, while JAK1 and JAK2 also play critical roles related to hematopoiesis, growth, and neuronal functions among others. A notable feature of JAK signaling is the requirement for a dimer of JAK kinases within the cytokine receptor complex, and cytokine receptors signaling through JAK1/JAK3, JAK1/JAK2, JAK1/TYK2, JAK2/TYK2, and JAK2/JAK2 have been described.</div><div class="NLM_p">The importance of the individual JAKs in cytokine signaling has resulted in significant efforts to identify isoform selective inhibitors.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Several inhibitors have entered clinical evaluation for autoimmune diseases as well as various cancers and myeloproliferative disorders, resulting in two FDA approvals to date (tofacitinib (<b>1</b>) and ruxolitinib (<b>2</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> That said, the majority of inhibitors reported to date lack selectivity within the JAK family. Therefore, the therapeutic potential of JAK3 selective inhibitors remains to be addressed. Indeed, in recent years there has been a debate on the role of JAK3 versus JAK1 for the common γ-chain cytokines utilizing this heterodimeric kinase pair.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recently, we illustrated that a selective JAK3 inhibitor could effectively inhibit IL-15 mediated signaling in vitro, reaffirming the therapeutic potential of selective JAK3 inhibition.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FDA approved JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Sequence alignment of the ATP binding site for the four JAK family members illustrates that JAK3 has only two unique residues that could be utilized to design selective inhibitors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, available crystal structures for each JAK isoform highlight very minor conformational differences among the set.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This structural information, combined with the higher ATP affinity of JAK3 versus other family members, illustrates the extraordinary challenge associated with the design of highly selective, ATP competitive JAK3 inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The unique residue Cys-909 in JAK3 provides an opportunity to engineer selectivity for JAK3 in a covalent manner to overcome the high sequence and shape similarity within the ATP binding cavity. This idea has been reported in the literature, most notably by the disclosure of highly selective JAK3 covalent inhibitors with supporting in vitro characterization.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Targeting JAK3 in a covalent manner provides alternative dimensions in drug design, such as the potential for an extended pharmacodynamic (PD) effect following target inactivation. Covalent modification also presents unique liabilities, such as off-target reactivity which could lead to undesired pharmacology and nontraditional metabolic clearance. We recently disclosed the selective covalent JAK3 inhibitor <b>11</b> (PF-06651600) and summarized efficacy results from multiple preclinical in vivo models of inflammatory diseases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This highly optimized covalent inhibitor of JAK3 provides rapid kinase inactivation while possessing minimal chemical reactivity, resulting in an inhibitor with good ADME properties and overall selectivity. In this paper, we describe the research efforts that culminated in the discovery of <b>11</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Initial Design and Impact of Reactivity on Translation</h3><div class="NLM_p">The crystal structure of <b>1</b> in complex with the kinase domain of JAK3 provided the inspiration for the design of inhibitors that would interact in a covalent manner with Cys-909.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Rotation around the pyrimidyl amine N–C bond would potentially place the amide substituent in close proximity with Cys-909, where an appropriately designed electrophile could capture the nucleophilic cysteine (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a). Placing an acrylamide on the tofacitinib core resulted in compound <b>3</b>, which had modest inhibition of JAK3 but poor JAK family selectivity, indicating that the affinity was mainly due to reversible (<i>K</i><sub>i</sub>) protein interactions (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). This hypothesis was supported by X-ray crystal structure analysis, which indicated that the pyrolopyrimidine hinge binder scaffold was well-ordered in the active site, while the acrylamide substituted piperidine was highly disordered (data not shown). Since JAK3 has the highest affinity for ATP among its family members, the <i>K</i><sub>i</sub> component of target inhibition must not be the major driver for potency, as that would only provide modest selectivity gains through covalent interaction with Cys-909. In order to increase the selectivity for JAK3, the inactivation rate (<i>k</i><sub>inact</sub>) had to be improved. Modeling studies indicated that removal of the <i>N</i>-methyl and piperidine cis methyl groups would result in an analog with a low energy conformation, placing the electrophilic warhead in close proximity to Cys-909, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Indeed, preparation of compound <b>4</b> revealed a significant improvement in potency (JAK3 IC<sub>50</sub> = 56 nM, [ATP] = 1 mM). An IC<sub>50</sub> can be an excellent measure of potency of irreversible inhibitors when produced under conditions of relatively long assay reaction times, as this enables a good correlation with the time independent potency measurement <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> In fact, the greater ease associated with IC<sub>50</sub> determination and the logical translation to functional responses in both in vitro cell-based and in vivo assays renders IC<sub>50</sub> the parameter of choice for SAR determination. The high JAK3 selectivity for <b>4</b> relative to <b>3</b> indicated that a significant improvement in the <i>k</i><sub>inact</sub> parameter had been achieved. The covalent bond forming event of <b>4</b> with Cys-909 was further verified in a follow-on study where the compound was shown to have a dissociation rate of >8 h.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Crystal structure of tofacitinib in JAK3 illustrating key movement around the N–C axis that would place the amide in close proximity to Cys-909. (b) Dependency of the NMe group on conformational energetics with conformer A being favored by 70:30 for <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Design of Covalent Inhibitors of JAK3 with JAK Enzyme Inhibition Data<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0014.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The enzyme assay was performed using the following description: (◆)ATP concentration for JAK3 is 4 μM at <i>K</i><sub>m</sub>; (#) ATP concentration for JAK1 is 40 μM at <i>K</i><sub>m</sub>; (∗) these assays utilized 1 mM ATP.</p></div></div><div></div></div><div class="NLM_p">The concept of high JAK3 specificity utilizing a covalent handle was extended via a range of electrophiles and motifs that would place the electrophile appropriately in the vicinity of Cys-909 resulting in analogs such as the anilinoacrylamide <b>6</b>, which demonstrated potent JAK3 inhibition (IC<sub>50</sub> = 29 nM). Compounds <b>4</b> and <b>6</b> represent two different series (i.e., aliphatic and aryl aminoacrylamides) that were explored in parallel. While the majority of the potency for each series was obtained through rapid covalent inactivation (i.e., <i>k</i><sub>inact</sub>), each achieved this via significantly different principles. Our quantification of electrophilicity utilizing glutathione (GSH) as a trapping reagent illustrated that the two series have very different inherent chemical reactivities (aryl aminoacrylamides, <i>T</i><sub>1/2</sub> = 0.4–4h; aliphatic aminoacrylamides, 4–40 h).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Aryl aminoacrylamides have been successfully utilized in the design of irreversible inhibitors for JAK3,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> EGFR,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and BTK,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> resulting in potent inhibitors; therefore, it was unclear how differing relative reactivities would translate to off-target effects. The impact of reactivity became quite apparent when evaluating the translation from a cell-based PBMC assay to one conducted in human whole blood, a medium that is rich in proteins (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). While the aliphatic aminoacrylamides demonstrated a solid correlation between assays, the aryl aminoacrylamides provided a poor translation. The reason for the differential translation for aliphatic vs aryl aminoacrylamides has not been fully elucidated; however, the enhanced reactivity of aryl aminoacrylamides described above was likely a major contributor. In addition, blood stability studies conducted with representatives from both series demonstrated a similar trend (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). Therefore, while the aryl aminoacrylamide class of compounds generated some of our most potent analogs in enzymatic and PBMC cell-based assays, it was clear that the level of chemical reactivity inherent to this series needed to be attenuated to provide optimal potency in a whole blood environment.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Correlation between our IL-15 PBMC assay and the corresponding HWB assay. Anilinoacrylamide = blue, aliphaticacrylamide = green. (b) Stability of the compounds in HWB: <i>T</i><sub>1/2</sub>, <100 min, magenta; 100–200 min, tan; 200–300 min, yellow; >300 min, green (<i>n</i> = 107).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Identification of Key Parameters Leading to the Discovery of Orally Active JAK3 Specific Inhibitors</h3><div class="NLM_p">The identification of compound <b>4</b> illustrated an important guiding principle for future design. The analogs would need to have a sufficient <i>K</i><sub>i</sub> component to effectively compete with ATP and initiate binding to the protein, but this could only be a minor component of enzyme inhibition. Rapid inactivation (<i>k</i><sub>inact</sub>) continued to be the major driver for optimization, as it was determined to be the key for achieving sufficient selectivity. Simply increasing chemical reactivity was deemed an unproductive strategy for <i>k</i><sub>inact</sub> optimization given the results discussed above for the aryl aminoacrylamides. When considering the individual events involved in covalent adduct formation, the initial bound complex EI would not necessarily represent the reactive complex EI* (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Therefore, increasing the concentration of the reversibly bound EI* complex should result in acceleration of covalent capture. The increase in chemical reactivity needed to obtain potent compounds in the series represented by <b>6</b> likely indicated that a low concentration of the EI* complex was present.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The design principle of increased EI* complex concentration can be illustrated with compound <b>4</b>. The crystal structures of <b>4</b> and <b>6</b> bound to JAK3 provided significant guidance for additional design with a focus on stabilization of the reactive conformation (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a,b). Both of the compounds are Cys-909 adducts, but their conformations are significantly different with regard to acrylamide alignment. For <b>4</b>, the acrylamide is observed making two hydrogen bonds: one to a conserved water molecule that is interacting with the ligand pyrimidine nitrogen and the second to the NH of the Cys-909 amide. While these observations are after covalent bond formation, our assumption is that they exist in the EI* complex as well, stabilizing the reactive conformation and providing activation of the acrylamide for addition to the Cys-909. In contrast, the acrylamide in <b>6</b> does not retain any of these interactions, thus requiring increased inherent chemical reactivity to capture the Cys-909. These insights were applied to the design of a more ring constrained compound <b>7</b> providing a potent inhibitor of JAK3. The X-ray crystal structure of <b>7</b> bound to Jak3 illustrates that the cyclization of the piperidine ring back to the linker amine constrains the rotation around the piperidine-N bond and stabilizes the piperidine in the appropriate chair conformation to present the acrylamide for nucleophilic attack by Cys-909, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>c.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Illustration of individual binding and reactive events required for covalent modification of Cys-909 in JAK3: E = enzyme, S = substrate, I = inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of compounds bound to JAK3 with a covalent bond to Cys-909: (a) <b>4</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTS">5TTS</a>; (b) <b>6</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTV">5TTV</a>; (c) <b>7</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTU">5TTU</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">JAK1, JAK2, and TYK2 resynthesis rates are fairly rapid and in the range of 2–4 h.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The lack of information for JAK3 prompted measurement of the resynthesis rate in PBMC cells, which was determined to be 3.5 h.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This relatively rapid resynthesis rate indicated that the potential for an extended pharmacodynamic (PD) effect due to covalent inhibition was out of scope. This is contrary to our experience with slowly resynthesized biological targets such as FAAH<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and BTK.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In these cases, relatively short-term drug exposure could provide long-term target inhibition in vivo. For JAK3, excellent pharmacokinetics (PK) with low clearance would be required in order to achieve sustained target inactivation and a high level of efficacy. Compounds <b>4</b> (data not shown) and <b>7</b> suffered from moderate to poor PK in rat despite very reasonable oxidative stability as judged by liver microsomes (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). A set of PK experiments with compound <b>7</b> and the corresponding acetate derivative <b>8</b> provided key insights into drug clearance mechanisms. For both compounds, very high clearance was observed in an in vivo rat PK experiment (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). In order to gauge the contribution of oxidative metabolism to overall clearance, the same experiment was performed following the administration of the broad cytochrome P450 (CYP450) inhibitor aminobenzotriazole (ABT). In this instance, the acetate <b>8</b> illustrated a significant reduction in clearance while acrylamide <b>7</b> was still highly cleared, suggesting the presence of non-CYP450 clearance pathways. Indeed, glutathione-<i>S</i>-transferase (GST) mediated glutathione (GSH) addition to the acrylamide was found to account for this discrepancy.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In order to build an SAR understanding of GST-mediated clearance, a whole blood stability assay was developed to provide an in vitro surrogate measure of whole body GST mediated clearance. The validation of this assay as a predictive tool has been described recently.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. ADME Properties of JAK3 Covalent Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HLM (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">RLM (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">RRCK (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">human blood <i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center">rat blood <i>T</i><sub>1/2</sub> (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="."><15</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="left">∼332<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char=".">70</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">192</td><td class="colsep0 rowsep0" align="left">164</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="."><15</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">>360</td><td class="colsep0 rowsep0" align="left">161</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">A broad range of stability was observed over multiple experiments (<i>n</i> = 3, <i>T</i><sub>1/2</sub> of >260, >360, 303).</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vivo Rat Pharmacoketic Clearance of Compounds <b>7</b> and <b>8</b>, in the absence and Presence of the Broad Based CYP450 Inhibitor ABT</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">compd</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>7</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>), −ABT</td><td class="colsep0 rowsep0" align="left">109</td><td class="colsep0 rowsep0" align="left">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>), +ABT</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">10</td></tr></tbody></table></div></div><div class="NLM_p">Despite the poor PK of compound <b>7</b>, it was evaluated in an in vivo study utilizing the mouse delayed type hypersensitivity (DTH) which is a T-cell dependent preclinical model that was utilized to characterize <b>7</b>. In the prophylactic mouse DTH model, a Th1 response was induced by priming mice with sheep red blood cells (sRBCs) subcutaneously on day 0 and a challenge of sRBC was injected to the right hind footpads on day 5 to elicit a measurable inflammatory response. Compound <b>7</b> was dosed once daily throughout the study. <b>7</b> significantly inhibited the DTH reaction in the right hind footpad in a dosage-dependent manner, and efficacy was observed with dosages as low as 3 mg/kg twice daily. <b>1</b> was also efficacious with twice-daily dosing at 30 mg/kg in this DTH model (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This provided our preliminary support that selective inhibition of JAK3 would result in in vivo functional consequences.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of <b>7</b>. Eight-week-old female BALB/c mice (Taconic) were sensitized with 2 × 10<sup>7</sup> sheep red blood cells (sRBCs) subcutaneously on day 0. Oral dosing began on day 0 prior to the sensitization and continuing through day 6. The mice were challenged with 1 × 10<sup>8</sup> sRBCs in the right hind foot pad, and the left hind footpad received an injection of sterile PBS. Paw thickness was measured prior to the injection for a baseline measurement and then again at 24 h via caliper. Paw thickness was significantly reduced in a dose-dependent manner compared to the mice that were dosed with the vehicle. All compounds were dosed twice daily except where otherwise noted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Design of Orally Active JAK3 Specific Inhibitors</h3><div class="NLM_p">There is very limited knowledge regarding design strategies to modulate GST mediated clearance, and generally speaking, the GSTs are a class of enzymes that can tolerate a wide range of substrates.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Early on, we attempted to inhibit chemical reactivity by adding substituents to the acrylamide, as steric hindrance around the electrophile should reduce the ability of GSTs to catalyze GSH addition. This approach provided a significant reduction in GST-mediated clearance but unfortunately was not compatible with JAK3 affinity. For example, addition of a β-methyl to the acrylamide moiety of <b>4</b> resulted in a nearly inactive analog <b>9</b> (IC<sub>50</sub> > 1000 nM). An alternative approach was the incorporation of a remote steric handle to modulate GST binding, a strategy utilized in a related series of cyanamide JAK3 inhibitors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This strategy was attempted with analog <b>4</b> wherein methyl substitution was explored at various piperidine ring positions. A key initial analog was <b>10</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>), which showed enhanced blood stability relative to the desmethyl analog <b>4</b> but unfortunately was poorly active against JAK3. Our rationale for the poor activity involved destabilization of the reactive conformation needed to capture the Cys-909 due to a potential steric clash with side chain residue Leu-956 in the ATP pocket. Our modeling efforts indicated that moving the aminopyrrolopyrimidine group from the 2- to the 4-position would result in a highly favorable ground state conformation for interaction with Cys-909 without a steric clash to any residue in the ATP pocket of JAK3. In this conformation, we expected interaction of the acrylamide carbonyl with the NH of Cys-909 further stabilizing the reactive conformation and potentially activating the acrylamide for nucleophilic addition. This concept was realized in compound <b>11</b> which was found to be a highly specific inhibitor of JAK3 (IC<sub>50</sub> = 33 nM), devoid of relevant activity vs other JAK enzymes at 1 mM ATP concentration and demonstrated by X-ray crystallography to be covalently attached to Cys-909.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The high in vitro potency of <b>11</b> translated to excellent activity illustrated in both cellular (IL-15 stimulated PBMCs, IC<sub>50</sub> = 51 nM) and human whole blood assays (IL-15 stimulated HWB assay IC<sub>50</sub> = 197 nM) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The importance of free drug concentration of <b>11</b> driving JAK3 pharmacology was apparent following conversion of the whole blood IC<sub>50</sub> to a free IC<sub>50</sub> of 106 nM, which is within 2-fold of the PBMC IC<sub>50</sub>. A comparable profile of inhibition for other common γ-chain cytokine signaling was observed while exquisitely sparing the inhibition of cytokines which signal through other JAK kinase pairs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The observed cellular functional potency correlated well with occupancy of the JAK3 enzyme by <b>11</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Importantly, the placement of the 2-methyl moiety resulted in a stable compound as judged by human liver microsomes, hepatocytes, and blood stability assays. In vivo pharmacokinetic studies demonstrated low clearance of compound <b>11</b> in rat and dog but rapid clearance in monkey (relative to liver blood flow) and lower oral availability (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The pharmacokinetic profiles across species had a direct relationship to stability in hepatocytes and blood, illustrating the value of applying in vitro tools to predict in vivo pharmacokinetic behavior. The high oral bioavailability of <b>11</b> in a number of species (rat/dog) was consistent with its high in vitro passive permeability (RRCK, 15 × 10<sup>–6</sup> cm/s), high aqueous solubility (>2 mg/mL), and low hepatic clearance. The metabolic clearance of <b>11</b> was determined to be mediated through both oxidative metabolism (acrylamide and ring oxidation primarily through CYP3A4) and glutathione conjugation (on the acrylamide). Renal and biliary clearance of <b>11</b> was low in rat. Through an understanding of clearance mechanisms and in vitro to in vivo correlations, human blood clearance of <b>11</b> was predicted to be approximately 5.6 mL min<sup>–1</sup> kg<sup>–1</sup>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Human oral bioavailability was likewise predicted to be approximately 90% with a half-life of approximately 2 h. These results prompted a systematic evaluation of the impact of methyl substitution at other positions on the piperidine ring (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Analogs with ring substitution favoring the chair conformation observed in the <b>4</b>-JAK3 crystal structure typically place the electrophile in close proximity to Cys-909 and provide potency (<b>15</b> and <b>19</b>). The impact on GST-mediated clearance was more subtle, as both enantiomer configuration (<b>14</b> vs <b>12</b>) and relative stereochemical configuration (<b>11</b> vs <b>12</b>) had a dramatic impact on blood stability. This exercise enabled the identification of an additional analog (<b>19</b>) with both excellent potency (IC<sub>50</sub> = 56 nM) and blood stability via a surprisingly remote steric effect.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro and in Vivo Pharmacokinetic Properties of <b>11</b> in Various Species<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species CL assay</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte CL<sub>int,u</sub> ((μL/min)/million cells)</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">>360</td><td class="colsep0 rowsep0" align="left">161</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">>360</td><td class="colsep0 rowsep0" align="left">>360</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">observed in vivo CL<sub>b</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.3<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo plasma <i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.8<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po bioavailability (%)</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">109</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">CL<sub>int,u</sub> = unbound intrinsic clearance; CL<sub>b</sub> = blood clearance.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Predicted from allometric scaling of unbound <i>V</i><sub>ss</sub>.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Predicted human half-life.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Evaluation of Remote Small Steric Effect on JAK3 Potency and GST Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0015.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Compound <b>11</b> demonstrated a high degree of selectivity vs a panel of 305 kinases (Invitrogen, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Approximately 200 kinases contain a CYS residue within the ATP binding site.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Within this set, 11 kinases contain a CYS at the same position as that found in JAK3. When evaluated against this subset, compound <b>11</b> demonstrated measurable activity against eight of the targets (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). IC<sub>50</sub> data generated for a subset of these targets utilizing 1 mM ATP showed generally good selectivity vs JAK3. The contribution of <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub> to activity was also determined for a subset of these targets. It is interesting to note that the <i>k</i><sub>inact</sub> contribution is the dominant feature with regard to JAK3 inhibition, illustrating how well-optimized the compound is for alignment of the electrophile, with rapid kinase inactivation by Cys-909 addition. In contrast, the inactivation of ITK is very slow and the majority of its affinity is associated with the <i>K</i><sub>i</sub> contribution. The very slow inactivation rate would require significant residence time for capture in a cellular environment with high ATP levels suggesting that <b>11</b> would be an ineffective inhibitor of ITK. In addition the utilization of strictly <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> as a measure of selectivity ignores the differential impact competition with ATP has on functional outcome as seen when comparing BMX and TXK. We observed very weak affinity for three other kinases (SLK, FGR, and FLT3) containing CYS in the ATP site, and none of those kinases were inhibited in a covalent manner.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Kinome selectivity of <b>11</b> determined at 1 μM for 305 kinases determined at Invitrogen. The percent inhibition is color coded and ranges from 0% inhibition (darker green) to 100% inhibition (darker red) with 50% inhibition displayed in yellow. The selectivity determined by Gini coefficient is 0.88. (b) Kinases tested that contained CYS in the ATP site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inactivation Rates of <b>11</b> toward Kinases with CYS at the Same Location as JAK3<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub> (s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> (M<sup>–1</sup>·s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (1 mM ATP) (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">2.32</td><td class="colsep0 rowsep0" align="left">6.31</td><td class="colsep0 rowsep0" align="left">3.68 × 10<sup>5</sup></td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX</td><td class="colsep0 rowsep0" align="left">0.00564</td><td class="colsep0 rowsep0" align="left">0.545</td><td class="colsep0 rowsep0" align="left">1.03 × 10<sup>4</sup></td><td class="colsep0 rowsep0" align="char" char=".">606</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="left">0.000144</td><td class="colsep0 rowsep0" align="left">0.0269</td><td class="colsep0 rowsep0" align="left">5.35 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="char" char=".">8510</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK</td><td class="colsep0 rowsep0" align="left">0.000487</td><td class="colsep0 rowsep0" align="left">0.131</td><td class="colsep0 rowsep0" align="left">3.79 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="char" char=".">193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">0.00156</td><td class="colsep0 rowsep0" align="left">0.679</td><td class="colsep0 rowsep0" align="left">2.30 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="char" char=".">592</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">0.124</td><td class="colsep0 rowsep0" align="left">62.3</td><td class="colsep0 rowsep0" align="left">1.99 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="char" char=".">607</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="left">0.0278</td><td class="colsep0 rowsep0" align="left">32.4</td><td class="colsep0 rowsep0" align="left">8.58 × 10<sup>2</sup></td><td class="colsep0 rowsep0" align="char" char=".">19000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">25200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">>50000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">>50000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAP2K7</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">>50000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were determined at Carna Bioscience. Note: Given the experimental design [see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>], exact solutions for individual kinetic parameters, <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub>, were obtained only for BMX, ITK, and TXK; the solutions reported for all other kinases are lower limits. For all kinases tested, the ratio (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) is accurately determined.</p></div></div></div><div class="NLM_p last">The potent inhibition of in vitro cellular signaling demonstrated with <b>11</b> clearly illustrates that selective inhibition of JAK3 can effectively modulate signaling via the common γ-chain cytokine receptor which utilizes the heterodimeric JAK1/JAK3 pair. Furthermore, the high degree of efficacy reported for <b>11</b> and <b>7</b> in a variety of in vivo inflammatory disease models (AIA, DTH, CIA, and EAE) driven by γ-chain signaling unambiguously demonstrates the therapeutic potential for selective JAK3 inhibition in a number of human diseases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> On the basis of these results, <b>11</b> has been selected for clinical evaluation.</div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, and <b>9</b> are described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>3</b>, the acrylamide analog of tofactinib, was readily synthesized from the known amine <i>N</i>-methyl-<i>N</i>-((3<i>R</i>,4<i>R</i>)-4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine <b>21</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and acryloyl chloride in dichloromethane/DIPEA in 32% yield. Compound <b>4</b> was synthesized beginning from the known 4-chloro-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>22</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> followed by S<sub>n</sub>Ar displacement of the chlorine with <i>tert</i>-butyl (<i>R</i>)-3-aminopiperidine-1-carboxylate <b>23</b> to give <b>24</b> in 42% yield.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The tosyl group at N-1 was subsequently removed under basic conditions (LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O) to give <b>25</b> in 70% yield. Removal of the Boc group of <b>25</b> with 4 N HCl/dioxane to give <b>26</b> and installation of the acrylamide (acryloyl chloride, TEA/DCM/EtOH) provided <b>4</b> in 33% yield. Similarly, compound <b>9</b> was synthesized using (<i>E</i>)-but-2-enoyl chloride in 32% yield. Compound <b>5</b> was prepared from 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> followed by S<sub>n</sub>Ar displacement of the 4-Cl with (<i>R</i>)-<i>tert</i>-butyl 3-(methylamino)piperidine-1-carboxylate to give compound <b>29</b> in 60% yield. Subsequent reduction of the 2-Cl gave <b>29</b>, which was treated with acid to give <b>30</b>. The secondary amine of <b>30</b> was then acylated with acryloyl chloride to give compound <b>5</b>. Finally, compound <b>6</b> was synthesized via Suzuki coupling<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>32</b> with (3-aminophenyl)boronic acid <b>33</b> under standard conditions (Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O) to provide intermediate <b>34</b> in 50% yield, followed by acylation of the anilino nitrogen with acryloyl chloride (THF/TEA) to give <b>6</b> in 20% isolated yield.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Acrylamides <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of acryloyl chloride, 1.3 equiv of TEA, DCM, 0 °C, 1 h, 32%; (b) 1.2 equiv of <b>23</b>, 1.2 of equiv DIPEA, <i>n</i>-BuOH, 70 °C, 14 h, 42%; (c) 2 equiv of LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (1:1:1), 60 °C, 1 h, 70%; (d) 4 N HCl/dioxane, rt, 92%; (e) 1.0 equiv of acryloyl chloride, DCM/EtOH (10:1), 4.4 equiv of TEA, 0 °C, 2 h, 33%; (f) 1.0 equiv of (<i>E</i>)-but-2-enoyl chloride, DCM/EtOH (10:1), 4.4 equiv of TEA, 0 °C, 2 h, 38%; (g) 1.0 equiv of <b>28</b>, 5.0 equiv of DIPEA, <i>n</i>-BuOH, 130 °C, 60%; (h) 10% Pd/C, MeOH/THF (∼2:1), 50 psi, H<sub>2</sub>, 48 h, 100%; (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 76%; (j) 0.86 equiv of acrylogyl chloride, THF/H<sub>2</sub>O, NaHCO<sub>3</sub>, 5 °C, 1 h, 14%; (k) 1.2 equiv of <b>32</b>, 3.0 equiv of K<sub>2</sub>CO<sub>3</sub> dioxane/H<sub>2</sub>O (5:1), 0.1 equiv of Pd(PPh<sub>3</sub>)<sub>4</sub>, 110 °C, 16 h, 50%; (l) 1.0 equiv of acryloyl chloride, THF, 4.0 equiv of TEA, 0 °C, 2 h, 20%.</p></p></figure><div class="NLM_p">The syntheses of compounds <b>7</b> and <b>8</b> are described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The racemic <i>tert</i>-butyl octahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-1-carboxylate amine <b>35</b> was treated with Cbz-Cl to give <b>36</b> in 90% yield followed by removal of the Boc group to give intermediate <b>37</b> in 85% yield. The racemic (<i>cis</i>-fused) compound <b>37</b> was separated by chiral supercritical fluid chromatography (SFC) to give the enantiomeric pair of <b>38a</b> and <b>38b</b>. The absolute stereochemistry of <b>38b</b> was determined by X-ray crystallography (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf" class="ext-link">Supporting Information</a>). Nucleophilic aromatic substitution of the more activated chlorine at the 4-position of 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> with compound <b>38a</b> (<i>R</i>,<i>R</i>) provided <b>39</b> in 80% yield. Reduction of the Cbz group and 2-chloro with 10% Pd/C–H<sub>2</sub> provided compound <b>40</b> in 90% yield. Final installation of the acrylamide was accomplished using aqueous basic conditions and acryloyl chloride to give analog <b>7</b> in 81% yield. Compound <b>8</b> was prepared in a similar manner except using acetyl chloride.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>7</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2.2 equiv of DIPEA, 1.2 equiv of CbzCI, DCM, 45 min, 90%; (b) 4 N HCl/dioxane, rt, 15 h, 85%; (c) SFC purification, AS 250 mm × 50 mm, 10 μm, CO<sub>2</sub>/EtOH (0.05%DEA); (d) 1.1 equiv of <b>38a</b>, 4.5 equiv of DIPEA, <i>n</i>-BuOH, 80 °C, 3 h, 80%; (e) 10 mol % 10%Pd/C, EtOH, 50 psi H<sub>2</sub>, 65 °C, 48 h, 90%; (f) 1.1 equiv of acryloyl chloride, 3.3 equiv of NaHCO<sub>3</sub>, H<sub>2</sub>O, CH<sub>3</sub>CN, 0 °C, 81%; (g) 1.1 equiv of AcCl, 5.1 equiv of DIPEA, DCM, 0 °C, 74%.</p></p></figure><div class="NLM_p">For compound <b>10</b>, the synthesis was accomplished as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. 4-Iodo-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>41</b> and racemic benzyl (2<i>R</i>,3<i>R</i>)-3-amino-2-methylpiperidine-1-carboxylate <b>42</b> were reacted under S<sub>n</sub>Ar conditions to give <b>43</b>, which was then treated with base to effect tosyl group removal to give <b>44</b> in 91% yield. The Cbz group was removed under transfer hydrogenation conditions (Pd(OH)<sub>2</sub>/cyclohexadiene) to give the free piperidine <b>45</b>, which was subsequently acylated (acryloyl chloride/DCM/DIPEA) to give <b>10</b> in 71% yield.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of <b>42</b>, 4.0 equiv of DIPEA, <i>n</i>-BuOH, 85 °C, 18 h, 36%; (b) 3.0 equiv of LiOH·H<sub>2</sub>O, MeOH/H<sub>2</sub>O (3:1), 60 °C, 1.5 h, 91%; (c) 1.0 equiv of Pd(OH)<sub>2</sub>, MeOH, 40 equiv of cyclohexadiene, 14 h, 52%; (d) 1.1 equiv of acryloyl chloride, DCM, 5.0 equiv of DIPEA, DCM, 0 °C, 2 h, 71%.</p></p></figure><div class="NLM_p">The syntheses of examples <b>11</b>–<b>14</b> are described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Beginning from 6-methylpyridin-3-amine <b>46</b> the free amino group was protected as the Boc derivative to give pyridine <b>47</b>, which was then reduced using PtO<sub>2</sub>/H<sub>2</sub>/HOAc at 50 °C to give piperidine <b>48</b> as a mixture of diastereomers (∼2:1 cis/trans). The piperidine nitrogen of the diastereomeric mixture <b>48</b> was subsequently protected as the Cbz carbamate to give <b>49</b> as a diastereomeric mixture. Compound <b>49</b> was separated into its diasteromeric pair using chiral SFC to give compound <b>50a</b> (rac-trans, pk1) and compound <b>50b</b> (rac-cis, pk2). The Boc groups of <b>50a</b> and <b>50b</b> were removed under standard conditions to give <b>51a</b> (rac-trans) and <b>51b</b> (rac-cis). For compounds <b>11</b> and <b>12</b>, the cis isomer <b>51b</b> was reacted with <b>38</b> to give intermediate <b>52</b> (rac-cis), which was then subjected to reduction conditions to give <b>53</b>. Compound <b>53</b> was then acylated to provide compound <b>54</b> as a rac-cis mixture. The racemic mixture was separated by chiral SFC to provide the enantiomeric pair <b>11</b> and <b>13</b>. The preparation of compounds <b>12</b> and <b>14</b> was similarly accomplished except <b>51b</b> (rac-trans) was utilized via intermediates <b>55</b>–<b>57</b> with chiral SFC of <b>57</b> (rac-trans) to give the enantiomeric pair <b>12</b> and <b>14</b>.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>11</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.3 equiv of Boc<sub>2</sub>O, EtOH, 0 °C, 14 h, 67%; (b) 10 mol % PtO<sub>2</sub>, HOAc, 55 psi H<sub>2</sub>, 50 °C, 100%, ∼2:1 cis/trans; (c) 1.5 equiv of CbzCl, 7.0 equiv of NaHCO<sub>3</sub>, THF/H<sub>2</sub>O (1:1), 100%; (d) chiral SFC, ChiralCel OD 300 mm × 50 mm, 10 μm, CO<sub>2</sub>/IPA (0.1% NH<sub>3</sub>); (e) 4 N HCl/dioxane, DCM, rt; (f) 1.1 equiv of <b>51b</b> or <b>51a</b>, 5.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 14 h, 86%; (g) 10 mol % 10%Pd/C, MeOH/THF (6:1), 45 psi H<sub>2</sub>, 25 °C, 48 h, 95%; (h) 1.2 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 38%; (i) chiral SFC, ChiralPak IC 300 mm × 50 μm, 10 μm, CO<sub>2</sub>/EtOH (0.05% NH3), 45%.</p></p></figure><div class="NLM_p">For compounds <b>15</b>–<b>18</b> the headpiece amine was synthesized as described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, similar to the piperidine amine <b>49</b> utilized for compounds <b>11</b>–<b>14</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) but utilizing 5-methylpyridin-3-amine as the pyridine precursor. Unlike the 2-methylamines, the 3-methylamine derivatives <b>61</b> and <b>62</b> were inseparable by chromatographic methods and therefore were carried on as a rac-cis/trans mixture <b>62</b>, with the potential for separation further along the synthesis. Indeed S<sub>n</sub>AR reaction of <b>62</b> (rac-cis/trans) with <b>38</b> provided a separable mixture, providing <b>63</b> and <b>64</b>. Intermediate <b>63</b> (rac-cis) was then taken forward. The Cbz group and Cl were removed to give <b>65</b>, and the acrylamide was installed to give <b>66</b> (rac- cis). Chiral SFC of <b>66</b> provided the enantiomeric pair <b>15</b> and <b>17</b>. Similarly, <b>64</b> (rac-trans) was taken forward via intermediates <b>67</b> and <b>68</b> and final chiral SFC to provide the enantiomeric pair <b>18</b> and <b>16</b>.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of Boc<sub>2</sub>O, THF, rt, 5 h, 69%; (b) 10 mol % PtO<sub>2</sub>, HOAc, 5 d, 55 psi H<sub>2</sub>, 50 °C, 100%, mixture cis/trans; (c) 1.2 equiv of CbzCl, 3.8 equiv of NaHCO<sub>3</sub>, rt, THF/H<sub>2</sub>O (2:1), 8 h, 45%; (d) 4 N HCl/dioxane, DCM, rt, 43%; (e) 1.1 equiv of <b>62a</b>,<b>b</b>, 4.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 30 h, 34% (cis) and 10% (trans); (f) 10 mol % 10% Pd/C, MeOH/THF (3:1), 50 psi H<sub>2</sub>, 40 °C, 3 d, 100%; (g) 1.1 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 2 h, 71% (for <b>64</b>); 50% (for <b>66</b>); (h) chiral SFC, AD 250 mm × 30 mm, 20 μm, CO<sub>2</sub>/MeOH (0.05% NH<sub>3</sub>), 45% (for <b>15</b> and <b>17</b>); 40% (for <b>18</b> and <b>16</b>).</p></p></figure><div class="NLM_p">Finally, the synthesis of compounds <b>19</b> and <b>20</b> is described in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The pyrrolopyrimidine <b>38</b> and racemic <i>tert</i>-butyl (3<i>R</i>,4<i>S</i>)-3-amino-4-methylpiperidine-1-carboxylate <b>69</b> were reacted under S<sub>n</sub>AR conditions to give compound <b>70</b> in 66% yield. The chlorine of <b>70</b> was reduced under catalytic hydrogenation conditions to give <b>71</b> (93% yield), which was then subjected to acidic conditions (4 N HCl/dioxane) to effect removal of the Boc group and provide <b>72</b>. Treatment of <b>72</b> with acryloyl chloride under aqueous basic conditions gave acrylamide <b>73</b> in 34% yield. The racemic acrylamide <b>73</b> was separated by chiral SFC to provide the enantiomeric pair <b>19</b> and <b>20</b>.</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of <b>69</b>, 3.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 24 h, 66%; (b) 10 mol % 10% Pd/C, MeOH/THF (3:1), 50 psi H<sub>2</sub>, 40 °C, 2 d, 93%; (c) 4 N HCl/dioxane, 0 °C, 100%; (d) 1.1 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 2 h, 34%; (e) chiral SFC, AD 250 mm × 30 mm, 5 μm, CO<sub>2</sub>/EtOH (0.05% NH<sub>3</sub>), 45% (for <b>19</b> and <b>20</b>).</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary we have disclosed the design of the first specific orally active JAK3 inhibitor in this report. The ultimate selection of <b>11</b> illustrated how to improve <i>k</i><sub>inact</sub> without an increase in chemical reactivity. Potency was coupled with minimizing GST mediated clearance by utilizing a remote steric effect through appropriate substitution of a methyl group on the piperdine ring. High metabolic stability resulted in an overall profile that made <b>11</b> suitable for oral dosing. The compound has exceptionally low reactivity for other proteins containing cysteine as judged by kinome, HSA, and human liver hepatocyte profiling illustrating its specific design for inhibition of JAK3. This compound has been utilized to illustrate the consequences on JAK3 inhibition in a range of in vitro and in vivo systems, once and for all settling the debate that it is sufficient to inhibit JAK3 only as the partner in the heterodimeric pair of JAK1/JAK3 kinase mediated cytokine signaling though the γ-common chain receptors. <b>11</b> is currently in clinical development for potential applications in inflammatory disease.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The JAK enzyme data and the PBMC data were obtained as previously described.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Stability of JAK3 Covalent Inhibitors in Rat and Human Whole Blood</h3><div class="NLM_p last">All animal experiments were performed following protocols reviewed and approved by Pfizer Institutional Animal Care and Use Committee. Pfizer facilitites that supported this work are accredited by AAALAC International. Rat blood was collected from three male Sprague–Dawley rats (200–250 g, Charles River Laboratories) and pooled for each study. Human blood was collected from one male and one female healthy subject at the Occupational Health & Wellness Center at Pfizer, Groton, CT, and pooled for each study. Both rat and human blood was collected freshly into K2-EDTA tubes and kept on ice. An aliquot of the blood was transferred to microtubes and prewarmed for 10 min at 37 °C using a heat block. The test compound was then added (1 μM final concentration), and the incubation was continued for 180 min at 37 °C in duplicates. An aliquot of the incubation mixture was removed at designated time points during the course of the incubation, mixed with an aliquot of acetonitrile containing an internal standard, vortexed, and centrifuged. The resulting supernatants were removed and subjected to LC–MS/MS analyses to determine parent compound concentrations. Peak area ratios of the parent compound vs the internal standard were used to determine the % of parent compound remaining vs incubation time.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> HWB IL-15 Induced STAT5 Phosphorylation Assay</h3><div class="NLM_p last">After serial dilution of the test compounds 1:2 in DMSO at desired concentration (500× of final), the compounds were further diluted in PBS (by adding 4 μL compound/DMSO in 96 μL of PBS, [DMSO] = 4%, 20× final). To 96-well polypropylene plates was added 90 μL of HWB (heparin treated human whole blood)/well, followed by 5 μL/well 4% DMSO in D-PBS or various concentrations of 20× inhibitor in 4% DMSO in D-PBS (w/o Ca<sup>2+</sup> or Mg<sup>2+</sup>) to give 1× in 0.2% DMSO. After mixing and incubating for 45 min at 37 °C, 5 μL of D-PBS (unstimulated control) or 20× stocks of 5 μL of human IL-15 (final concentration is 50 ng/mL) were added and mixed three times. After incubating 15 min at 37 °C, 1× Lyse/Fix buffer (BD Phosflow 5× Lyse/Fix Bbuffer) was added to all wells at 1000 μL/well, then incubated for 20 min at 37 °C and spun 5 min at 1200 rpm. After washing in 1000 μL of FACS buffer 1× and spinning for 5 min at 1200 rpm, an amount of 400 μL of ice cold Perm buffer III was added to each well. After mixing gently (1–2×) and incubating on ice for 30 min, spinning for 5 min at 1200 rpm without interruption, and washing 1× in cold 1000 mL of FACS buffer (D-PBS containing 0.1% BSA and 0.1% sodium azide) 250 μL/well of the desired AlexaFluor647-conjugated anti-phospho STAT5 antibody at 1:125 dilution in FACS buffer was added. Following incubating at 4 °C overnight, all the samples were transferred to 96-well polypropylene U-bottom plate and checked by flow cytometry gated on total lymphocytes. IC<sub>50</sub> values obtained are listed in the table.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> TR-FRET Inhibitor Binding and Kinase Inactivation (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) Assay</h3><div class="NLM_p">The kinetics of <b>11</b> binding to and inactivation of JAK3 and a set of possible off-target kinases were measured using a time-resolved Förster resonance energy transfer (TR-FRET) assay based on the LanthaScreen kinase binding assay (Invitrogen/Life Technologies, Carlsbad, CA). The assay system employs three components: (1) a recombinant, epitope-tagged kinase, (2) a europium-labeled, anti-epitope antibody (Eu-Ab), and (3) a kinase-specific Alexa Fluor-conjugated probe. A TR-FRET signal is generated between the Eu-Ab·kinase conjugate pair and probe when the probe is bound to the kinase.</div><div class="NLM_p">Assay buffer was 20 mM HEPES, pH 7.5, 10 mM MgCl<sub>2</sub>, 0.01% BSA, 1 mM DTT, 0.0005% Tween 20, and 2% DMSO. Serial dilutions of <b>11</b> were prepared at 100× final concentration in 100% DMSO, from which 4× <b>11</b> solutions were prepared by dilution into assay buffer (at 4% DMSO, no DTT) immediately prior to the start of the experiment. Experiments were performed in a Corning, low volume NBS, black 384-well plate (Corning catalog no. 3676). For each kinase, the standard procedure is to run multiple experiments at various compound concentrations and to employ various preincubation times intended to measure the time-dependence of covalent adduct formation.</div><div class="NLM_p">Two different procedures to measure the kinetics of <b>11</b> dissociation (off-rate assay) from JAK3 were employed: In brief, the kinase is first preincubated with compound for a measured time, after which an appropriate off-rate probe is added. In the first procedure, 5 μL of a 4× solution of <b>11</b> was combined with 10 μL of a 2× solution of (final concentrations): 2 nM Eu-Ab and 2.85 nM of JAK3-GST. This solution was allowed to preincubate for a variable amount of time (between 30 s or 120 min), after which 5 μL of 4× probe (150 nM, final concentration) was added. In the second procedure, a 2× solution (10 μL) containing 28.9 nM JAK3-GST and 20 nM anti-GST Eu-Ab (both are final concentrations) was mixed with 10 μL of 2× <b>11</b>: 0–1.5 μM (final concentration during preincubation time). Samples were manually mixed in individual 1.5 mL tubes and allowed to preincubate for 10, 20, or 60 s, at which time, 2 μL aliquots were quenched by addition of 20 μL of 148 nM (final concentration) probe KT236 (Invitrogen PV5592) in 2% DMSO. The approximate 10-fold dilution of compound greatly reduces the amount of covalent adduct formation during the pre-steady-state period after probe addition, which enables higher kinetic resolution of the assay. The quenched samples exhibited stable TR-FRET signals for well over an hour due to the very slow dissociation kinetics of the off-rate probe. These samples were then transferred to a black 384-well plate (Corning catalog no. 3676), and data were collected using an EnVision plate reader as above.</div><div class="NLM_p">To measure the kinetics of <b>11</b> binding to and/or inactivation (on-rate assay) of a target kinase, a 1.33× solution of (final concentrations) 2 nM Eu-Ab, 1–8 nM kinase (detailed below), and 150 nM of the appropriate on-rate probe was prepared and allowed to incubate for 1 h before addition of 15 μL of this solution to 5 μL of a 4× solution of <b>11</b>.</div><div class="NLM_p last">The assays were read using an EnVision plate reader (PerkinElmer, Waltham, MA). The excitation wavelength was 340 nm, and the output monitored was the emission ratio, calculated by dividing the signal from the emission peak of the probe (665 nm) by that of the europium (615 nm). Measurements were taken every 120 s for 1.5 h.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Kinase-Specific Inhibitor Binding and Kinase Inactivation Experimental Conditions</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> JAK3</h4><div class="NLM_p last">JAK3-GST: Human protein, GST-tagged, catalytic domain (amino acids 781–1124; Life Technologies catalog no. PR7507B) was used at 2.14 nM final concentration in the standard assay, as defined above. The conjugate antibody used was Eu-anti-GST Ab (Life Technologies catalog no. PV5594). The on-rate probe used was KT178 (Life Technologies catalog no. PV5593), <i>K</i><sub>d</sub> = 150 nM. The off-rate probe used was KT236 (Life Technologies catalog no. PV5592), <i>K</i><sub>d</sub> = 0.1 nM. The following experiments were performed: (A) standard on-rate assay using 2.85 nM JAK3 and [<b>11</b>] = 0, 0.49, 1.48, 4.44, 13.3, and 40 nM; (B) standard off-rate assay using 2.85 nM JAK3 and [<b>11</b>] = 0, 0.66, 1.98, 5.93, 17.8, 53.3 nM. The following experiments were performed following the standard protocol: [<b>11</b>] = 0, 0.66, 1.98, 5.93, 17.8, 53.3, 160, 480 nM; preincubation time was (C) 30 s, (D) 60 s, and (E) 1.5 h. The following experiments were performed using the variation of the off-rate protocol: During compound preincubation, [JAK3] was 28.9 nM, and [<b>11</b>] = 0, 0.0185, 0.056, 0.1667, 0.5, 1.5 μM; preincubation time was (F) 10 s, (G) 20 s, and (H) 60 s.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Possible Off-Target Kinases</h4><div class="NLM_p">The kinases BTK, BLK, BMX, ITK, and TEC contain a Cys residue at the H10 position and thus were tested as possible off-targets for <b>11</b> using the TR-FRET assay. The following combinations of enzyme, conjugate antibody, and probe were employed.</div><div class="NLM_p">BLK: His-tagged BLK, human full-length protein (Life Technologies cat. no. PV3683) was used at 5.75 nM final concentration in the standard assay, as defined above. The conjugate antibody system used was Eu-streptavidin (Life Technologies catalog no. PV5899) and biotin-anti-His Ab (Life Technologies catalog no. PV6089). The off-rate probe used was KT236 (Life Technologies catalog no. PV5592), <i>K</i><sub>d</sub> = 40 nM.</div><div class="NLM_p">BTK: Human, His-tagged BTK, full length protein (Life Technologies cat. no. P3363) was used at 1.26 nM final concentration in the standard assay, as defined above. The conjugate antibody used was Eu-anti-His Ab (Life Technologies catalog no. PV6089). The off-rate probe used was KT236 (Life Technologies catalog no. PV5592), <i>K</i><sub>d</sub> = 30.5 nM.</div><div class="NLM_p">BMX: His-tagged, human full-length BMX protein (Life Technologies cat. no. PV3371) was used at 2.0 nM final concentration in the standard assay, as defined above. The conjugate antibody system used was Eu-streptavidin (Life Technologies catalog no. PV5899) and biotin-anti-His Ab (Life Technologies catalog no. PV6089). The off-rate probe used was KT236 (Life Technologies catalog no. PV5592), <i>K</i><sub>d</sub> = 74 nM.</div><div class="NLM_p">ITK: GST-tagged ITK, human full-length protein (Life Technologies cat. no. PV3875) was used at 1.82 nM final concentration in the standard assay, as defined above. The conjugate antibody used was Eu-anti-GST Ab (Life Technologies catalog no. PV5594). The off-rate probe used was KT236 (Life Technologies catalog no. PV5592), <i>K</i><sub>d</sub> = 12.8 nM.</div><div class="NLM_p last">TEC: His-tagged TEC, human full length protein (Life Technologies cat. no. P3041) was used at 7.4 nM final concentration in the standard assay, as defined above. The conjugate antibody used was Eu-anti-His Ab (Life Technologies catalog no. PV6089). The off-rate probe used was KT178 (Life Technologies catalog no. PV5593), <i>K</i><sub>d</sub> = 1.0 nM. In all cases, the experiments were performed following the standard protocol: (A) [<b>11</b>] = 0, 4.9, 14.8, 44.4, 133.3, and 400 nM; preincubation time = 2 h. (B) [<b>11</b>] = 0, 0.5, 1.0, 2.0, 4.0, and 8.0 μM; preincubation time = 120 s.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Irreversible Inhibitor Binding (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) Data Analysis</h3><div class="NLM_p">All data pertaining to a specific kinase were simultaneously analyzed by the global fitting software, KinTek Explorer.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This analysis involves computationally fitting TR-FRET data as a function of both the concentrations of the reaction components (kinase, <b>11</b>, and probe) and time to a defined kinetic mechanism (steps 1–4, below). The computational process involves numerical integration of multiple differential equations that define the component processes to generate simulated data; the values of the kinetic rate constants are iteratively varied until a best fit between simulated and actual data are found.</div><div class="NLM_p">Step 1. E + I = E·I</div><div class="NLM_p">Step 2. E·I → E·I*</div><div class="NLM_p">Step 3. E + probe1 = E·probe1</div><div class="NLM_p">Step 4. E + probe2 = E·probe2</div><div class="NLM_p">The “observable” statement, used by the program to generate simulated data during data fitting, was<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/jm-2016-01694j_m001.gif" alt="" /></img></span>The parameters <i>a</i> and <i>b</i> are the intrinsic molar TR-FRET signals of a particular enzyme–probe complex and free probe, respectively, bkg is the background signal, and scale1 is a scale factor that is necessary for simultaneous fitting of data sets collected at different probe and/or Eu-Ab concentrations. The terms with square brackets indicate concentration of the indicated species.</div><div class="NLM_p last">Note that for the JAK3, TEC, BTK, and BLK data sets, even though the aggregate parameter (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) was accurately determined, only lower limits for the <i>individual parameters</i> (<i>k</i><sub>inact</sub> and <i>K</i><sub>i</sub>) could be determined. This limitation is imposed by the kinetics of the system (<i>k</i><sub>inact</sub>) and the time scale over which the kinetic data were measured (the minimum “dead time” in our experiments was on the order of 10–60 s required to manually prepare the sample and start data collection). The extent to which the kinetic parameters are well determined by global fitting can be empirically defined by “confidence contour analysis” as described in ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">35</a>.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Biochemical Inactivation Kinetic Assay of TXK Kinase</h3><div class="NLM_p">Recombinant TXK kinase (N-terminal GST-fusion protein, Carna Biosciences, Kobe, Japan) failed to produce a suitable TR-FRET signal in combination with anti-GST Eu-antibody (Life Technologies) and probe. Thus, an alternative approach was taken to measure <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>, utilizing the classic pyruvate kinase/lactate dehydrogenase (PK/LDH) coupled enzyme assay. In the PK/LDH assay, ADP, which is a product of the kinase reaction, is measured by coupling its production first to the dephosphorylation of phosphoenolpyruvate (PEP) to form pyruvate, which is coupled to NADH-dependent reduction of pyruvate to form lactate. The concomitant oxidation of NADH to form NAD<sup>+</sup> is monitored spectrophotometrically by loss of absorbance at 340 nm.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Assay Protocol</h4><div class="NLM_p last">The TXK kinase buffer was 50 mM HEPES, pH 7.5, 10 mM Mg<sub>2</sub>Cl, 0.01% Triton X-100, 1 mM DTT, and 1% DMSO. Also included (PK/LDH assay reagents) were 0.25 mM NADH (Sigma, N8129), 2.5 mM phosphoenolpyruvate (PEP) (Sigma, P0564), 12 U/mL pyruvate kinase (PK), and 18 U/mL lactate dehydrogenase (LDH) (Sigma P0294). Final substrate concentrations were 100 μM each ATP and Srctide peptide (sequence GEPLYWSFPAKKK, AnaSpec, Inc., Fremont, CA). Serial dilutions of <b>11</b> were prepared at 100× final concentration in 100% DMSO, from which 4× <b>11</b> solutions were prepared by dilution into assay buffer (at 4% DMSO, no DTT) immediately prior to the start of the experiment. Experiments were performed in a Corning 384-well black with clear bottom plate (Corning catalog no. 3544). In each experiment, 10 μL of <b>11</b> solution (concentration during preincubation: 0, 10.4167, 20.83, 41.67, 83.3, 333.3, 666.7, 1333.3, 2666.7 nM) was combined with 20 μL of solution containing TXK kinase (34 nM concentration during preincubation) + PK/LDH solution reagents. After a variably timed preincubation period (15 min, 30 min, 1 h, 1.5 h, and 2 h), 10 μL of 4× ATP/peptide substrate was added to initiate the reaction. The reaction was monitored by absorbance (340 nm) every 60 s for 1 h with an EnVision plate reader (PerkinElmer, Waltham, MA).</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Data Analysis for TXK Inactivation Kinetics</h3><div class="NLM_p">The absorbance data were converted to concentration data using the <i>apparent</i> difference molar absorptivity value of 0.004 13/μM product formed, which was empirically determined using a calibration curve prepared from a standard solution of NADH, measured using an EnVision plate reader under identical condition as the enzyme assay. The primary absorbance (<i>A</i><sub>340</sub>) data were plotted versus time and were linear. The observed <i>A</i><sub>340</sub> change (Δ<i>A</i><sub>340</sub>) and <i>y</i>-intercept were determined in Excel. The concentration of product at each time point was calculated from the primary (<i>A</i><sub>340</sub>) data by the equation<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/jm-2016-01694j_m002.gif" alt="" /></img></span>where <i>t</i> is the time in s.</div><div class="NLM_p">The product vs time data were analyzed by KinTek Explorer global fitting software (KinTek Corp., Austin, TX). The following kinetic steps for a general bisubstrate reaction were defined for global data analysis.</div><div class="NLM_p">Step 1. E + I = E·I</div><div class="NLM_p">Step 2. E·I → E·I*</div><div class="NLM_p">Step 3. E + ATP = E·ATP</div><div class="NLM_p">Step 4. E·ATP + peptide = E·ATP·peptide</div><div class="NLM_p">Step 5. E + peptide = E·peptide</div><div class="NLM_p">Step 6. E·peptide + ATP = E·ATP·peptide</div><div class="NLM_p">Step 7. E·ATP·peptide → E + phosphopeptide + ADP</div><div class="NLM_p last">The rate constants describing steps 3–7 were determined in separate preliminary experiment and set to their determined values during data fitting.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Sheep Red Blood Cell (SRBC) Induced Delayed-Type Hypersensitivity (DTH) Model</h3><div class="NLM_p last">BALB/c mice (Taconic, Germantown, NY) were kept at the animal facility of Pfizer Research in accordance with the Guide for the Care and Use of Laboratory Animals. All study protocols were approved by the Pfizer Institutional Animal Care and Use Committee. BALB/c mice (<i>n</i> = 10) were treated with vehicle or compounds orally for 7 days (day −1 to day 5). On day 0, mice were primed with a subcutaneous injection of sheep red blood cells (sRBCs). On day 5, the right hind footpad was measured using a caliper. The right hind footpad was then challenged by injecting sSRBCs. Foot pad swelling (ventrodorsal thickness) was measured 24 h later. The difference in thickness prior to and after challenge of the right hind footpad was reported as the change in right hind footpad thickness.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General</h3><div class="NLM_p">All chemicals, reagents, and solvents were purchased from commercial sources when available and used without further purification. Anhydrous solvents (dioxane, dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), toluene, acetonitrile) were purchased from Aldrich (SureSeal) and used in reactions without further purification. Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) using precoated Whatman 250 μm silica gel plates and visualized by UV light and by GC/MS. Silica gel chromatography was performed utilizing ACS grade solvents and ISCO or Biotage purification systems and prepackaged columns. Yields refer to purified compounds. <sup>1</sup>H NMR spectra (400 MHz field strength) and <sup>13</sup>C NMR spectra (101 MHz field strength) were obtained on a Bruker AV III spectrometer equipped with a BBFO probe. Alternatively, <sup>1</sup>H NMR spectra (500 MHz field strength) and <sup>13</sup>C NMR spectra (125 MHz field strength) were obtained on a Bruker 500 Avance III HD using a 5 mm Prodigy BBO cryoprobe. Chemical shifts were referenced to the residual <sup>1</sup>H solvent signals (CDCl<sub>3</sub>, δ 7.27; DMSO-<i>d</i><sub>6</sub>, δ 2.50; MeOH-<i>d</i><sub>4</sub>, δ 3.31; D<sub>2</sub>O, δ 4.75) and solvent <sup>13</sup>C signals (CDCl<sub>3</sub>, δ 77.00; DMSO-<i>d</i><sub>6</sub>, δ 39.51; MeOH-<i>d</i><sub>4</sub>, δ 49.15). Signals are listed as follows: chemical shift in ppm (multiplicity identified as s = singlet, br = broad, d = doublet, t = triplet, q = quartet, m = multiplet; coupling constants in Hz; integration). High resolution mass spectrometry (HRMS) was performed via atmospheric pressure chemical ionization (APCI) or electron scatter ionization (ESI) sources.</div><div class="NLM_p last">Purity of final compounds was determined by RP-HPLC to be >95% (UV detection (λ = 220 and 254 nM) and ELSD), prior to biological assay.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Synthesis of 1-((3<i>R</i>,4<i>R</i>)-4-Methyl-3-(methyl-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (<b>3</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-methyl-<i>N</i>-((3<i>R</i>,4<i>R</i>)-4-methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine <b>21</b> (77 mg, 0.31 mmol, WO 2000/2096909 A1, CAS no. 477600-74-1) in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) was added DIPEA (0.1 μL, 1.3 equiv). The reaction mixture was cooled to 0 °C, and then a solution of acryloyl chloride in CH<sub>2</sub>Cl<sub>2</sub> (27 μL in 1 mL) was added dropwise. After 1 h, water was added and the mixture passed through a phase separator and the organic concentrated. The residue was purified by chromatography (silica, MeOH/DCM, 0–7.5%) to give the desired product (30 mg, 32%). LC/MS (M + H) = 300.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.66 (br s, 1 H) 8.10 (s, 1 H) 7.14 (br s, 1 H) 6.71–6.96 (m, 1 H) 6.56 (br s, 1 H) 6.12 (d, <i>J</i> = 16.39 Hz, 1 H) 5.47–5.78 (m, 1 H) 4.86 (br s, 1 H) 3.87–4.10 (m, 2 H) 3.34–3.82 (m, 4 H) 2.41 (br s, 1 H) 1.43–1.86 (m, 2 H) 0.89–1.19 (m, 4 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.4, 156.9, 151.7, 150.5, 128.4, 128.3, 127.3, 120.7, 102.2, 101.7, 53.6, 53.1, 45.6, 41.9, 41.5, 33.9, 31.8, 31.4, 30.3, 14.06, 13.7. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>16</sub>H<sub>21</sub>N<sub>5</sub> O [M + H]<sup>+</sup> 300.1824; observed 300.1815.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthesis of (<i>R</i>)-1-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (<b>4</b>)</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 1: (<i>R</i>)-<i>tert</i>-Butyl 3-((7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carboxylate (<b>24</b>)</h4><div class="NLM_p last">To a stirred solution of 4-chloro-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>22</b> (8.73 g, 28.4 mmol) in <i>n</i>-butanol (100 mL) was added DIPEA (6.0 mL, 1.2 equiv) and (<i>R</i>)-3-aminopiperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>23</b> (6.82 g, 1.2 equiv, AlfaAesar, catalog no. H26937, CAS no. 188111-79-7). The reaction mixture was heated at 70 °C overnight. The solvent was removed under reduced pressure and the crude residue was purified by column chromatography (100–200 mesh silica, 0–3% MeOH in DCM) to obtain <b>24</b> (5.6 g, 42%). LC–MS (ESI) <i>m</i>/<i>z</i> 472.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.25 (s, 1 H) 7.95 (d, <i>J</i> = 8.31 Hz, 2 H) 7.55 (d, <i>J</i> = 3.91 Hz, 2 H) 7.41 (d, <i>J</i> = 8.07 Hz, 2 H) 6.95 (br s, 1 H) 3.90–4.07 (m, 1 H) 3.43–3.69 (m, 1 H) 3.05–3.30 (m, 1 H) 2.34 (s, 3 H) 1.92 (br s, 1 H) 1.77 (br s, 1 H) 0.91–1.68 (m, 13 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 155.7, 153.8, 153.3, 149.9, 145.6, 134.6, 130.0, 127.5, 121.9, 104.78, 103.8, 78.2, 64.9, 47.4, 46.3, 27.8, 21.0, 15.1, 14.0. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>S [M + Na]<sup>+</sup> 494.1838; observed 494.1831.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 2: (<i>R</i>)-<i>tert</i>-Butyl 3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carboxylate (<b>25</b>)</h4><div class="NLM_p last">To a stirred solution of <b>24</b> (29.4 g, 62 mmol) in MeOH (96 mL), THF (96 mL), and water (96 mL) was added LiOH·H<sub>2</sub>O (2.99 g, 125 mmol, 2 equiv). The mixture was heated at 60 °C for 1 h. After the reaction mixture was cooled to room temperature, the organic solvent was evaporated in vacuo. The aqueous mixture was made slightly acidic and then extracted with ethyl acetate (4 × 150 mL). The organic fractions were combined and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude material was purified by column chromatography (100–200 mesh silica, 0–2% MeOH in DCM) to provide 8.5 g (70%) of <b>25</b> as an off white solid. LC–MS (ESI) <i>m</i>/<i>z</i> 318.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.48 (br s, 1 H) 8.11 (s, 1 H) 7.14 (br s, 1 H) 6.97–7.11 (m, 1 H) 6.59 (br s, 1 H) 4.06 (br s, 1 H) 3.54–3.97 (m, 1 H) 2.71–3.13 (m, 1 H) 1.99 (d, <i>J</i> = 9.05 Hz, 1 H) 1.78 (br s, 1 H) 1.11–1.68 (m, 13 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 155.4, 153.9, 151.2, 150.3, 120.8, 102.5, 98.7, 78.4, 46.2, 33.5, 28.1, 27.9, 21.7, 13.9. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>16</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 318.1930; observed 318.1760.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 3: (<i>R</i>)-<i>N</i>-(Piperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine HCl Salt (<b>26</b>)</h4><div class="NLM_p last">To a stirred solution of <b>25</b> in dioxane (40 mL) was added 4 M HCl in dioxane (60 mL) dropwise. The reaction was stirred for ∼1 h and then diluted with diethyl ether to form a solid, which was filtered and collected. The solid was dried on high vacuum to give amine HCl salt <b>26</b> (4.6 g, 92%). LC–MS (ESI) <i>m</i>/<i>z</i> 218.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.48 (br s, 1 H) 8.09 (s, 1 H) 7.19 (d, <i>J</i> = 7.83 Hz, 1 H) 7.07 (br s, 1 H) 6.60 (d, <i>J</i> = 2.20 Hz, 1 H) 4.20 (br s, 1 H) 3.51 (br s, 1 H) 3.21 (d, <i>J</i> = 2.69 Hz, 1 H) 2.94 (d, <i>J</i> = 11.98 Hz, 1 H) 2.54–2.65 (m, 2 H) 1.97 (br s, 1 H) 1.68–1.84 (m, 1 H) 1.44–1.62 (m, 2 H); <sup>13</sup>C NMR (125 MHz, DMSO- <i>d</i><sub>6</sub>) δ ppm 155.3, 151.3, 150.2, 120.8, 102.4, 98.7, 50.1, 46.1, 45.0, 30.2, 24.0; <i>DMSO + D<sub>2</sub>O:</i><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.90–8.19 (m, 1 H) 7.07 (d, <i>J</i> = 1.47 Hz, 1 H) 6.57 (d, <i>J</i> = 2.20 Hz, 1 H) 4.17 (br s, 1 H) 3.56–3.88 (m, 7 H) 3.17 (d, <i>J</i> = 11.74 Hz, 1 H) 2.93 (d, <i>J</i> = 12.23 Hz, 1 H) 2.55–2.63 (m, 1 H) 1.95 (d, <i>J</i> = 9.78 Hz, 1 H) 1.67–1.81 (m, 1 H) 1.33–1.63 (m, 2 H). <i>D</i><sub>2</sub><i>O:</i><sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O) δ ppm 8.02 (s, 1 H) 7.11 (d, <i>J</i> = 3.42 Hz, 1 H) 6.44 (d, <i>J</i> = 3.67 Hz, 1 H) 3.95–4.22 (m, 1 H) 3.31 (dd, <i>J</i> = 12.23, 3.18 Hz, 1 H) 2.95–3.17 (m, 1 H) 2.50–2.87 (m, 2 H) 1.98–2.21 (m, 1 H) 1.77–1.93 (m, 1 H) 1.42–1.74 (m, 2 H). HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>11</sub>H<sub>15</sub>N<sub>5</sub> [M + H]<sup>+</sup> 218.1406; observed 218.1360.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Step 4: (<i>R</i>)-1-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (<b>4</b>)</h4><div class="NLM_p last">To a round-bottom flask containing (<i>R</i>)-<i>N</i>-(piperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine HCl salt <b>26</b> (1.0 g, 3.44 mmol) were added DCM (30 mL), EtOH (3 mL), and TEA (2.11 mL, 4.4 equiv). After 30 min, acrylolyl chloride in 20 mL of DCM was added dropwise and the reaction stirred at rt for 2 h. The mixture was poured into water, and the layers were separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent removed to give crude product (∼900 mg). The material was purified by chromatography (silica, DCM/MeOH) to give <b>4</b> (310 mg, 33%). LC–MS (ESI) <i>m</i>/<i>z</i> 272.1 [M + H]<sup>+</sup>; rotamers observed. <sup>1</sup>H NMR at 300 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.51 (br s, 1 H) 8.12 (d, <i>J</i> = 18.34 Hz, 1 H) 7.16–7.32 (m, 1 H) 7.09 (t, <i>J</i> = 2.69 Hz, 1 H) 6.67–6.91 (m, 1 H) 6.60 (d, <i>J</i> = 8.07 Hz, 1 H) 6.09 (t, <i>J</i> = 14.92 Hz, 1 H) 5.50–5.72 (m, 1 H) 4.55 (d, <i>J</i> = 10.76 Hz, 0.5 H) 4.03–4.21 (m, 3 H) 4.00 (d, <i>J</i> = 12.96 Hz, 0.5 H) 2.84–3.15 (m, 1.5H) 2.64 (t, <i>J</i> = 11.25 Hz, 0.5 H) 2.04 (br s, 1 H) 1.83 (d, <i>J</i> = 4.40 Hz, 1 H) 1.37–1.75 (m, 2 H). <sup>1</sup>H NMR at 313 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.46 (br s, 1 H) 7.95–8.27 (m, 1 H) 7.19 (br s, 1 H) 7.08 (d, <i>J</i> = 5.38 Hz, 1 H) 6.66–6.90 (m, 1 H) 6.60 (br s, 1 H) 6.08 (d, <i>J</i> = 15.65 Hz, 1 H) 5.47–5.72 (m, 1 H) 4.55 (br.s., 0.5 H) 4.13 (br s, 2 H) 3.98 (br.s., 0.5 H) 2.86–3.19 (m, 1.5 H) 2.66 (br.s., 0.5 H) 2.05 (d, <i>J</i> = 8.80 Hz, 1 H) 1.83 (d, <i>J</i> = 10.03 Hz, 1 H) 1.37–1.74 (m, 2 H); <sup>1</sup>H NMR at 353 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.31 (br s, 1 H) 8.13 (s, 1 H) 7.06 (d, <i>J</i> = 2.93 Hz, 1 H) 6.99 (d, <i>J</i> = 6.60 Hz, 1 H) 6.73 (dd, <i>J</i> = 15.04, 11.13 Hz, 1 H) 6.60 (d, <i>J</i> = 2.93 Hz, 1 H) 6.07 (dd, <i>J</i> = 16.75, 1.83 Hz, 1 H) 5.63 (d, <i>J</i> = 10.27 Hz, 1 H) 4.19–4.53 (m, 1 H) 3.93–4.18 (m, 2 H) 3.03 (br s, 2 H) 2.02–2.14 (m, 1 H) 1.85 (dt, <i>J</i> = 13.33, 3.85 Hz, 1 H) 1.63–1.74 (m, 1 H) 1.44–1.57 (m, 1 H). <sup>13</sup>C NMR at 353 K: <sup>13</sup>C NMR(125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.4, 155.2, 150.9, 150.1, 128.5, 126.0, 120.5, 102.3, 98.3, 48.2, 48.2, 46.6, 29.9, 23.3. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>11</sub>H<sub>15</sub>N<sub>5</sub> [M + H]<sup>+</sup> 272.1511; observed 272.1775.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Synthesis of (<i>R</i>)-1-(3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (<b>5</b>)</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 1: <i>tert</i>-Butyl (<i>R</i>)-3-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)(methyl)amino)piperidine-1-carboxylate (<b>29</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> (300 mg, 1.6 mmol) and DIPEA (1.03 g, 7.98 mmol) in <i>n</i>-BuOH (14 mL) was added <i>tert</i>-butyl (<i>R</i>)-3-(methylamino)piperidine-1-carboxylate <b>28</b> (342 mg, 1.60 mmol). The reaction mixture was heated to 130 °C for 18 h and then the solvent removed in vacuo. The residue was dissolved into DCM and washed with water. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent removed to give the crude material, which after chromatography (silica, ethyl acetate/pet ether 50–75%) gave the desired product <b>29</b> (350 mg, 60%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 7.09 (d, <i>J</i> = 3.51 Hz, 1 H) 6.65 (d, <i>J</i> = 3.51 Hz, 1 H) 4.52–4.80 (m, 1 H) 3.97–4.27 (m, 2 H) 3.37–3.29 (m, 3 H) 3.01 (t, <i>J</i> = 11.80 Hz, 1 H) 2.75 (br s, 1 H) 1.77–2.02 (m, 3 H) 1.60–1.72 (m, 1 H) 1.50 (s, 9 H). LC/MS (M + H) expected 366.1687, observed 366.1.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 2: <i>tert</i>-Butyl (<i>R</i>)-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carboxylate (<b>30</b>)</h4><div class="NLM_p last">To a dry Parr hydrogenation bottle were added <b>29</b> (350 mg, 0.96 mmol), MeOH/THF (15 mL:8 mL), and 10% Pd/C (183 mg). The mixture was shaken for 48 h at 50 psi H<sub>2</sub>. The reaction mixture was then filtered through Celite and the solvent removed to give the crude product <b>30</b> (320 mg, 100%), which was used in the next step without further purification. LC/MS (M + H) expected 332.2087, observed 332.2.</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step 3: (<i>R</i>)-<i>N</i>-Methyl-<i>N</i>-(piperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>31</b>)</h4><div class="NLM_p last">To a solution of <b>30</b> (320 mg, 0.97 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15.0 mL) at 0 °C was added TFA (5.0 mL) dropwise. After 2 h, the solvent was removed to give a yellow oil, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The mixture then washed with saturated Na<sub>2</sub>CO<sub>3</sub> (pH ≈ 8). The organic extract was collected, dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent removed to give the desired product (<b>31</b>, 170 mg, 76%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.12 (s, 1 H) 7.11 (d, <i>J</i> = 3.51 Hz, 1 H) 6.70 (d, <i>J</i> = 3.51 Hz, 1 H) 4.24–4.23 (m,, 1 H) 3.28 (s, 3 H) 2.69–3.13 (m, 4 H) 2.35–2.63 (m, 1 H) 1.65–2.05 (m, 3 H). LC/MS (M + H) expected 232.1484, observed 232.1.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 4: (<i>R</i>)-1-(3-(Methyl-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (<b>5</b>)</h4><div class="NLM_p last">To a solution of <b>31</b> (100 mg, 0.43 mmol) in THF (8 mL) and sat. NaHCO<sub>3</sub> (5 mL) cooled to 5 °C was added slowly acryloyl chloride (33.8 mg, 0.37 mmol, in 2 mL of THF) dropwise. After 1 h at 0 °C, the reaction mixture was poured into water/CH<sub>2</sub>Cl<sub>2</sub> and the layers were separated. The organic layer was collected, dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent removed to give a residue, which was purified by chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) to give the desired product. The product was further purified by HPLC (Phenomenex, C-18, 25 mm × 50 mm × 10 μm, H<sub>2</sub>O/CH<sub>3</sub>CN (+0.05% NH<sub>4</sub>OH) 15–45%, 10 min) to give the final product <b>5</b> (15 mg, 14%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ ppm 10.55 (br s, 1 H) 8.32 (s, 1 H) 7.08 (d, <i>J</i> = 3.01 Hz, 1 H) 6.50–6.79 (m, 2 H) 6.18–6.44 (m, 1 H) 5.49–5.88 (m, 1 H) 4.61–5.06 (m, 2 H) 3.93–4.31 (m, 1 H) 3.34 (br s, 3 H) 2.44–3.20 (m, 2 H) 1.63–2.19 (m, 4 H); LC/MS (M + H) expected 286.1668, observed 285.9.</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Synthesis of <i>N</i>-(3-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)phenyl)acrylamide (<b>6</b>)</h3><div id="sec4_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 1: 3-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)aniline (<b>34</b>)</h4><div class="NLM_p last">To a solution of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>32</b> (15 g, 98 mmol), (3-aminophenyl)boronic acid <b>33</b> (18 g, 117 mmol) in dioxane/H<sub>2</sub>O (450 mL:90 mL) were added K<sub>2</sub>CO<sub>3</sub> (40.1 g, 294 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (11.25 g, 9.8 mmol) under N<sub>2</sub>. The mixture was degassed four times with N<sub>2</sub> and the mixture heated to 110 °C for 16 h. TLC (petroleum ether/EtOAc = 1:3) indicated the starting material was consumed completely. The mixture was concentrated, and water (500 mL) and CH<sub>2</sub>Cl<sub>2</sub> (500 mL) were added. The resulting mixture was filtered and the filtrate extracted with CH<sub>2</sub>Cl<sub>2</sub> (500 mL × 3). The organic layer was washed with brine (700 mL × 2) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed and the crude material purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/methanol = 1–5%) to give <b>34</b> (10 g, 50%) as yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO): δ 12.19 (s, 1H), 8.79 (s, 1H), 7.63–7.62 (m, 1H), 7.45 (s, 1H), 7.33–7.32 (d, 1H), 7.23–7.19 (m, 1H), 6.86–6.85 (m, 1H), 6.74–6.72 (m, 1H), 5.32 (s, 1H). LC–MS (ESI) <i>m</i>/<i>z</i> 211.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step 2. <i>N</i>-(3-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)phenyl)acrylamide (<b>6</b>)</h4><div class="NLM_p last">To a solution of <b>34</b> (200 mg, 0.95 mmol) in 10 mL of THF at 0 °C was added DIPEA (500 mg, 3.72 mmol). A solution of acryloyl chloride (86 mg, 0.95 mmol) in 0.5 mL of THF was added dropwise. After addition, the mixture was stirred at 0 °C for 30 min. The mixture was stirred at room temperature for 2 h. TLC (PE/EA = 1/3) indicated the starting material was consumed completely. Methanol (5 mL) was added and reaction concentrated to give crude material, which was purified by HPLC to give <b>6</b> (50 mg, 20%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO): δ 12.29 (s, 1H), 10.40 (s, 1H), 8.84 (s, 1H), 8.65(s, 1H), 7.94–7.92 (d, 1H), 7.84–7.82 (d, 1H), 7.70–7.69 (d, 1H), 7.56–7.53 (m, 1H), 6.97–6.96 (d, 1H), 6.52–6.45 (m, 1H), 6.34–6.31 (d, 1H), 5.82–5.80 (d, 1H). LC–MS (ESI) <i>m</i>/<i>z</i> 264.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Synthesis of 1-((3a<i>S</i>,7a<i>S</i>)-1-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)octahydro-6<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-6-yl)prop-2-en-1-one (<b>7</b>)</h3><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step 1: (3a<i>S</i>,7a<i>R</i>)-<i>tert</i>-Butyl Octahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-1-carboxylate (<b>36</b>)</h4><div class="NLM_p last">To a stirred solution of (3a<i>S</i>,7a<i>R</i>)-<i>tert</i>-butyl octahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-1-carboxylate <b>35</b> (200 g, 0.885 mol) and DIPEA (251 g, 1.95 mol) in DCM (2L) at 0 °C was added dropwise Cbz-Cl (181 g, 1.06 mol) over a period of 45 min. After the addition, the resulting mixture was stirred at room temperature for 16 h. TLC (DCM/MeOH, 10:1) showed the starting material was consumed completely. The reaction mixture was evaporated to dryness and then partitioned between EtOAc (8 L) and water (3 L); the organic layer was washed with water (3 L) and brine (3 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give <b>36</b> (1.1 kg, 90%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 1.15–1.48 (m, 9 H) 1.51–1.65 (m, 1 H) 1.68–1.90 (m, 2 H) 2.32 (br s, 1 H) 2.72 (t, <i>J</i> = 11.04 Hz, 1 H) 2.97 (br s, 1 H) 3.13–3.56 (m, 3 H) 3.73 (s, 2 H) 3.85–4.28 (m, 1 H) 4.91–5.14 (m, 2 H) 7.12–7.38 (m, 5 H).</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Steps 4–6: (3a<i>R</i>, 7a<i>R</i>)-Benzyl Hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate and (3a<i>S</i>,7a<i>S</i>)-Benzyl Hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate (<b>37a</b> and <b>37b</b>)</h4><div class="NLM_p last">To a 0 °C stirred solution of (3a<i>S</i>,7a<i>R</i>)-<i>tert</i>-butyl octahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-1-carboxylate <b>36</b> (280 g, 0.68 mol) in DCM (600 mL) was added dropwise 4 N HCI in dioxane (2.5 L) over a period of 1 h. The reaction mixture was stirred at room temperature for 15 h. TLC (petroleum ether/EtOAc, 2:1) showed the starting material was consumed completely. The reaction mixture was evaporated to dryness and then partitioned between MTBE (6 L) and water H<sub>2</sub>O (4 L), and the aqueous phase was then basified to pH 9–10 and extracted with DCM (3 L × 4). The combined organic layers were concentrated to give <i>rac</i>-(3a<i>R</i>,7a<i>R</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate <b>37</b> (687 g, 85%), which was separated by SFC to give <b>38b</b>, (3a<i>S</i>,7a<i>S</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate (280 g, 42.2%), and <b>38a</b>, (3a<i>R</i>,7a<i>R</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate (270, 39.3%) as yellow oil. (<b>38a</b>, peak 2 was (3a<i>R</i>,7a<i>R</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate, <i>t</i><sub>R</sub> = 9.81 min, [α]<sub>D</sub><sup>25</sup> +9.78; peak 1, <b>38b</b> was (3a<i>S</i>,7a<i>S</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate, <i>t</i><sub>R</sub> = 10.63 min, [α]<sub>D</sub><sup>25</sup> −8.97). <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 1.28–1.63 (m, 3 H) 1.68–1.90 (m, 2 H) 1.97—2.09 (m, 1 H) 2.71–3.19 (m, 4 H) 3.26–3.43 (m, 1 H) 3.55–3.77 (m, 2 H) 5.02 (br s, 2 H) 7.10–7.35 (m, 5 H). Separation conditions. Instrument: SFC 350. Column: AS 250 mm × 50 mm, 10 μm. Mobile phase: A, supercritical CO<sub>2</sub>; B, EtOH (0.05%DEA), A:B = 65:35 at 240 mL/min. Column temp: 38 °C. Nozzle pressure: 100 bar. Nozzle temp: 60 °C. Evaporator temp: 20 °C. Trimmer temp: 25 °C;. Wavelength: 220 nm. Absolute stereochemistry determined by single X-ray (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_14_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Step 7: (3a<i>S</i>,7a<i>S</i>)-Benzyl 1-(2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl) hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate (<b>39</b>)</h4><div class="NLM_p last">A mixture of (3a<i>R</i>,7a<i>R</i>)-benzyl hexahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-6(2<i>H</i>)-carboxylate, <b>38a</b>, peak 2 (135 g, 0.52 mol), DIPEA (268 g, 2.1 mol) and <b>27</b> (88.7 g, 0.47 mol) in <i>n</i>-BuOH (1 L) was heated to 80 °C for 3 h. TLC (petroleum ether/ether, 2:1) showed <b>27</b> was consumed completely. The reaction mixture was cooled to room temperature and evaporated to dryness via oil pump at 45 °C. The residue was partitioned between DCM (2 L) and water (1.5 L); the organic layer was washed with water (1 L) and brine (1 L), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give <b>39</b> (310 g, 80%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.58–2.35 (m, 5 H) 2.90–3.28 (m, 2 H) 3.58—4.07 (m, 3 H) 4.35 (br s, 2 H) 5.16 (br s, 2 H) 6.46–6.85 (m, 1 H) 7.12–7.57 (m, 6 H) 11.87 (br s, 1 H).</div></div><div id="sec4_14_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 8: 4-((3a<i>S</i>,7a<i>R</i>)-Octahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>40</b>)</h4><div class="NLM_p last">To a dry Parr hydrogenation bottle, Pd/C (12 g) was added under Ar atmosphere. Then a solution of <b>39</b> (62 g, 0.15 mol) in EtOH (1.2 L) was added and the resulting mixture was hydrogenated under 50 psi of H<sub>2</sub> at 65 °C for 48 h. TLC (petroleum ether/EtOAc, 1:1) showed the starting material was consumed completely; the reaction mixture was filtered and the filter cake was washed with warm MeOH and water (v/v 1:1,500 mL × 2). The combined filtrate was evaporated to give <b>40</b> (190 g, 90%) as a white solid.</div></div><div id="sec4_14_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step 9: 1-((3a<i>R</i>,7a<i>R</i>)-1-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)tetrahydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-6(2<i>H</i>,7<i>H</i>,7a<i>H</i>)-yl)prop-2-en-1-one (<b>7</b>)</h4><div class="NLM_p last">To a solution of <b>40</b> (150 g, 0.54 mol) in aq NaHCO<sub>3</sub> (150 g, 1.79 mol) in H<sub>2</sub>O (1.5 L) at 0 °C was added dropwise a solution of acryloyl chloride (53.3 g, 0.59 mol) in MeCN (150 mL) carefully. After the addition, the resulting mixture was stirred at room temperature for 2 h. TLC (DCM/MeOH, 5:1) showed <b>40</b> was consumed completely. The reaction mixture was extracted with DCM (500 mL × 4), and the combined organic layers were concentrated to give the crude product, which was purified by column chromatography to give <b>7</b> (130 g, 81%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.58 (s, 1H) 8.09–8.07 (d, <i>J</i> = 9.2 Hz, 1H) 7.115(s, 1H), 6.82–6.78 (m, 1H), 6.51 (m, 1H), 6.05–6.01 (m, 1H), 5.69–5.85 (m, 1H), 4.69–4.68 (m, 0.5H), 4.27 (s, 1H), 3.90–3.74 (m,3H), 3.13–3.24 (m, 2H), 2.74–2.71 (m, 0.5H), 2.19–1.74 (m, 4.5 H).</div></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Synthesis of 1-((3a<i>R</i>,7a<i>R</i>)-1-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)octahydro-6<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-6-yl)ethan-1-one (<b>8</b>)</h3><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 1: 1-((3a<i>R</i>,7a<i>R</i>)-1-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)octahydro-6<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-6-yl)ethan-1-one (<b>8</b>)</h4><div class="NLM_p last">To a solution of <b>40</b> (70 mg, 0.22 mmol) in DCM at 0 °C was added DIPEA (0.20 mL, 1.1 mmol) followed by addition of a solution of acetyl chloride (16 μL in 10.0 mL of DCM) . The resulting mixture was stirred at room temperature for 2 h. TLC (DCM/MeOH, 5:1) showed <b>40</b> was consumed completely. The reaction mixture was diluted with water (30 mL) and DCM (25 mL). The pH was adjusted to ∼5 with 1 N HCL. The layers were separated, and the aqueous mixture was extracted with DCM (10 mL × 3). The combined organic layers were concentrated to give the crude product, which was purified by column chromatography to give <b>8</b> (46.6 mg, 74%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.59 (d, <i>J</i> = 14.83 Hz, 1 H) 7.88–8.40 (m, 1 H) 7.13 (br s, 1 H) 6.58 (br s, 1 H) 4.66 (dd, <i>J</i> = 12.68, 5.66 Hz, 0.5 H) 4.17–4.47 (m, 1 H) 3.37–4.10 (m, 4 H) 3.26 (t, <i>J</i> = 11.51 Hz, 1 H) 2.63 (t, <i>J</i> = 11.71 Hz, 1 H) 1.49–2.30 (m, 7.5 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 168.0, 151.2, 151.0, 121.0, 120.9, 100.7, 59.7, 54.9, 47.0, 45.1, 41.8, 25.7, 24.8, 21.1, 20.9; LC–MS (ESI) <i>m</i>/<i>z</i> 286.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Synthesis of (<i>R</i>,<i>E</i>)-1-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-yl)but-2-en-1-one (<b>9</b>)</h3><div class="NLM_p last">To a round-bottom flask containing <b>26</b> (300 mg, 1.03 mmol) were added DCM (10 mL), EtOH (1 mL), and TEA (0.634 mL, 4.4 equiv). After 30 min, (<i>E</i>)-but-2-enoyl chloride in 5 mL of DCM was added dropwise and the reaction stirred at rt for 2 h. The mixture was poured into water, and the layers were separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed to give crude product (∼295 mg). The material was purified by chromatography (silica, DCM/MeOH) to give <b>9</b> (38%). LC–MS (ESI) <i>m</i>/<i>z</i> 286.18 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.51 (br s, 1 H) 8.14 (d, <i>J</i> = 13.27 Hz, 1 H) 6.96–7.36 (m, 2 H) 6.29–6.84 (m, 3 H) 4.54 (br s, 1 H) 4.10 (dd, <i>J</i> = 10.15, 4.68 Hz, 4 H) 2.78–3.27 (m, 3 H) 2.62 (br s, 1 H) 1.35–2.24 (m, 9 H).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Synthesis of <i>rac</i>-1-((2<i>R</i>,3<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>10</b>)</h3><div id="sec4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 1: <i>rac</i>-Benzyl (2<i>R</i>,3<i>R</i>)-2-Methyl-3-((7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidine-1-carboxylate (<b>43</b>)</h4><div class="NLM_p last">To a round-bottom flask containing 4-iodo-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>41</b> (510 mg, 2.05 mmol, CAS no. 906092-45-3, WO 2007/117494 A1 20071018) in <i>n</i>-BuOH (6.8 mL) were added DIPEA (2.8 mL, 16 mmol) and <i>rac</i>-benzyl (2<i>S</i>,3<i>S</i>)-3-amino-2-methylpiperidine-1-carboxylate <b>42</b> (896 mg, 2.24 mmol, 1.1 equiv, CAS no. 912451-60-6, WO 2008132500 A2 20081106). The reaction mixture was heated to 85 °C for 18 h and then allowed to cool to room temperature. The solvent was removed in vacuo and the residue purified by chromatography (silica, ethyl acetate/heptane, 10–60%) to give <b>43</b> as foam (382 mg, 36%). LC–MS (ESI) <i>m</i>/<i>z</i> 519.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.43 (s, 1 H) 8.07 (d, <i>J</i> = 8.20 Hz, 2 H) 7.45 (d, <i>J</i> = 3.12 Hz, 1 H) 7.28–7.41 (m, 8 H) 6.44 (d, <i>J</i> = 3.51 Hz, 1 H) 5.08–5.29 (m, 2 H) 4.85–4.98 (m, 1 H) 4.78 (br s, 1 H) 4.00–4.11 (m, 1 H) 2.74–2.95 (m, 1 H) 2.4 (s, 3 H) 1.82–1.92 (m, 1 H) 1.72–1.81 (m, 1 H) 1.57–1.69 (m, 1 H) 1.19–1.35 (m, 1 H) 1.09 (d, <i>J</i> = 6.83 Hz, 3 H).</div></div><div id="sec4_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step 2. <i>rac</i>-Benzyl (2<i>R</i>,3<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidine-1-carboxylate (<b>44</b>)</h4><div class="NLM_p last">To a round-bottom flask containing <b>43</b> (374 mg, 0.72 mmol) in MeOH/H<sub>2</sub>O (5.5 mL:2.0 mL) was added LiOH·H<sub>2</sub>O (51 mg, 2.1 mmol). The reaction mixture was stirred at 60 °C for 1.5 h and then cooled to room temperature. The reaction mixture was diluted with water (30 mL)/CH<sub>2</sub>Cl<sub>2</sub> (25 mL) and the pH adjusted to ∼5 with 1 M HCl. The layers were separated, and the aqueous solution was extracted with DCM (15 mL × 3). The organic extracts were combined and washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed to give the product <b>44</b> (241 mg, 91%). LC–MS (ESI) <i>m</i>/<i>z</i> 365.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 10.00 (br s, 1 H) 8.34 (s, 1 H) 7.30–7.45 (m, 5 H) 7.05 (br s, 1 H) 6.41 (br s, 1 H) 5.11–5.26 (m, 2 H) 4.95–5.08 (m, 1 H) 4.11 (d, <i>J</i> = 12.49 Hz, 1 H) 2.95–2.88 (m, 1 H) 1.89–2.00 (m, 1 H) 1.60–1.85 (m, 5 H) 1.16 (d, <i>J</i> = 8 Hz, 3 H).</div></div><div id="sec4_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 3: <i>N</i>-((2<i>R</i>,3<i>R</i>)-2-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>45</b>)</h4><div class="NLM_p last">To a solution of <b>44</b> (241 mg, 0.66 mmol) in MeOH (12 mL) was added Pd(OH)<sub>2</sub> (352 mg, 0.50 mmol) and cyclohexadiene (2.3 g, 2.65 mL, 28 mmol, 40 equiv). The reaction mixture was heated to reflux for 14 h and then cooled to room temperature. The reaction was then filtered through Celite and the filtrate concentrated under reduced pressure to give an oil, which after chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH (2% in DCM)) gave the desired product <b>45</b> (79.6 mg, 52%). LC–MS (ESI) <i>m</i>/<i>z</i> 232.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.47 (br s, 1 H) 8.08 (s, 1 H) 7.08 (br s, 1 H) 6.35–6.82 (m, 2 H) 4.31 (br s, 1 H) 2.80–3.02 (m, 2 H) 2.56–2.69 (m, 2 H) 1.88 (br s, 1 H) 1.60 (br s, 2 H) 1.35 (br s, 1 H) 0.96 (d, <i>J</i> = 6.63 Hz, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 156.0, 151.4, 150.2, 120.7, 102.5, 98.5, 53.5, 47.9, 45.5, 29.3, 21.2, 18.1. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>12</sub>H<sub>17</sub>N<sub>5</sub> [M + H]<sup>+</sup> 232.1562; observed 232.1556.</div></div><div id="sec4_18_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 4: <i>rac</i>-1-((2<i>R</i>,3<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>10</b>)</h4><div class="NLM_p last">To a vial containing <b>45</b> (35 mg, 0.15 mmol) were added DCM (1.5 mL) and DIPEA (0.13 mL, 0.74 mmol). The mixture was cooled to 0 °C, and a solution of acryloyl chloride (15 uL (0.18 mmol) in 0.7 mL of DCM) was added dropwise. The mixture was stirred at 0 °C for 2 h and then diluted with water (25 mL) and DCM (20 mL). The pH was adjusted to a pH ≈ 5 with 1 M HCl, and the layers were separated. The aqueous solution was extracted with DCM (10 mL × 3). The organic extracts were combined, dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed to give an oil, which was treated with ethyl acetate/heptane to precipitate the desired product <b>10</b> as a solid (31 mg, 71%). LC–MS (ESI) <i>m</i>/<i>z</i> 286.4 [M + H]<sup>+</sup>. Mixture of rotamers, <sup>1</sup>H NMR at 300 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.56 (br s, 1 H) 8.16 (d, <i>J</i> = 10.51 Hz, 1 H) 7.23–7.49 (m, 1 H) 7.13 (br s, 1 H) 6.76–6.91 (m, 1 H) 6.71 (br s, 1 H) 6.00–6.27 (m, 1 H) 5.61–5.83 (m, 1 H) 5.15 (br s, 0.5 H) 4.78 (br s, 1 H) 4.15–4.45 (m, 2 H) 3.91–3.93 (m, 0.5 H) 3.06–3.23 (m, 0.5 H) 2.74–2.89 (m, 0.5 H) 1.71–2.00 (m, 3 H) 1.05–1.22 (m, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.8,164.6, 155.1, 151.3, 150.2, 129.34, 128.7, 126.9, 126.7, 120.9, 102.4, 98.8, 50.3, 49.7, 48.9, 45.7, 35.1, 25.2, 24.5, 24.4, 24.1, 11.0, 10.3, 9.9. <sup>1</sup>H NMR at 313 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.46 (br s, 1 H) 8.11 (br s, 1 H) 7.00–7.37 (m, 2 H) 6.58–6.90 (m, 2 H) 6.11 (br s, 1 H) 5.68 (br s, 1 H) 5.11 (br s, 0.5 H) 4.47–4.84 (m, 0.5 H) 4.10–4.44 (m, 1.5 H) 3.75–3.97 (m, 0.5 H) 3.08 (m, 0.5 H) 2.76 (m, 0.5 H) 1.66–2.02 (m, 3 H) 1.39–1.60 (m, 1 H) 0.93–1.20 (m, 3 H). <sup>1</sup>H NMR at 353 K (peaks coalesce): <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.31 (br s, 1 H) 8.12 (s, 1 H) 6.92–7.15 (m, 2 H) 6.55–6.82 (m, 2 H) 6.08 (dd, <i>J</i> = 16.87, 1.71 Hz, 1 H) 5.66 (dd, <i>J</i> = 10.64, 2.08 Hz, 1 H) 4.93 (br s, 1 H) 4.05–4.36 (m, 2 H) 2.80–3.01 (m, 1 H) 1.65–2.03 (m, 3 H) 1.40–1.62 (m, 1 H) 0.93–1.22 (m, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.6, 155.0, 151.0, 150.2, 125.7, 120.4, 102.3, 98.4, 24.1. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>15</sub>H<sub>19</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 286.1668; observed 286.1665.</div></div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Synthesis of 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>11</b>) and 1-((2<i>R</i>,5<i>S</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>12</b>)</h3><div id="sec4_19_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 1: <i>tert</i>-Butyl (6-Methylpyridin-3-yl)carbamate (<b>47</b>)</h4><div class="NLM_p last">To a solution of 6-methylpyridin-3-amine <b>46</b> (25 g, 231. mmol)) in EtOH (100 mL) at 0 °C was added (Boc)<sub>2</sub>O (55.5 g, 298 mmol) dropwise slowly. After the addition, the solution was stirred at room temperature overnight. TLC (petroleum ether/EtOAc, 2:1) showed 6-methylpyridin-3-amine was consumed completely. The reaction mixture was filtered, and the filter cake was washed with EtOH (30 mL × 3). The combined filtrate was concentrated in vacuo to afford a yellow residual, which was purified by chromatography (petroleum ether/EtOAc, 4:1 to 1:1) to give <b>47</b> (32.5 g, 67.4%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.41 (br s, 1 H) 8.47 (s, 1 H) 7.74 (d, <i>J</i> = 8.3 Hz, 1 H) 7.13 (d, <i>J</i> = 8.3 Hz, 1 H) 2.37 (s, 3 H) 1.47 (s, 9 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 152.8, 151.1, 139.2, 133.6, 125.6, 122.6, 79.4, 28.0, 23.2. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>11</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 209.1290; observed 209.1285.</div></div><div id="sec4_19_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Step 2: <i>tert</i>-Butyl (6-Methylpiperidin-3-yl)carbamate (<b>48</b>)</h4><div class="NLM_p last">To a dry hydrogenation bottle, PtO<sub>2</sub> (2.5 g) was added under Ar atmosphere. Then a solution of <b>47</b> (33 g, 158.5 mmol) in HOAc (300 mL) was added, and the resulting mixture was hydrogenated under 55 psi of H<sub>2</sub> at 50 °C for 30 h. TLC (petroleum ether/EtOAc, 2:1) showed the starting material was consumed completely. The reaction mixture was filtered, and the filter cake was washed with MeOH (50 mL × 2). The combined filtrate was evaporated to give <b>48</b> (34 g, 100%) as a yellow oil (∼2:1 cis/trans), which was used directly in the next step without further purification. LC–MS (ESI) <i>m</i>/<i>z</i> 215.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 6.49–6.77 (m, 1 H) 3.48 (br s, 1 H) 3.26 (br s 0.5 H) 2.98 (d, <i>J</i> = 11.00 Hz, 0.5 H) 2.66–2.85 (m, 2 H) 2.40–2.51 (m, 0.5 H) 2.27 (t, <i>J</i> = 11.00 Hz, 0.5 H) 1.49–1.85 (m, 3 H) 1.38–1.49 (m, 9 H) 1.20–1.35 (m, 2 H) 0.93–1.16 (m, 3 H).</div></div><div id="sec4_19_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Step 3: <i>rac</i>-<i>cis</i>/<i>trans</i>-Benzyl 5-((<i>tert</i>-Butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate (<b>49</b>)</h4><div class="NLM_p last">To a stirred solution of <b>48</b> (27.0 g, 126 mmol) and NaHCO<sub>3</sub> (74.2 g, 883 mmol) in THF (350 mL)/H<sub>2</sub>O (350 mL) was added CbzCl (32.17 g, 189 mmol) dropwise at room temperature. After the addition, the resulting mixture was stirred at room temperature for 2 h. TLC (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) showed the starting material was consumed completely. The reaction mixture was extracted with EtOAc (300 mL × 2). The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give crude product. The crude product was purified by chromatography (petroleum ether/ethyl acetate, 30:1 to 10:1) to give <b>49</b> (44.0 g, 100%, ∼2:1 cis/trans) as a colorless oil. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.29–7.44 (m, 7 H) 6.78–6.97 (m, 1 H) 5.00–5.12 (m, 2 H) 4.50 (d, <i>J</i> = 5.62 Hz, 0.3 H) 4.22–4.36 (m, 1.2 H) 3.95 (d, <i>J</i> = 12.96 Hz, 1.2 H) 3.57 (br s, 0.2 H) 3.22 (br s, 0.8 H) 3.02 (dd, <i>J</i> = 13.82, 2.32 Hz, 0.3 H) 2.55–2.67 (m, 0.8 H) 1.95–2.06 (m, 0.3 H) 1.75–1.87 (m, 0.3 H) 1.45–1.68 (m, 4 H) 1.31–1.44 (m, 11 H) 1.18–1.29 (m, 0.5 H) 1.02–1.14 (m, 4 H).</div></div><div id="sec4_19_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 4: <i>rac</i>-Benzyl (2<i>S</i>,5<i>R</i>)-5-((<i>tert</i>-Butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate (<b>50a</b>) and <i>rac</i>-Benzyl (2<i>S</i>,5<i>S</i>)-5-((<i>tert</i>-Butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate (<b>50b</b>)</h4><div class="NLM_p last">The <i>rac</i>-<i>cis</i>/<i>trans</i>-benzyl 5-((<i>tert</i>-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate <b>49</b> (44 g) was separated by chiral SFC to give <i>rac</i>-<i>trans</i>-benzyl (2<i>R</i>,5<i>R</i>)-5-((<i>tert</i>-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate <b>50a</b> (peak 1, 12.3 g, 27.95%) and <i>rac</i>-<i>cis</i>-<i>benzyl</i> (2<i>S</i>,5<i>R</i>)-5-((<i>tert</i>-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate <b>50b</b> (peak 2, 24.5 g, 55.68%). Peak 2, cis material <b>50b</b> (as determined by <sup>1</sup>H NMR spectra) was carried on to Boc removal. Prep SFC column: ChiralCel OD 300 mm × 50 mm, 10 μm. Mobile phase: A, supercritical CO<sub>2</sub>; B, IPA (0.1% NH<sub>3</sub>H<sub>2</sub>O), A:B = 85:15 at 180 mL/min. Column temp: 38 °C. Nozzle pressure: 100 bar. Nozzle temp: 60 °C. Evaporator temp: 20 °C. Trimmer temp: 25 °C. Wavelength: 220 nm. <b>50a</b>: trans isomer (pk1), <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.29–7.40 (m, 5 H) 5.09–5.19 (m, 2 H) 4.88 (br s, 1 H) 4.47 (br s, 1 H) 4.05 (d, <i>J</i> = 14.18 Hz, 1 H) 3.81 (br s, 1 H) 3.11 (d, <i>J</i> = 13.45 Hz, 1 H) 1.65–1.92 (m, 3 H) 1.34–1.48 (m, 10 H) 1.17 (d, <i>J</i> = 6.85 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 156.0, 155.1, 136.7, 128.5, 128.0, 127.7, 79.3, 67.1, 46.2, 44.7, 42.8, 28.4, 24.5, 23.1, 15.4. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>19</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub> [M + Na]<sup>+</sup> 371.1947; observed 371.1943. <b>50b</b>: cis-isomer (pk2), <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.30–7.44 (m, 5 H) 5.01–5.24 (m, 2 H) 4.43–4.58 (m, 1 H) 4.38 (br s, 1 H) 4.26 (d, <i>J</i> = 10.03 Hz, 1 H) 3.48 (br s, 1 H) 2.58 (t, <i>J</i> = 12.10 Hz, 1 H) 1.88 (d, <i>J</i> = 10.03 Hz, 1 H) 1.77 (tt, <i>J</i> = 13.66, 4.68 Hz, 1 H) 1.53–1.65 (m, 2 H) 1.44 (s, 9 H) 1.14 (d, <i>J</i> = 7.09 Hz, 3 H); <sup>13</sup>C NMR (125 MHz,) δ ppm 155.1, 155.0, 136.8, 128.5, 127.9, 127.8, 79.5, 67.1, 45.3, 43.6, 28.9, 28.3, 26.0, 22.7, 15.4. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>19</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub> [M + Na]<sup>+</sup> 371.1947; observed 371.1945.</div></div><div id="sec4_19_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Step 5. <i>rac</i>-Benzyl (2<i>S</i>,5<i>S</i>)-5-Amino-2-methylpiperidine-1-carboxylate (<b>51a</b>) and Benzyl (2<i>S</i>,5<i>R</i>)-5-Amino-2-methylpiperidine-1-carboxylate (<b>51b</b>)</h4><div class="NLM_p last">To a solution of <i>rac</i>-(2<i>S</i>,5<i>R</i>)-benzyl 5-((<i>tert</i>-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate <b>50b</b> (pk 2, 40.0 g, 115.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (60 mL) at 0 °C was added (4 M HCl (g)/dioxane (200 mL) dropwise. After the addition, the solution was stirred at room temperature for 4 h. TLC (petroleum ether/EtOAc, 2:1) showed the starting material was consumed completely. The reaction mixture was concentrated to give (31.0 g, 94.8%) <b>51b</b> as a white solid (HCl salt). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.21 (br s, 3 H) 7.21–7.46 (m, 5 H) 4.96–5.19 (m, 2 H) 4.25–4.46 (m, 1 H) 4.15 (dd, <i>J</i> = 12.35, 3.30 Hz, 1 H) 2.83–3.10 (m, 2 H) 1.87–1.80 (m, 1 H) 1.49–1.76 (m, 3 H) 1.11 (d, <i>J</i> = 6.85 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 154.2, 136.7, 128.4, 127.9, 127.6, 66.4, 46.7, 45.1, 40.2, 27.6, 22.6, 15.1. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>14</sub>H<sub>20</sub>N<sub>2</sub> O<sub>2</sub> [M + Na]<sup>+</sup> 271.1422; observed 271.1414. Similarly the trans-isomer (<b>50a</b>) was treated with 4 N HCl/diox to give <b>51a</b> (94%). Trans (<b>51a</b>): <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.18 (br s, 3 H) 7.04–7.54 (m, 5 H) 4.90–5.17 (m, 2 H) 4.36–4.30 (m,, 1 H) 3.99 (d, <i>J</i> = 14.67 Hz, 1 H) 3.39 (br s, 1 H) 3.23 (dd, <i>J</i> = 14.55, 2.57 Hz, 1 H) 1.85–2.03 (m, 2 H) 1.77–1.70 (m, 1 H) 1.30–1.47 (m, 1 H) 1.11 (d, <i>J</i> = 6.85 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 154.9, 136.7, 128.4, 127.8, 127.5, 66.4, 45.8, 44.7, 22.8, 20.6, 15.3. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 249.1603; observed 249.1598.</div></div><div id="sec4_19_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Step 6: <i>rac</i>-(2<i>S</i>,5<i>R</i>)-Benzyl 5-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidine-1-carboxylate (<b>52</b>)</h4><div class="NLM_p last">A mixture of <b>27</b> (21.8 g, 0.116 mol), DIPEA (67.7 g, 0.525 mol), and racemic <i>cis</i>-(2<i>S</i>,5<i>R</i>)-benzyl 5-amino-2-methylpiperidine-1-carboxylate <b>51b</b> (30 g, 0.105 mol) in <i>n</i>-BuOH (300 mL) was heated to 140 °C overnight. LC–MS indicated the reaction was completed. The reaction mixture was cooled to room temperature and evaporated to dryness; the residue was partitioned with EtOAc (500 mL) and water (500 mL). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give crude product, which was triturated with MTBE to give (36 g, 86%) <b>52</b> as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.70 (br s, 1 H) 7.71 (d, <i>J</i> = 7.83 Hz, 1 H) 7.26–7.48 (m, 5 H) 7.10 (s, 1 H) 6.56 (s, 1 H) 4.93–5.20 (m, 2 H) 4.39 (br s, 1 H) 3.91–4.26 (m, 2 H) 3.18 (d, <i>J</i> = 5.14 Hz, 1 H) 2.77 (br s, 1 H) 1.54–1.91 (m, 4 H) 1.17 (d, <i>J</i> = 7.09 Hz, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 156.1, 152.5, 150.8, 136.9, 128.4, 127.8, 127.4, 121.6, 101.2, 98.9, 66.2, 48.6, 42.5, 28.5, 24.5. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>20</sub>H<sub>22</sub>ClN<sub>5</sub> O<sub>2</sub> [M + H]<sup>+</sup> 400.1540; observed 400.1535.</div></div><div id="sec4_19_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 7: <i>rac</i> -<i>N</i>-((3<i>R</i>,6<i>S</i>)-6-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>53</b>)</h4><div class="NLM_p last">To a dry hydrogenation bottle, 10% dry Pd/C (7 g) was added under Ar atmosphere. Subsequently, a solution of <b>52</b> (36 g, 0.09 mol) in MeOH (1500 mL) and THF (250 mL) was added and the resulting mixture was shaken on a Parr apparatus (45 psi of H<sub>2</sub> at 25 °C for 48 h). LC–MS indicated the Cbz was removed completely, but ∼30% of chloride remained. The reaction mixture was filtered, and the filtrate was subjected to the reaction conditions again with 5 g of 10% dry Pd/C under 50 psi of H<sub>2</sub> at 45 °C for 12 h. LC–MS showed the reaction was completed. The reaction mixture was filtered through a pad of Celite, and the cake was washed with MeOH three times. The combined filtrates were concentrated to give <b>53</b> (23 g, 94.6%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.47 (br s, 1 H) 8.08 (s, 1 H) 7.08 (d, <i>J</i> = 2.69 Hz, 1 H) 6.85 (d, <i>J</i> = 7.34 Hz, 1 H) 6.65 (br s, 1 H) 4.03–4.25 (m, 1 H) 2.95 (d, <i>J</i> = 12.47 Hz, 1 H) 2.82 (dd, <i>J</i> = 12.72, 2.69 Hz, 1 H) 2.56–2.66 (m, 1 H) 2.04 (br s, 1 H) 1.86–1.97 (m, 1 H) 1.63 (tt, <i>J</i> = 12.72, 3.91 Hz, 1 H) 1.40–1.49 (m, 1 H) 1.24–1.39 (m, 1 H) 1.04 (d, <i>J</i> = 6.36 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 155.4, 151.9, 150.2, 120.7, 102.4, 98.7, 50.7, 49.4, 44.3, 29.5, 28.2, 21.8. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>12</sub>H<sub>17</sub>N<sub>5</sub> [M + H]+ 232.1562; observed 232.1558.</div></div><div id="sec4_19_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Step 8: <i>rac</i>-1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>54</b>)</h4><div class="NLM_p last">To a stirred solution of HCl salt <b>53</b> (5.00 g, 18.5 mmol) in THF (250 mL) and saturated aq NaHCO<sub>3</sub> solution (250 mL) was added acryloyl chloride (2.02 g, 22.2 mmol) dropwise at 0 °C carefully. After addition, the resulting mixture was stirred at 0 °C for 4 h. TLC (DCM/MeOH/NH<sub>4</sub>OH, 10:1:1) showed <b>53</b> was consumed completely. The reaction mixture was diluted with H<sub>2</sub>O (125 mL) and extracted with EtOAc (125 mL × 3). The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The most volatile components were removed in vacuo. The crude product was purified by column chromatography on silica gel (DCM/MeOH, 10:1) to give pure product. The product was triturated with EtOAc (150 mL) and filtered to give <b>54</b> (2.0 g, 38% yield) as a white solid. Rotamers observed. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.52 (br s, 1 H) 8.11 (d, <i>J</i> = 15.65 Hz, 1 H) 7.22–7.37 (m, 1 H) 7.05–7.15 (m, 1 H) 6.72–6.90 (m, 1 H) 6.55 (br s, 1 H) 6.10 (dd, <i>J</i> = 16.75, 2.08 Hz, 1 H) 5.68 (dd, <i>J</i> = 10.51, 1.71 Hz, 1 H) 4.81 (br s, 0.5 H) 4.56 (d, <i>J</i> = 10.03 Hz, 0.5 H) 4.38 (br s, 0.5 H) 3.96–4.20 (m, 1.5 H) 2.96 (t, <i>J</i> = 11.86 Hz, 0.5 H) 2.56–2.68 (m, 0.5 H) 1.60–1.91 (m, 4 H) 1.09–1.30 (m, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.8, 164.5, 155.3, 151.4, 150.3, 129.0, 127.0, 121.0, 102.5, 98.5, 47.6, 46.9, 46.4, 44.4, 42.7, 40.4, 29.4, 28.5, 25.1, 16.5, 15.2. <sup>1</sup>H NMR at 353 K: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.31 (br s, 1 H) 8.12 (s, 1 H) 6.95–7.22 (m, 2 H) 6.76 (dd, <i>J</i> = 16.75, 10.64 Hz, 1 H) 6.56 (dd, <i>J</i> = 3.18, 1.71 Hz, 1 H) 6.08 (dd, <i>J</i> = 16.87, 2.45 Hz, 1 H) 5.66 (dd, <i>J</i> = 10.64, 2.32 Hz, 1 H) 3.93–4.21 (m, 1 H) 3.10 (s, 3 H) 1.56–2.00 (m, 4 H) 1.22 (d, <i>J</i> = 6.85 Hz, 3 H). <sup>13</sup>C NMR at 353 K: <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 164.5, 155.2, 151.0, 150.2, 128.9, 125.9, 120.5, 102.3, 98.1, 46.9, 28.7, 24.9, 15.4. HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>15</sub>H<sub>19</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 286.1668; observed 286.1664.</div></div><div id="sec4_19_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Step 9: (+)-1-((2<i>R</i>,5<i>S</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>13</b>) and (−)-1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>11</b>)</h4><div class="NLM_p last">Compound <b>54</b> was purified by chiral SFC to give pure enantiomers. Peak 1, <i>t</i><sub>R</sub> = 7.81 min (4.63 g, +) <b>13</b> and peak 2, <i>t</i><sub>R</sub> = 8.45 min, (4.42 g, −) <b>11</b> SFC conditions. Column: ChiralPak IC (300 mm × 50 mm, 10 μm). Mobile phase: 40% ethanol (0.05% NH<sub>3</sub> in H<sub>2</sub>O) in CO<sub>2</sub>. Flow rate: 200 mL/min. Wavelength: 220 nm. The absolute stereochemistry was assigned based on X-ray crystallographic analysis with protein (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf" class="ext-link">Supporting Information</a>). <b>13</b>: peak 1, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.52 (br s, 1 H) 8.11 (d, <i>J</i> = 15.65 Hz, 1 H) 7.22–7.37 (m, 1 H) 7.05–7.15 (m, 1 H) 6.72–6.90 (m, 1 H) 6.55 (br s, 1 H) 6.10 (dd, <i>J</i> = 16.75, 2.08 Hz, 1 H) 5.68 (dd, <i>J</i> = 10.51, 1.71 Hz, 1 H) 4.81 (br s, 0.5 H) 4.56 (d, <i>J</i> = 10.03 Hz, 0.5 H) 4.38 (br s, 0.5 H) 3.96–4.20 (m, 1.5 H) 2.96 (t, <i>J</i> = 11.86 Hz, 0.5 H) 2.56–2.68 (m, 0.5 H) 1.60–1.91 (m, 4 H) 1.09–1.30 (m, 3 H). LC–MS (ESI) <i>m</i>/<i>z</i> 286.2 [M + H]<sup>+</sup>; [α]<sub>D</sub><sup>20</sup> +0.34 (<i>c</i> 0.6, MeOH). HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>15</sub>H<sub>19</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 286.1668; observed 286.1625. <b>11</b>: peak 2, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.52 (br s, 1 H) 8.11 (d, <i>J</i> = 15.65 Hz, 1 H) 7.22–7.37 (m, 1 H) 7.05–7.15 (m, 1 H) 6.72–6.90 (m, 1 H) 6.55 (br s, 1 H) 6.10 (dd, <i>J</i> = 16.75, 2.08 Hz, 1 H) 5.68 (dd, <i>J</i> = 10.51, 1.71 Hz, 1 H) 4.81 (br s, 0.5 H) 4.56 (d, <i>J</i> = 10.03 Hz, 0.5 H) 4.38 (br s, 0.5 H) 3.96–4.20 (m, 1.5 H) 2.96 (t, <i>J</i> = 11.86 Hz, 0.5 H) 2.56–2.68 (m, 0.5 H) 1.60–1.91 (m, 4 H) 1.09–1.30 (m, 3 H); LC–MS (ESI) <i>m</i>/<i>z</i> 286.2 [M + H]<sup>+</sup>; [α]<sub>D</sub><sup>20</sup> −0.36 (<i>c</i> 0.6, MeOH). HRMS (ESI) <i>m</i>/<i>z</i>: calculated for C<sub>15</sub>H<sub>19</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 286.1668; observed 286.1692.</div></div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Synthesis of 1-[(2<i>R</i>,5<i>R</i>)-2-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>12</b>) pk2 and 1-[(2<i>S</i>,5<i>S</i>)-2-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>14</b>) pk1</h3><div id="sec4_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Step 1: <i>rac</i>-(2<i>R</i>,5<i>R</i>)-Benzyl 5-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidine-1-carboxylate (<b>55</b>)</h4><div class="NLM_p last">A mixture of <b>27</b> (266.5 mg, 1.425 mmol), DIPEA (613 mg, 4.75 mmol), and <i>rac</i>-(2<i>R</i>,5<i>R</i>)-benzyl 5-amino-2-methylpiperidine-1-carboxylate <b>51a</b> (270 mg, 0.950 mmol) in <i>n</i>-BuOH (10 mL) was heated to 130 °C overnight. LC–MS indicated <b>51b</b> was consumed completely. The reaction mixture was cooled to room temperature and evaporated to dryness in vacuo and the residue purified by chromatography (silica, PE/EA, 12–100%) to give <b>55</b> (290 mg, 76.5%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.70 (br s, 1H), 7.57 (d, <i>J</i> = 5.8 Hz, 1H), 7.21–6.98 (m, 6H), 6.78 (br s, 1H), 5.04–4.92 (m,1H), 4.92–4.79 (m, 1H), 4.34 (br s, 1H), 4.29–4.14 (m, 2H), 3.19 (d, <i>J</i> = 12.3 Hz,1H), 2.27–2.12 (m, 1H), 2.08–1.95 (m, 1H), 1.66 (d, <i>J</i> = 11.5 Hz, 1H), 1.44–1.30 (m,1H), 1.22–1.10 (m, 3H).</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Step 2: <i>rac</i>-<i>N</i>-((3<i>R</i>,6<i>R</i>)-6-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>56</b>)</h4><div class="NLM_p last">To a Parr bottle, 10% Pd/C (100 mg) was added under Ar atmosphere. Then a solution of (2<i>R</i>,5<i>R</i>)-benzyl 5-((2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidine-1-carboxylate <b>55</b> (290 mg, 0.727 mmol) in MeOH (20 mL) was added and the resulting mixture was hydrogenated under 45 psi of H<sub>2</sub> at 25 °C for 18 h. After TLC (DCM/MeOH, 10:1) indicated the starting material to be consumed, the reaction mixture was filtered and the filter cake was washed with MeOH. The combined filtrate was evaporated to give <b>56</b> (180 mg, 100%) as a white solid.</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 3: <i>rac</i>-1-((2<i>R</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (<b>57</b>)</h4><div class="NLM_p last">To a stirred solution of <b>56</b> (130 mg, 0.563 mmol) in aq NaHCO<sub>3</sub> solution (1 mL) and THF (1 mL) at 0 °C was added acryloyl chloride (55.7 mg, 0.619 mmol) dropwise. After the addition, the resulting mixture was stirred at 0 °C for 3 h. TLC (CH<sub>2</sub>CI<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 10:1:1) indicated <b>56</b> was consumed completely. The reaction mixture was diluted with H<sub>2</sub>0 (5 mL) and extracted with EtOAc (5 mL × 4), and the combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give crude product, which was purified by prep TLC to give <b>57</b> (30 mg, 18.75%).</div></div><div id="sec4_20_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Step 4. 1-[(2<i>S</i>,5<i>S</i>)-2-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>14</b>) and 1-[(2<i>R</i>,5<i>R</i>)-2-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>12</b>)</h4><div class="NLM_p last">Compound <b>57</b> was purified by chiral SFC to give two peaks, with stereochemistry arbitrarily assigned: <b>14</b>, pk1 (5.1 mg), and <b>12</b>, pk2 (5.2 mg). SFC conditions: Column: ChiralPak IC 250 mm × 4.6 mm i.d., 5 pm. Mobile phase: ethanol (0.05% DEA) in CO<sub>2</sub> from 5% to 40%. Flow rate: 2.35 mL/min. Wavelength: 215 nm. <b>14</b>: pk1, LC–MS (ESI) <i>m</i>/<i>z</i> 286.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.15 (s, 1H), 7.06 (d, <i>J</i> = 3.5 Hz, 1H), 6.64 (d, <i>J</i> = 3.3 Hz, 1H), 6.28 (br s, 1H), 5.95 (br s, 1H), 5.34 (br s, 1H), 4.59 (br s, 1H), 4.38 (br s, 2H), 3.53–3.34 (m, 1H), 2.25–2.09 (m, 2H), 1.80 (br s, 1H), 1.57–1.45 (m,1H), 1.29 (d, <i>J</i> = 6.8 Hz, 3H). <b>12</b>: pk2, LC–MS (ESI) <i>m</i>/<i>z</i> 286.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.16 (s, 1H), 7.07 (d, <i>J</i> = 3.5 Hz, 1H), 6.65 (d, <i>J</i> = 3.3 Hz, 1H), 6.30 (br s, 1H), 5.96 (br s, 1H), 5.35 (br s,1H), 4.59 (s, 1H), 4.50–4.22 (m, 2H), 3.52–3.34 (m, 1H), 2.23–2.17 (m, 2H), 1.89–1.76 (m, 1H), 1.57–1.48 (m, 1H), 1.29 (s, 3H).</div></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Synthesis of 1-((3<i>R</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>15</b>) and 1-((3<i>S</i>,5<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>17</b>)</h3><div id="sec4_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Step 1: <i>tert</i>-Butyl (5-Methylpyridin-3-yl)carbamate (<b>59</b>)</h4><div class="NLM_p last">A solution of 5-methylpyridin-3-amine <b>58</b> (20 g, 185 mmol) and (Boc)<sub>2</sub>O (44.4 g, 203.5 mmol) in THF (360 mL) was stirred at room temperature for 5 h. TLC (PE/EtOAc, 1:1) indicated the reaction was complete. The reaction mixture was concentrated and triturated with MTBE to give <b>59</b> (26.4 g, 69%) as a white solid. <sup>1</sup>H NMR(400 MHz, CDCI<sub>3</sub>) δ 8.21 (d, <i>J</i> = 2.3 Hz, 1H), 8.15–8.10 (m, 1H), 7.88 (br s, 1H), 6.66 (br s, 1H), 2.33 (s, 3H), 1.53 (s, 9H).</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Step 2: <i>rac</i>-<i>cis</i>/<i>trans</i>-<i>tert</i>-Butyl (5-Methylpiperidin-3-yl)carbamate (<b>60</b>)</h4><div class="NLM_p last">To a dry hydrogenation bottle, PtO<sub>2</sub> (3.0 g) was added under N<sub>2</sub> atmosphere. A solution of compound <b>59</b> (26.4 g, 127 mmol) in HOAc (300 mL) was added, and the resulting mixture was heated to 50 °C under 55 psi of H<sub>2</sub> for 5 days. <sup>1</sup>H NMR indicated starting material was consumed. The reaction mixture was filtered, and the filter cake was washed with MeOH. The combined filtrate was evaporated under high vacuum to give <b>60</b> (27.3 g, 100%) as a yellow oil. LC–MS (ESI) <i>m</i>/<i>z</i> 214.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Step 3: <i>rac</i>-<i>cis</i>/<i>trans</i>-Benzyl 3-((<i>tert</i>-Butoxycarbonyl)amino)-5-methylpiperidine-1-carboxylate (<b>61</b>)</h4><div class="NLM_p last">To a solution of <b>60</b> (27.3 g, 127 mmol) in THF (200 mL) and H<sub>2</sub>0 (100 mL) was added NaHCO<sub>3</sub> (40.53 g, 482 mmol, 3.8 equiv) at room temperature, and the reaction was stirred at room temperature for 1 h. CbzCI (26 g, 152 mmol, 1.2 equiv) was added dropwise, and stirred at room temperature for 8 h. TLC (PE/EtOAc, 2:1) showed the reaction to be complete. The reaction mixture was extracted with EtOAc (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by column chromatography (PE/EtOAc, 8:1 to 4:1) to give <b>61</b> (20 g, 45%, containing some benzyl alcohol) as a white solid. LC–MS (ESI) 348.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Step 4: <i>rac</i>-<i>cis</i>/<i>trans</i>-Benzyl 3-Amino-5-methylpiperidine-1-carboxylate (<b>62</b>)</h4><div class="NLM_p last">To a solution of <b>61</b> (20 g, 57.4 mmol) in DCM (40 mL) was added 4 N HCI (g)/dioxane (50 mL) dropwise at room temperature, and the reaction stirred at room temperature for 6 h. LCMS showed the reaction to be complete. The reaction mixture was concentrated, filtered, and then triturated with MTBE to give <b>62</b> (5.8 g, 43%, 0.817 mol HCI) as a gray solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.43–7.27 (m, 5H), 5.14 (s, 2H), 4.50–4.39 (m, 1H), 4.12 (d, <i>J</i> = 10.3 Hz, 1H), 4.04–3.90 (m, 1H), 3.74–3.43 (m, 1H), 3.23–3.10 (m, 1H), 2.82–2.59 (m, 1H), 2.40 (s, 1H), 2.26–2.05 (m, 1H), 1.92 (d, J = 11.3 Hz, 1H), 1.78–1.58 (m, 1H), 1.30 (s, 1H), 1.25–1.05 (m, 2H), 1.01–0.93 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 248.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Step 5: <i>rac</i>-<i>cis</i>-(3<i>R</i>,5<i>S</i>)-Benzyl 3-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidine-1-carboxylate (<b>63</b>) and <i>rac</i>-<i>trans</i>-(3<i>R</i>,5<i>R</i>)-Benzyl 3-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidine-1-carboxylate (<b>64</b>)</h4><div class="NLM_p last">To a mixture of <b>62</b> (prepared similarly as described in WO201102904) (4 g, 14.046 mmol) and 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (2.9 g, 15.451 mmol, 1.1 equiv) in <i>n</i>-BuOH (70 mL) at room temperature was added DIPEA (7.248 g, 56.184 mmol, 4.0 equiv). The reaction mixture was heated to 140 °C for 30 h. After LCMS showed the reaction to be complete, the reaction mixture was concentrated to dryness in vacuo. The residue was dissolved in EtOAc (150 mL), and diluted with water (150 mL), and the organic layer was separated. The aqueous layer was extracted with EtOAc (150 mL × 2), and the combined organic layers were washed with brine, dried with sodium sulfate. The solvent was removed under reduced pressure. The residue was purified by column chromatography (PE/EtOAc, 6:1 to 2:1) to give <b>63</b> (rac-cis, spot 2 on the TLC plate, high polarity, 1.934 g, 34%) and <b>64</b> (rac-trans, spot 1 on the TLC plate, low polarity, 559 mg, 10%) as a yellow solid. <b>63</b>: pk2 (rac-cis), <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.70 (br s, 1H), 7.70 (d, <i>J</i> = 7.5 Hz, 1H), 7.45–7.24 (m, 5H), 7.09 (br s, 1H), 6.58 (br s, 1H), 5.21–5.01 (m, 2H), 4.33 (br s, 1H), 4.07–3.96 (m,2H), 3.17 (d, <i>J</i> = 5.3 Hz, 1H), 2.61–2.53 (m, 1H), 2.33 (br s, 1H), 2.06–1.94 (m, 1H),1.67 (br s, 1H), 1.29–1.13 (m, 1H), 0.91 (d, <i>J</i> = 6.5 Hz, 3H). <b>64</b>: pk1 (rac-trans), <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69 (br s, 1H), 7.63–6.59 (m, 8H), 5.05 (d, <i>J</i> = 16.8 Hz, 1H), 4.87 (br s, 1H), 4.35–3.95 (m,2H), 3.86–3.51 (m, 2H), 3.11–2.64 (m, 1H), 2.19 (br s, 1H), 1.90–1.72 (m, 2H),1.56 (br s, 1H), 0.91 (d, <i>J</i> = 6.5 Hz, 3H),</div></div><div id="sec4_21_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 6: <i>rac</i>-<i>cis</i>-<i>N</i>-((3<i>R</i>,5<i>S</i>)-5-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>65</b>)</h4><div class="NLM_p last">To a dry Parr hydrogenation bottle, dry Pd/C (500 mg) was added under N<sub>2</sub> atmosphere. Then, a solution of <b>63</b> (rac-cis, 1.934 g, 4.835 mmol) in CH<sub>3</sub>OH/THF (60 mL/20 mL) was added. The resulting mixture was heated to 40 °C under 50 psi of H<sub>2</sub> for 3 days. After LCMS showed the reaction to be complete and Cl atom was removed, the reaction mixture was filtered, and the filter cake was washed with MeOH. The combined filtrate was evaporated to give <b>65</b> (rac-cis, 1.4 g, 100%) as a pink solid. LC–MS (ESI) <i>m</i>/<i>z</i> 231.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Step 7: <i>rac</i>-<i>cis</i>-1-((3<i>R</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>66</b>)</h4><div class="NLM_p last">To a solution of <b>65</b> (400 mg, 1.49 mmol) in THF (20 mL) were added saturated aq NaHCO<sub>3</sub> (15 mL) at 0 °C and acryloyl chloride (149 mg, 1.64 mmol, 1.1 equiv) slowly. The reaction was stirred at 0 °C for 2 h. After TLC (EtOAc/MeOH, 10:1) showed the reaction to be complete, the reaction mixture was diluted with water (80 mL) and extracted with EtOAc (80 mL × 2). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash column chromatography (EtOAc/MeOH, 10:1) to give <b>66</b> (300 mg, 71%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.52 (br s, 1H), 8.10 (d, <i>J</i> = 14.3 Hz, 1H), 7.39–7.22 (m, 1H), 7.07 (br s, 1H), 6.94–6.78 (m, 1H), 6.56 (br s, 1H), 6.12 (dd, <i>J</i> = 8.9, 16.2 Hz, 1H), 5.69 (t, <i>J</i> = 10.4 Hz, 1H), 4.71 (d, <i>J</i> = 10.0 Hz, 1H), 4.47–4.29 (m, 1H), 4.03 (d, <i>J</i> = 11.0 Hz, 2H), 2.73 (t, <i>J</i> = 11.5 Hz, 1H), 2.58 (t, <i>J</i> = 12.3 Hz, 1H), 2.40–2.30 (m, 1H), 2.19 (t, <i>J</i> = 11.5 Hz, 1H), 2.05 (d, <i>J</i> = 11.8 Hz, 1H), 1.36–1.17 (m, 1H), 0.97–0.89 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Step 8: 1-((3<i>R</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>17</b>) and 1-((3<i>S</i>,5<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>15</b>)</h4><div class="NLM_p last">Compound <b>66</b> was separated by chiral SFC (AD, 250 mm × 30 mm, 20 μm, 35% MeOH/NH<sub>4</sub>OH, 80 mL/min) to give <b>17</b> (pk1, <i>t</i><sub>R</sub> = 7.81) and <b>15</b> (pk 2, <i>t</i><sub>R</sub> = 6.93 min). <b>17</b>: peak 1, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (br s, 1H), 8.10 (d, <i>J</i> = 14.3 Hz, 1H), 7.42–7.23 (m, 1H), 7.08 (br s, 1H), 6.86 (td, <i>J</i> = 11.4, 16.4 Hz, 1H), 6.57 (br s, 1H), 6.18–6.06 (m, 1H), 5.70 (t, <i>J</i> = 10.2 Hz, 1H), 4.71 (d, <i>J</i> = 9.8 Hz, 1H), 4.48–4.30 (m, 1H), 4.03 (d, <i>J</i> = 11.8 Hz, 1H), 2.79–2.54 (m, 1H), 2.42–2.14 (m, 1H), 2.06 (d, <i>J</i> = 12.5 Hz, 1H), 1.63 (br s, 1H), 1.39–1.17 (m, 1H), 0.99–0.87 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H]<sup>+</sup>. <b>15</b>: peak 2, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (br s, 1H), 8.10 (d, <i>J</i> = 14.6 Hz, 1H), 7.38–7.23 (m, 1H), 7.08 (br s, 1H), 6.94–6.79 (m, 1H), 6.56 (br s,1H), 6.12 (dd, <i>J</i> = 7.8, 16.8 Hz, 1H), 5.75–5.64 (m, 1H), 4.71 (d, <i>J</i> = 11.8 Hz, 1H), 4.49–4.30 (m, 1H), 4.03 (d, <i>J</i> = 11.5 Hz, 1H), 2.81–2.54 (m, 1H), 2.42–2.15 (m, 1H), 2.06 (d, <i>J</i> = 12.3 Hz, 1H), 1.62 (br s, 1H), 1.38–1.18 (m, 1H), 0.99–0.88 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Synthesis of 1-[(3<i>R</i>,5<i>R</i>)-3-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>16</b>) and 1-((3<i>S</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>18</b>)</h3><div id="sec4_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 1: <i>rac</i>-<i>N</i>-((3<i>S</i>,5<i>S</i>)-5-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>67</b>)</h4><div class="NLM_p last">To a dry hydrogenation bottle, Pd/C (200 mg) was added under N<sub>2</sub> atmosphere. Then, a solution of compound <b>64</b> (rac-trans, 559 mg, 1.398 mmol) in CH<sub>3</sub>OH/THF (30 mL/10 mL) was added, and the resulting mixture was heated to 40 °C under 50 psi of H<sub>2</sub> for 3 days. LC–MS showed the reaction was completed. The reaction mixture was filtered, and the filter cake was washed with MeOH. The combined filtrate was evaporated to give compound <b>67</b> (rac-trans, 413 mg, 100%) as a pink solid.</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Step 2: <i>rac</i>-1-((3<i>S</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>68</b>)</h4><div class="NLM_p last">To a solution of compound <b>67</b> (413 mg, 1.542 mmol) in THF (20 mL) was added saturated aq NaHCO<sub>3</sub> (15 mL) and acryloyl chloride (154 mg, 1.70 mmol, 1.1 equiv) at 0 °C. The reaction was stirred at 0 °C for 2 h. TLC (EtOAc/MeOH = 10:1) showed the reaction was completed. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash column chromatography (EtOAc/MeOH = 10:1) to give <b>68</b> (221 mg, 50%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.48 (br s, 1H), 8.30–8.04 (m, 1H), 7.13–6.96 (m, 2H), 6.83 (dd, <i>J</i> = 10.3, 16.8 Hz, 1H), 6.69–6.54 (m, 1H), 6.36 (dd, <i>J</i> = 10.5, 16.6 Hz, 1H), 6.08 (d, <i>J</i> = 17.8 Hz, 1H), 5.89 (d, <i>J</i> = 17.1 Hz, 1H), 5.66 (d, <i>J</i> = 8.8 Hz, 1H), 5.35 (d, <i>J</i> = 10.5 Hz, 1H), 4.47–4.20 (m, 1H), 4.04–3.84 (m, 2H), 3.61–3.37 (m, 2H), 2.88–2.75 (m, 1H), 2.15 (br s, 1H), 1.93–1.76 (m, 1H), 1.71–1.53 (m, 1H), 0.98–0.88 (m, 3H); LC–MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H].</div></div><div id="sec4_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Step 3: 1-[(3<i>R</i>,5<i>R</i>)-3-Methyl-5-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one (<b>16</b>) and 1-((3<i>S</i>,5<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-methylpiperidin-1-yl)prop-2-en-1-one (<b>18</b>)</h4><div class="NLM_p last">Compound <b>68</b> (150 mg) was separated by chiral SFC to give two peaks arbitrarily assigned: <b>16</b> (pk 1, <i>t</i><sub>R</sub> = 5.81 min, 60 mg, 80%) as a white solid and <b>18</b> (<i>t</i><sub>R</sub> = 6.29 min, pk 2, 60 mg, 80%) as a white solid. SFC conditions: ChiralPak AD (250 mm × 30 mm, 5 μm); 20% EtOH, NH<sub>4</sub>OH; 60 mL/min. <b>16</b>: pk 1, <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (br s, 1H), 8.19–8.07 (m, 1H), 7.06 (d, <i>J</i> = 6.0 Hz, 2H),6.84 (dd, <i>J</i> = 10.2, 16.4 Hz, 1H), 6.70–6.55 (m, 1H), 6.35 (dd, <i>J</i> = 10.4, 16.7 Hz, 1H),6.08 (d, <i>J</i> = 18.6 Hz, 1H), 5.88 (dd, <i>J</i> = 2.3, 16.8 Hz, 1H), 5.66 (d, <i>J</i> = 10.3 Hz, 1H), 5.35 (dd, <i>J</i> = 2.3, 10.5 Hz, 1H), 4.41–4.21 (m, 1H), 4.06–3.84 (m, 2H), 3.61–3.42 (m,1H), 2.85–2.75 (m, 1H), 2.15 (br s, 1H), 1.99–1.78 (m, 1H), 1.73–1.50 (m, 1H),1.23 (s, 1H), 1.00–0.86 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 286.1 [M + H]<sup>+</sup>. <b>18</b>: pk 2, <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 11.51 (br s, 1H), 8.19–8.05 (m, 1H), 7.06 (br s, 1H),6.84 (dd, <i>J</i> = 10.3, 16.8 Hz, 1H), 6.69–6.55 (m, 1H), 6.35 (dd, <i>J</i> = 10.5, 16.6 Hz, 1H),6.08 (d, <i>J</i> = 16.6 Hz, 1H), 5.88 (d, <i>J</i> = 15.1 Hz, 1H), 5.66 (d, <i>J</i> = 9.3 Hz, 1H), 5.35 (d, <i>J</i> = 10.0 Hz, 1H), 4.42–4.19 (m, 1H), 4.06–3.82 (m, 1H), 3.62–3.44 (m, 1H), 2.86–2.73 (m, 1H), 2.15 (br s, 1H), 1.96–1.77 (m, 1H), 1.72–1.53 (m, 1H), 1.23 (br s,1H), 1.01–0.64 (m, 3H). LC–MS (ESI) <i>m</i>/<i>z</i> 286.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Synthesis of 1-((3<i>R</i>,4<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidin-1-yl)prop-2-en-1-one (<b>19</b>) and 1-((3<i>S</i>,4<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidin-1-yl)prop-2-en-1-one (<b>20</b>)</h3><div id="sec4_23_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Step 1: <i>rac</i>-(3<i>R</i>,4<i>S</i>)-<i>tert</i>-Butyl 3-((2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidine-1-carboxylate (<b>70</b>)</h4><div class="NLM_p last">To a solution of <b>69</b> (prepared as described in WO2011029046) (500 mg, 2.33 mmol) and 2, 4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>38</b> (483 mg, 2.56 mmol, 1.1 equiv ) in <i>n</i>-BuOH (15 mL) was added DIPEA (903 mg, 6.99 mmol, 3.0 equiv) at room temperature, and the mixture was heated to 140 °C overnight. After LCMS indicated the reaction was complete, the reaction mixture was concentrated to dryness in vacuo. The residue was dissolved in EtOAc (50 mL) and diluted with water (50 mL). The layers were separated, the aqueous layer was extracted with EtOAc (50 mL × 2), and the combined organic layers were washed with brine, dried with sodium sulfate. The solvent was removed under reduced pressure. The residue was purified by column chromatography (EtOAc/PE = 8–50%) to give <b>70</b> (rac-trans, 563 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 11.92 (br s, 1H), 7.14 (br s, 1H), 6.46 (br s, 1H), 4.40 (d, <i>J</i> = 9.3 Hz, 1H), 4.08–3.65 (m, 2H), 2.98–2.63 (m, 2H), 1.90–1.60 (m, 3H), 1.52–1.38 (m, 1H), 1.48 (s, 9H), 1.11–1.05 (m, 3H).</div></div><div id="sec4_23_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Step 2: <i>rac</i>-(3<i>R</i>,4<i>S</i>)-<i>tert</i>-Butyl 3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidine-1-carboxylate (<b>71</b>)</h4><div class="NLM_p last">To a dry Parr hydrogenation bottle, dry Pd/C (100 mg) was added under N<sub>2</sub> atmosphere. A solution of <b>70</b> (560 mg, 1.531 mmol) in MeOH/THF (30 mL/10 mL) was added, and the resulting mixture was heated to 40 °C under 50 psi of H<sub>2</sub> for 2 days. After LCMS showed the reaction to be complete, the reaction mixture was filtered and the filter cake was washed with MeOH. The combined filtrate was evaporated to give <b>71</b> (520 mg, 93%) as a yellow solid. LC/MS (ESI) <i>m</i>/<i>z</i> 332.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Step 3: <i>rac</i>-<i>N</i>-((3<i>R</i>,4<i>S</i>)-4-Methylpiperidin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>72</b>)</h4><div class="NLM_p last">To a solution of <b>71</b> (520 mg, 1.531 mmol) in DCM (15 mL) at 0 °C was added 4.0 M HCI/dioxane (15 mL). The reaction mixture was allowed to warm to room temperature and stirred for 3 h. After LCMS indicated the reaction to be complete, the reaction mixture was concentrated to give <b>72</b> (410 mg, 100%) as a solid. LC/MS (ESI) <i>m</i>/<i>z</i> 232.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Step 4: <i>rac</i>-1-((3<i>R</i>,4<i>S)</i>-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidin-1-yl)prop-2-en-1-one (<b>73</b>)</h4><div class="NLM_p last">To a solution of <b>72</b> (410 mg, 1.530 mmol) in THF (20 mL) and saturated NaHCO<sub>3</sub> (15 mL) at 0 °C was added acryloyl chloride (152 mg, 1.683 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 2 h. After TLC (EtOAc/MeOH, 10:1) indicated the reaction to be complete, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash column chromatography (MeOH/EtOAc, 2–10%) and lyophilized to give <b>73</b> (150 mg, 34%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (br s, 1H), 8.08 (d, <i>J</i> = 15.1 Hz, 1H), 7.32–7.20 (m, 1H), 7.08 (br s, 1H), 6.81 (dt, <i>J</i> = 10.5, 17.3 Hz,1H), 6.59 (br s, 1H), 6.12 (d, <i>J</i> = 14.8 Hz, 1H), 5.69 (d, <i>J</i> = 10.3 Hz, 1H), 4.65–4.39 (m, 1H), 4.27–4.04 (m, 1H), 3.94–3.71 (m, 1H), 3.08–2.96 (m, 0.5H), 2.89–2.77 (m, 0.5H), 2.71–2.60 (m, 0.5H), 2.46–2.28 (m, 0.5H), 1.82 (d, <i>J</i> = 12.3 Hz, 2H), 1.29–1.12 (m, 1H), 0.94 (dd, <i>J</i> = 6.0, 12.3 Hz, 3H). LC/MS (ESI) <i>m</i>/<i>z</i> 286.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Step 5: 1-((3<i>R</i>,4<i>S</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidin-1-yl)prop-2-en-1-one (<b>19</b>) and 1-((3<i>S</i>,4<i>R</i>)-3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-methylpiperidin-1-yl)prop-2-en-1-one (<b>20</b>)</h4><div class="NLM_p last">Compound <b>73</b> (120 mg) was separated by chiral SFC (Chiral Pak-AD (250 mm × 30 mm, 5 μm), 30% EtOH (0.05% NH<sub>3</sub> in H<sub>2</sub>0) in CO<sub>2</sub>) to give a pair of enantiomers (peak 1, <i>t</i><sub>R</sub> = 4.93 min, 47.8 mg) and (peak 2, <i>t</i><sub>R</sub> = 5.64 min, 48.2 mg) as white solids, absolute stereochemistry arbitrarily assigned. <b>19</b>: peak 1 data, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (br s, 1H), 8.08 (d, <i>J</i> = 15.1 Hz, 1H), 7.32–7.20 (m, 1H), 7.08 (br s, 1H), 6.81 (dt, <i>J</i> = 10.5, 17.3 Hz, 1H), 6.59 (br s, 1H), 6.12 (d, <i>J</i> = 14.8 Hz, 1H), 5.69 (d, <i>J</i> = 10.3 Hz, 1H), 4.65–4.39 (m, 1H), 4.27—4.04 (m, 1H), 3.94–3.71 (m, 1H), 3.08–2.96 (m, 0.5H), 2.89–2.77 (m, 0.5H), 2.71—2.60 (m, 0.5H), 2.46–2.28 (m, 0.5H), 1.82 (d, <i>J</i> = 12.3 Hz, 2H), 1.29–1.12 (m, 1H), 0.94 (dd, <i>J</i> = 6.0, 12.3 Hz, 3H). LC/MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H]<sup>+</sup>. <b>20</b>: peak 2 data, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (br s, 1H), 8.08(d, <i>J</i> = 15.1 Hz, 1H), 7.32–7.20 (m, 1H), 7.08 (br s, 1H), 6.81 (dt, <i>J</i> = 10.5, 17.3 Hz, 1H), 6.59 (br s, 1H), 6.12 (d, <i>J</i> = 14.8 Hz, 1H), 5.69 (d, <i>J</i> = 10.3 Hz, 1H), 4.65–4.39 (m,1H), 4.27–4.04 (m, 1H), 3.94–3.71 (m, 1H), 3.08–2.96 (m, 0.5H), 2.89–2.77 (m,0.5H), 2.71–2.60 (m, 0.5H), 2.46–2.28 (m, 0.5H), 1.82 (d, <i>J</i> = 12.3 Hz, 2H), 1.29—1.12 (m, 1H), 0.94 (dd, <i>J</i> = 6.0, 12.3 Hz, 3H). LC/MS (ESI) <i>m</i>/<i>z</i> 285.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> X-ray Crystallography</h3><div class="NLM_p">Crystals of Jak3 were prepared as described previously.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Briefly, the Jak3 kinase domain, encompassing residues 812–1124 and including a 6× His tag, was purified in the presence of the pan-Jak inhibitor, CMP-6,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and crystallized as a complex under the reported conditions. To generate the desired complexes, Jak3/CMP-6 crystals were soaked for ∼24 h in the reservoir solution supplemented with 3 mM compound, resulting in full exchange of the bound CMP-6 for the compound of interest. Data for Jak3/compound <b>2</b> were collected at 100 K on a Rigaku FRE X-ray generator outfitted with a Saturn 944 CCD detector and processed with HKL2000.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Data for Jak3/compound <b>3</b> were collected at 100 K at the Life Sciences Collaborative Access Team Beamline 21-ID-D (Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA) and processed using HKL2000.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> All other data manipulations utilized the CCP4<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> suite of programs. For all data sets, a common test set of reflections corresponding to ∼5% of the total were used throughout refinement. All structures were solved by rigid body refinement in REFMAC<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> using a reference structure of Jak3 with all ligands and waters removed. Iterative rounds of refinement using AUTOBUSTER<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> were interspersed with manual model building in COOT.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The covalent linkage between the acrylamide and the sulfur of Cys 909 was refined and maintained to ideal geometry throughout the refinement process. Crystallographic data statistics and refinement results are detailed in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Authors will release the atomic coordinates and experimental data upon article publication.</div><div class="NLM_table-wrap" id="tbl7">Table 7<div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">compd</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>7</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB code</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTS">5TTS</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTV">5TTV</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTU">5TTU</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">(A) Data Collection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unit cell (Å)</td><td class="colsep0 rowsep0" align="left"><i>a</i> = 47.4</td><td class="colsep0 rowsep0" align="left"><i>a</i> = 46.6</td><td class="colsep0 rowsep0" align="left"><i>a</i> = 47.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>b</i> = 75.8</td><td class="colsep0 rowsep0" align="left"><i>b</i> = 75.7</td><td class="colsep0 rowsep0" align="left"><i>b</i> = 75.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>c</i> = 89.6</td><td class="colsep0 rowsep0" align="left"><i>c</i> = 88.7</td><td class="colsep0 rowsep0" align="left"><i>c</i> = 90.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">50–2.34</td><td class="colsep0 rowsep0" align="left">20–1.95</td><td class="colsep0 rowsep0" align="left">90–1.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(high res)</td><td class="colsep0 rowsep0" align="left">(2.38–2.34)</td><td class="colsep0 rowsep0" align="left">(2.02–1.95)</td><td class="colsep0 rowsep0" align="left">(1.73–1.72)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">99.2 (89.3)</td><td class="colsep0 rowsep0" align="left">97.0 (97.9)</td><td class="colsep0 rowsep0" align="left">99.3 (75.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>sym</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.05 (0.39)</td><td class="colsep0 rowsep0" align="left">0.06 (0.33)</td><td class="colsep0 rowsep0" align="left">0.03 (0.37)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">χ<sup>2</sup></td><td class="colsep0 rowsep0" align="left">1.65 (1.49)</td><td class="colsep0 rowsep0" align="left">1.05 (0.62)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">4.5 (3.1)</td><td class="colsep0 rowsep0" align="left">4.4 (4.1)</td><td class="colsep0 rowsep0" align="left">6.1 (3.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">⟨<i>I</i>⟩/⟨σ(<i>I</i>)⟩</td><td class="colsep0 rowsep0" align="left">36.0 (3.9)</td><td class="colsep0 rowsep0" align="left">27.0 (3.9)</td><td class="colsep0 rowsep0" align="left">28.8 (2.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">(B) Refinement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>work</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.202</td><td class="colsep0 rowsep0" align="left">0.192</td><td class="colsep0 rowsep0" align="left">0.197</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>free</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.263</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.212</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. amino acid residues</td><td class="colsep0 rowsep0" align="left">274</td><td class="colsep0 rowsep0" align="left">281</td><td class="colsep0 rowsep0" align="left">275</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. waters</td><td class="colsep0 rowsep0" align="left">184</td><td class="colsep0 rowsep0" align="left">125</td><td class="colsep0 rowsep0" align="left">230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd bond length (Å)</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd angles (deg)</td><td class="colsep0 rowsep0" align="left">1.06</td><td class="colsep0 rowsep0" align="left">1.13</td><td class="colsep0 rowsep0" align="left">0.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average <i>B</i> (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">47.5</td><td class="colsep0 rowsep0" align="left">32.2</td><td class="colsep0 rowsep0" align="left">38.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran (%)</td><td class="colsep0 rowsep0" align="left">98.9</td><td class="colsep0 rowsep0" align="left">98.2</td><td class="colsep0 rowsep0" align="left">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran outliers (%)</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">0.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><i>R</i><sub>sym</sub> = ∑<i><sub>hkl</sub></i>(|<i>I<sub>hkl</sub></i> – ⟨<i>I<sub>hkl</sub></i>⟩|)/∑<i><sub>hkl</sub></i>⟨<i>I<sub>hkl</sub></i>⟩, where <i>I<sub>hkl</sub></i> is the intensity of reflection <i>hkl</i> and ⟨<i>I<sub>hkl</sub></i>⟩ is the average intensity of multiple observations.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last"><i>R</i><sub>work</sub> = ∑|<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub>|/∑<i>F</i><sub>o</sub>, where <i>F</i><sub>o</sub> and <i>F</i><sub>c</sub> are the observed and calculated structure factor amplitudes, respectively.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last"><i>R</i><sub>free</sub> is the <i>R</i>-factor for a randomly selected 5% of reflections that were not used in the refinement.</p></div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01694">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01694" class="ext-link">10.1021/acs.jmedchem.6b01694</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Single molecule X-ray crystallography data for <b>38b</b> and kinetics of covalent modification of on-target and off-target kinases by <b>11</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_001.csv">jm6b01694_si_001.csv (1.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf">jm6b01694_si_002.pdf (968.86 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01694" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atli Thorarensen</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6791-5809" title="Orcid link">http://orcid.org/0000-0002-6791-5809</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ce8fbaa2a7e09aa6a1bcafbcaba0bdaba08ebea8a7b4abbce0ada1a3"><span class="__cf_email__" data-cfemail="5f1e2b3336710b37302d3e2d3a312c3a311f2f3936253a2d713c3032">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Telliez</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e341b1f10533c1f0e0a170d0a1b502a1b1212171b043e0e1817041b0c501d1113"><span class="__cf_email__" data-cfemail="4b012e2a2566092a3b3f22383f2e651f2e2727222e310b3b2d22312e3965282426">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin E. Dowty</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Banker</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Juba</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Jussif</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsung Lin</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabien Vincent</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert M. Czerwinski</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agustin Casimiro-Garcia</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ray Unwalla</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John I. Trujillo</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sidney Liang</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Balbo</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Che</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam M. Gilbert</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew F. Brown</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Hayward</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin Montgomery</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Leung</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Yang</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Soucy</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Hegen</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jotham Coe</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Langille</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Felix Vajdos</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill Chrencik</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry, and ‡Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer Worldwide
R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="hlFld-Affiliation affiliation">∥Pharmacokinetics, Dynamics, and Metabolism, ⊥Primary Pharmacology
Group, and #Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors of this article are employed by Pfizer Inc.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8305-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the numerous members of Pfizer’s decade long JAK research project teams who designed, prepared, and evaluated JAK compounds, thus enabling the design and discovery of <b>11</b>. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Use of the LS-CAT sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). Use of the IMCA-CAT beamline 17-ID (or 17-BM) at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. This research was funded by Pfizer Inc.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i98" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i98"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i99" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i99"> Abbreviations Used</h2><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">NME</td><td class="NLM_def"><p class="first last">new molecular entity</p></td></tr><tr><td class="NLM_term">Cys</td><td class="NLM_def"><p class="first last">cysteine</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">FAAH</td><td class="NLM_def"><p class="first last">fatty acid amide hydrolase</p></td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">aminobenzotriazole</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione-<i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">DTH</td><td class="NLM_def"><p class="first last">delayed type hypersensitivity</p></td></tr><tr><td class="NLM_term">sRBC</td><td class="NLM_def"><p class="first last">sheep red blood cell</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">SLK</td><td class="NLM_def"><p class="first last">STE20-like serine/threonine-protein kinase</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">receptor-type tyrosine-protein kinase FLT3</p></td></tr><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">cytoplasmic tyrosine-protein kinase BMX</p></td></tr><tr><td class="NLM_term">TXK</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase TXK</p></td></tr><tr><td class="NLM_term">TEC</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase Tec</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">HER4</td><td class="NLM_def"><p class="first last">receptor tyrosine-protein kinase erbB-4</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">receptor tyrosine-protein kinase erbB-2</p></td></tr><tr><td class="NLM_term">AIA</td><td class="NLM_def"><p class="first last">adjuvant-induced arthritis</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J.</span><span> </span><span class="NLM_article-title">JAK kinases in health and disease: An update</span> <span class="citation_source-journal">Open Rheumatol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+An+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0ljPQcYvgrTpfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520An%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective TYK2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1517/13543776.2012.723693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+TYK2+inhibitor+patents&doi=10.1517%2F13543776.2012.723693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0ljglR3Lyek2AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520TYK2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249%26doi%3D10.1517%2F13543776.2012.723693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Wilson, L. J.</span><span> </span><span class="NLM_article-title">Recent patents in the discovery of small molecule inhibitors of JAK3</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1517/13543771003709767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1517%2F13543771003709767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20402545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=609-623&author=L.+J.+Wilson&title=Recent+patents+in+the+discovery+of+small+molecule+inhibitors+of+JAK3&doi=10.1517%2F13543771003709767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent patents in the discovery of small molecule inhibitors of JAK3</span></div><div class="casAuthors">Wilson, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Protein kinase enzymes have become increasingly important as the target of many disease modification drug discovery programs.  Disruption of JAK3 function results in quant. and qual. deficiencies in both B- and T-cell compartments of the immune system of JAK3 deficient mice and development of severe combined immunodeficiency in humans with the JAK3 genetic aberration.  JAK3 plays a specific role in immune function and lymphoid development and it only resides in the hematopoietic system, thus the rationale for selective targeting.  Inhibitors of JAK3 have shown utility in many different autoimmune disorders, including allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergic and asthmatic diseases.  These inhibitors are making their way into clin. trials with profound effects, thus, validating the target and strategy.  Areas covered in this review: A review that covers around 90 patents and patent applications made in the last 10 years in the area involving JAK3 inhibitors is provided.  Specifically, what this content will provide is the genus, highlighted compds. of particular interest, filing organization and some biol. measure of these compds. as inhibitors of this protein kinase or none if it is not provided.  Some information from original research articles appearing in peer reviewed literature is provided, but this article is not a review of the literature.  Furthermore, an overview of the current clin. status and future outcomes of this field is provided as summary.  What the reader will gain: A strong understanding for the current state of the art in patents dealing with inhibitors of JAK3 including genus and species designations, potential com. interest of this target in the pharmaceutical community, depth of coverage by nos. of examples and selected proof of action against the target.  Also, a brief understanding of the biol. and pharmacol. involved in the processes involving the research, discovery, characterization and clin. status of JAK3 inhibitors.  Take home message: This review is intended for medicinal chemists and patent agents who want to get a quick understanding of the state of the art in the field of JAK3 inhibitors.  It further serves as a ref. point to go into more depth on any series reported and to be able to evaluate any original research ideas in this area in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro9U4cmf9rH7Vg90H21EOLACvtfcHk0ljglR3Lyek2AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWhtrY%253D&md5=ddc7a801bc9fd439ac204f3bc6f106e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F13543771003709767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003709767%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DL.%2BJ.%26atitle%3DRecent%2520patents%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520JAK3%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D609%26epage%3D623%26doi%3D10.1517%2F13543771003709767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lj5l0oz7dXmTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x"> (</span><span class="NLM_issue">5237</span><span class="NLM_x">) </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&issue=5237&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5237%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drückes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the Janus kinase Jak3-Are they effective?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4617</span><span class="NLM_x">–</span> <span class="NLM_lpage">4621</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2014.08.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4617-4621&author=G.+Thomaauthor=P.+Dr%C3%BCckesauthor=H.+G.+Zerwes&title=Selective+inhibitors+of+the+Janus+kinase+Jak3-Are+they+effective%3F&doi=10.1016%2Fj.bmcl.2014.08.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DDr%25C3%25BCckes%26aufirst%3DP.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520Janus%2520kinase%2520Jak3-Are%2520they%2520effective%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4617%26epage%3D4621%26doi%3D10.1016%2Fj.bmcl.2014.08.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.+B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+Kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0lj5l0oz7dXmTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520Kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Alicea-Vela̅zquez, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">The use of structural biology in Janus kinase targeted drug discovery</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Vela%CC%85zquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+Janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0ljcDapl9ZuB5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Vela%25CC%2585zquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520Janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Goedken, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argiriadi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banach, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiamengo, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, J. W.</span><span> </span><span class="NLM_article-title">Tricyclic covalent inhibitors selectively target Jak3 through an active-site thiol</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">4573</span><span class="NLM_x">–</span> <span class="NLM_lpage">4589</span><span class="refDoi"> DOI: 10.1074/jbc.M114.595181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1074%2Fjbc.M114.595181" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=4573-4589&author=E.+R.+Goedkenauthor=M.+A.+Argiriadiauthor=D.+L.+Banachauthor=B.+A.+Fiamengoauthor=S.+E.+Foleyauthor=K.+E.+Frankauthor=J.+S.+Georgeauthor=C.+M.+Harrisauthor=A.+D.+Hobsonauthor=D.+C.+Ihleauthor=D.+Marcotteauthor=P.+J.+Mertaauthor=M.+E.+Michalakauthor=S.+E.+Murdockauthor=M.+J.+Tomlinsonauthor=J.+W.+Voss&title=Tricyclic+covalent+inhibitors+selectively+target+Jak3+through+an+active-site+thiol&doi=10.1074%2Fjbc.M114.595181"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.595181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.595181%26sid%3Dliteratum%253Aachs%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DArgiriadi%26aufirst%3DM.%2BA.%26aulast%3DBanach%26aufirst%3DD.%2BL.%26aulast%3DFiamengo%26aufirst%3DB.%2BA.%26aulast%3DFoley%26aufirst%3DS.%2BE.%26aulast%3DFrank%26aufirst%3DK.%2BE.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHobson%26aufirst%3DA.%2BD.%26aulast%3DIhle%26aufirst%3DD.%2BC.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DMerta%26aufirst%3DP.%2BJ.%26aulast%3DMichalak%26aufirst%3DM.%2BE.%26aulast%3DMurdock%26aufirst%3DS.%2BE.%26aulast%3DTomlinson%26aufirst%3DM.%2BJ.%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26atitle%3DTricyclic%2520covalent%2520inhibitors%2520selectively%2520target%2520Jak3%2520through%2520an%2520active-site%2520thiol%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D4573%26epage%3D4589%26doi%3D10.1074%2Fjbc.M114.595181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyskens, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herter-Sprie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannessen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akbay, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Development of selective covalent JAK3 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6589</span><span class="NLM_x">–</span> <span class="NLM_lpage">6606</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00710</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00710" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6589-6606&author=L.+Tanauthor=K.+Akahaneauthor=R.+McNallyauthor=K.+M.+Reyskensauthor=S.+B.+Ficarroauthor=S.+Liuauthor=G.+S.+Herter-Sprieauthor=S.+Koyamaauthor=M.+J.+Pattisonauthor=K.+M.+Labellaauthor=L.+Johannessenauthor=E.+A.+Akbayauthor=K.+K.+Wongauthor=D.+A.+Frankauthor=J.+A.+Martoauthor=A.+T.+Lookauthor=S.+Arthurauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Development+of+selective+covalent+JAK3+inhibitors&doi=10.1021%2Facs.jmedchem.5b00710"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00710%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAkahane%26aufirst%3DK.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DReyskens%26aufirst%3DK.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DPattison%26aufirst%3DM.%2BJ.%26aulast%3DLabella%26aufirst%3DK.%2BM.%26aulast%3DJohannessen%26aufirst%3DL.%26aulast%3DAkbay%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DArthur%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520selective%2520covalent%2520JAK3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6589%26epage%3D6606%26doi%3D10.1021%2Facs.jmedchem.5b00710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lhkFROZBq3U_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">We evaluated the conformational preference of compounds <b>4</b> and <b>5</b> with high-level DFT calculations (ref) using the M06-2X method and 6-31G* basis set. These calculations suggest that conformer A where the N–H group is oriented toward the pyrrole ring is energetically favored over the alternative rotational isomer in the gas phase by ∼0.6 kcal/mol and resulting in a 70:30 distribution for the two conformers. In contrast for the N-Me group both conformers are almost equally populated in the gas phase with the conformational energy difference being only 0.02 kcal/mol.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi-Fard, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, H. L.</span><span> </span><span class="NLM_article-title">Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1002/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=1404-1414&author=T.+S.+Maurerauthor=M.+A.+Tabrizi-Fardauthor=H.+L.+Fung&title=Impact+of+mechanism-based+enzyme+inactivation+on+inhibitor+potency%3A+implications+for+rational+drug+discovery&doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1520-6017%2528200011%252989%253A11%253C1404%253A%253AAID-JPS4%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DTabrizi-Fard%26aufirst%3DM.%2BA.%26aulast%3DFung%26aufirst%3DH.%2BL.%26atitle%3DImpact%2520of%2520mechanism-based%2520enzyme%2520inactivation%2520on%2520inhibitor%2520potency%253A%2520implications%2520for%2520rational%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D89%26spage%3D1404%26epage%3D1414%26doi%3D10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Thorarensen, A.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thorarensen%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+computational+methods+for+the+characterization+of+covalent+reactive+groups+for+the+prospective+design+of+irreversible+inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lhkFROZBq3U_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520computational%2520methods%2520for%2520the%2520characterization%2520of%2520covalent%2520reactive%2520groups%2520for%2520the%2520prospective%2520design%2520of%2520irreversible%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lhvim8F1sXPxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5112</span><span class="NLM_x">–</span> <span class="NLM_lpage">5128</span><span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+Liauthor=Y.+Zuoauthor=G.+Tangauthor=Y.+Wangauthor=Y.+Zhouauthor=X.+Wangauthor=T.+Guoauthor=M.+Xiaauthor=N.+Dingauthor=Z.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0lhvim8F1sXPxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0liAQDsugBDNjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Siewert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Esterl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, F.</span><span> </span><span class="NLM_article-title">Different protein turnover of interleukin-6-type cytokine signaling components</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1046/j.1432-1327.1999.00719.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1046%2Fj.1432-1327.1999.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10491180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1999&pages=251-257&author=E.+Siewertauthor=W.+M%C3%BCller-Esterlauthor=R.+Starrauthor=P.+C.+Heinrichauthor=F.+Schaper&title=Different+protein+turnover+of+interleukin-6-type+cytokine+signaling+components&doi=10.1046%2Fj.1432-1327.1999.00719.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Different protein turnover of interleukin-6-type cytokine signalling components</span></div><div class="casAuthors">Siewert, Elmar; Muller-Esterl, Werner; Starr, Robin; Heinrich, Peter C.; Schaper, Fred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Interleukin (IL)-6 and IL-6-type cytokines signal through the gp130/Jak/STAT signal transduction pathway.  The key components involved are the signal transducing receptor subunit gp130, the Janus kinases Jak1, Jak2 and Tyk2, STAT1 and STAT3 of the family of signal transducers and activators of transcription, the protein tyrosine phosphatase SHP2 and the suppressors of cytokine signalling SOCS1, SOCS2 and SOCS3.  Whereas considerable information has been accumulated concerning the time-course of activation for the individual signalling mols., data on the availability of the proteins involved in IL-6-type cytokine signal transduction are scarce.  Nevertheless, availability of these mols., detd. by the balance of protein synthesis and degrdn., also influences IL-6-type cytokine signal transduction.  Here, we present a comprehensive set of data on the half-lives of the key mols. involved in the IL-6 signal transduction pathway.  The turnover rates for the various proteins differ substantially.  Three groups of signalling proteins can be discriminated: whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3 and SHP2 have an extremely slow turnover rate.  Interestingly, the half-life of STAT3β, a splice variant of STAT3α, is reduced to almost 50% of the half-life of STAT3α.  The Janus kinases Jak1, Jak2, Tyk2 and gp130 show intermediate half-lives.  The data imply that signalling components activated by post-translational modifications are long-lived whereas the activity of very short-lived proteins is regulated mainly at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykEOWrPY1qrVg90H21EOLACvtfcHk0liAQDsugBDNjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D&md5=9a92232aa03148d1a70e5a9c2cd89733</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DSiewert%26aufirst%3DE.%26aulast%3DM%25C3%25BCller-Esterl%26aufirst%3DW.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DSchaper%26aufirst%3DF.%26atitle%3DDifferent%2520protein%2520turnover%2520of%2520interleukin-6-type%2520cytokine%2520signaling%2520components%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D265%26spage%3D251%26epage%3D257%26doi%3D10.1046%2Fj.1432-1327.1999.00719.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Telliez, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jussif, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unwalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajdos, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoghegan, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel JAK3-selective inhibitor: Functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3442</span><span class="NLM_x">–</span> <span class="NLM_lpage">3451</span><span class="refDoi"> DOI: 10.1021/acschembio.6b00677</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00677" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3442-3451&author=J.+B.+Telliezauthor=M.+E.+Dowtyauthor=L.+Wangauthor=J.+Jussifauthor=T.+Linauthor=L.+Liauthor=E.+Moyauthor=P.+Balboauthor=W.+Liauthor=Y.+Zhaoauthor=K.+Crouseauthor=C.+Dickinsonauthor=P.+Symanowiczauthor=M.+Hegenauthor=M.+E.+Bankerauthor=F.+Vincentauthor=R.+Unwallaauthor=S.+Liangauthor=A.+M.+Gilbertauthor=M.+F.+Brownauthor=M.+Haywardauthor=J.+Montgomeryauthor=X.+Yangauthor=J.+Baumanauthor=J.+I.+Trujilloauthor=A.+Casimiro-Garciaauthor=F.+F.+Vajdosauthor=L.+Leungauthor=K.+F.+Geogheganauthor=A.+Quaziauthor=D.+Xuanauthor=L.+H.+Jonesauthor=E.+Hettauthor=K.+Wrightauthor=J.+D.+Clarkauthor=A.+Thorarensen&title=Discovery+of+a+novel+JAK3-selective+inhibitor%3A+Functional+differentiation+of+JAK3-selective+inhibition+over+pan-JAK+or+JAK1-selective+inhibition&doi=10.1021%2Facschembio.6b00677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DBalbo%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCrouse%26aufirst%3DK.%26aulast%3DDickinson%26aufirst%3DC.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DQuazi%26aufirst%3DA.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DHett%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520JAK3-selective%2520inhibitor%253A%2520Functional%2520differentiation%2520of%2520JAK3-selective%2520inhibition%2520over%2520pan-JAK%2520or%2520JAK1-selective%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D3442%26epage%3D3451%26doi%3D10.1021%2Facschembio.6b00677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foltin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beidler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6545</span><span class="NLM_x">–</span> <span class="NLM_lpage">6553</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2011.08.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6545-6553&author=M.+J.+Meyersauthor=S.+A.+Longauthor=M.+J.+Pelcauthor=J.+L.+Wangauthor=S.+J.+Bowenauthor=B.+A.+Schweitzerauthor=M.+V.+Wilcoxauthor=J.+McDonaldauthor=S.+E.+Smithauthor=S.+Foltinauthor=J.+Rumseyauthor=Y.+S.+Yangauthor=M.+C.+Walkerauthor=S.+Kamtekarauthor=D.+Beidlerauthor=A.+Thorarensen&title=Discovery+of+novel+spirocyclic+inhibitors+of+fatty+acid+amide+hydrolase+%28FAAH%29.+Part+2.+Discovery+of+7-azaspiro%5B3.5%5Dnonane+urea+PF-04862853%2C+an+orally+efficacious+inhibitor+of+fatty+acid+amide+hydrolase+%28FAAH%29+for+pain&doi=10.1016%2Fj.bmcl.2011.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DLong%26aufirst%3DS.%2BA.%26aulast%3DPelc%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DBowen%26aufirst%3DS.%2BJ.%26aulast%3DSchweitzer%26aufirst%3DB.%2BA.%26aulast%3DWilcox%26aufirst%3DM.%2BV.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DFoltin%26aufirst%3DS.%26aulast%3DRumsey%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DWalker%26aufirst%3DM.%2BC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%2520spirocyclic%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529.%2520Part%25202.%2520Discovery%2520of%25207-azaspiro%255B3.5%255Dnonane%2520urea%2520PF-04862853%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%2520for%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6545%26epage%3D6553%26doi%3D10.1016%2Fj.bmcl.2011.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2011.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=21958547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12jsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.+H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.bmcl.2011.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Kim, Kyung-Hee; Maderna, Andreas; Schnute, Mark E.; Hegen, Martin; Mohan, Shashi; Miyashiro, Joy; Lin, Laura; Li, Evelyn; Keegan, Sean; Lussier, Jennifer; Wrocklage, Christopher; Nickerson-Nutter, Cheryl L.; Wittwer, Arthur J.; Soutter, Holly; Caspers, Nicole; Han, Seung-Il; Kurumbail, Ravi; Dunussi-Joannopoulos, Kyri; Douhan, John, III; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6258-6263</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors.  The syntheses and SAR of this series of compds. are presented as well as the X-ray crystal structure of the lead compd. I in complex with a gate-keeper variant of ITK enzyme.  The lead compd. showed good in vivo efficacy in preclin. RA models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfyHkAnJXNpLVg90H21EOLACvtfcHk0lgKU-ZPwdp-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12jsbfO&md5=500482f7b4005a5c343da07c0e7d2319</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263%26doi%3D10.1016%2Fj.bmcl.2011.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shibata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0lgKU-ZPwdp-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span> </span><span class="NLM_article-title">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1124/dmd.116.072983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1124%2Fdmd.116.072983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=27784718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1-7&author=L.+Leungauthor=X.+Yangauthor=T.+J.+Strelevitzauthor=J.+Montgomeryauthor=M.+F.+Brownauthor=M.+A.+Zientekauthor=C.+Banfieldauthor=A.+M.+Gilbertauthor=A.+Thorarensenauthor=E.+Martinauthor=M.+E.+Dowty&title=Clearance+prediction+of+targeted+covalent+inhibitors+by+in+vitro-in+vivo+extrapolation+of+hepatic+and+extrahepatic+clearance+mechanisms&doi=10.1124%2Fdmd.116.072983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span></div><div class="casAuthors">Leung, Louis; Yang, Xin; Strelevitz, Timothy J.; Montgomery, Justin; Brown, Matthew F.; Zientek, Michael A.; Banfield, Christopher; Gilbert, Adam M.; Thorarensen, Atli; Dowty, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of target-specific covalent enzyme inhibitors appears attractive from both an efficacy and a selectivity viewpoint considering the potential for enhanced biochem. efficiency assocd. with an irreversible mechanism.  Aside from potential safety concerns, clearance prediction of covalent inhibitors represents a unique challenge due to the inclusion of nontraditional metabolic pathways of direct conjugation with glutathione (GSH) or via GSH S-transferase-mediated processes.  In this article, a novel pharmacokinetic algorithm was developed using a series of Pfizer kinase selective acrylamide covalent inhibitors based on their in vitro-in vivo extrapolation of systemic clearance in rats.  The algorithmencompasses the use of hepatocytes as an in vitro model for hepatic clearance due to oxidative metab. and GSH conjugation, and the use of whole blood as an in vitro surrogate for GSH conjugation in extrahepatic tissues.  Initial evaluations with clin. covalent inhibitors suggested that the scaling algorithm developed from rats may also be useful for human clearance prediction when species-specific parameters, such as hepatocyte and blood stability and blood binding, were considered.  With careful consideration of clearance mechanisms, the described in vitro-in vivo extrapolation approach may be useful to facilitate candidate optimization, selection, and prediction of human pharmacokinetic clearance during the discovery and development of targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvIMBCrCxzNLVg90H21EOLACvtfcHk0lgKU-ZPwdp-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D&md5=8c8b918b087278b2025e0ae56a7abe37</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072983%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26atitle%3DClearance%2520prediction%2520of%2520targeted%2520covalent%2520inhibitors%2520by%2520in%2520vitro-in%2520vivo%2520extrapolation%2520of%2520hepatic%2520and%2520extrahepatic%2520clearance%2520mechanisms%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1%26epage%3D7%26doi%3D10.1124%2Fdmd.116.072983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamper, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrer, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilworth, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmeier, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radabaugh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zutshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of an oral potent selective inhibitor of hematopoietic prostaglandin D synthase (HPGDS)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/ml900025z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900025z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=59-63&author=C.+P.+Carronauthor=J.+I.+Trujilloauthor=K.+L.+Olsonauthor=W.+Huangauthor=B.+C.+Hamperauthor=T.+Diceauthor=B.+E.+Nealauthor=M.+J.+Pelcauthor=J.+E.+Dayauthor=D.+C.+Rohrerauthor=J.+R.+Kieferauthor=J.+B.+Moonauthor=B.+A.+Schweitzerauthor=T.+D.+Blakeauthor=S.+R.+Turnerauthor=R.+Woerndleauthor=B.+L.+Caseauthor=C.+P.+Bonoauthor=V.+M.+Dilworthauthor=C.+L.+Funckes-Shippyauthor=B.+L.+Hoodauthor=G.+M.+Jeromeauthor=C.+M.+Kornmeierauthor=M.+R.+Radabaughauthor=M.+L.+Williamsauthor=M.+S.+Daviesauthor=C.+D.+Wegnerauthor=D.+J.+Welschauthor=W.+M.+Abrahamauthor=C.+J.+Warrenauthor=M.+E.+Dowtyauthor=F.+Huaauthor=A.+Zutshiauthor=J.+Z.+Yangauthor=A.+Thorarensen&title=Discovery+of+an+oral+potent+selective+inhibitor+of+hematopoietic+prostaglandin+D+synthase+%28HPGDS%29&doi=10.1021%2Fml900025z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml900025z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900025z%26sid%3Dliteratum%253Aachs%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DHamper%26aufirst%3DB.%2BC.%26aulast%3DDice%26aufirst%3DT.%26aulast%3DNeal%26aufirst%3DB.%2BE.%26aulast%3DPelc%26aufirst%3DM.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DRohrer%26aufirst%3DD.%2BC.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DMoon%26aufirst%3DJ.%2BB.%26aulast%3DSchweitzer%26aufirst%3DB.%2BA.%26aulast%3DBlake%26aufirst%3DT.%2BD.%26aulast%3DTurner%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DBono%26aufirst%3DC.%2BP.%26aulast%3DDilworth%26aufirst%3DV.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DB.%2BL.%26aulast%3DJerome%26aufirst%3DG.%2BM.%26aulast%3DKornmeier%26aufirst%3DC.%2BM.%26aulast%3DRadabaugh%26aufirst%3DM.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DM.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DWelsch%26aufirst%3DD.%2BJ.%26aulast%3DAbraham%26aufirst%3DW.%2BM.%26aulast%3DWarren%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHua%26aufirst%3DF.%26aulast%3DZutshi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%2BZ.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520an%2520oral%2520potent%2520selective%2520inhibitor%2520of%2520hematopoietic%2520prostaglandin%2520D%2520synthase%2520%2528HPGDS%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D59%26epage%3D63%26doi%3D10.1021%2Fml900025z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Casimiro-Garcia%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">Compound <b>11</b> is commercially available via Sigma Aldrich (catalog no. PZ0316).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Hett, E.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hett%2C+E.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHett%26aufirst%3DE." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0liiZ2y_Esekww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Wilcox, G. E.; Koecher, C.; Vries, T.; Flanagan, M. E.; Munchof, M. J.</span><span> </span><span class="NLM_article-title">Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3-d]pyrimidines as protein kinase inhibitors</span>. PCT Int. Appl. WO2002096909,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=G.+E.+Wilcox&author=C.+Koecher&author=T.+Vries&author=M.+E.+Flanagan&author=M.+J.+Munchof&title=Optical+resolution+of+%281-benzyl-4-methylpiperidin-3-yl%29-methylamine+and+the+use+thereof+for+the+preparation+of+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DG.%2BE.%26atitle%3DOptical%2520resolution%2520of%2520%25281-benzyl-4-methylpiperidin-3-yl%2529-methylamine%2520and%2520the%2520use%2520thereof%2520for%2520the%2520preparation%2520of%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cox, P. J.; Majaid, T. N.; Amendola, S.; Deprets, S. D.; Edlin, C.; Pedgrift, B. L.; Halley, F.; Edwards, M.; Baudoin, B.; McIay, L. M.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidines as protein kinase inhibitors</span>. PCT Int. Appl. WO 2003000695,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=P.+J.+Cox&author=T.+N.+Majaid&author=S.+Amendola&author=S.+D.+Deprets&author=C.+Edlin&author=B.+L.+Pedgrift&author=F.+Halley&author=M.+Edwards&author=B.+Baudoin&author=L.+M.+McIay&title=Preparation+of+pyrrolopyrimidines+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DP.%2BJ.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidines%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Patil, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonde, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kekan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span> </span><span class="NLM_article-title">An improved and efficient process for the preparation of tofacitinib citrate</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="refDoi"> DOI: 10.1021/op500274j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500274j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1714&author=Y.+S.+Patilauthor=N.+L.+Bondeauthor=A.+S.+Kekanauthor=D.+G.+Satheauthor=A.+Das&title=An+improved+and+efficient+process+for+the+preparation+of+tofacitinib+citrate&doi=10.1021%2Fop500274j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fop500274j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500274j%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%2BS.%26aulast%3DBonde%26aufirst%3DN.%2BL.%26aulast%3DKekan%26aufirst%3DA.%2BS.%26aulast%3DSathe%26aufirst%3DD.%2BG.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DAn%2520improved%2520and%2520efficient%2520process%2520for%2520the%2520preparation%2520of%2520tofacitinib%2520citrate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1714%26doi%3D10.1021%2Fop500274j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span>Purchased from Alfa-Aesar (CAS no. 188111-79-7, catalog no. H26937).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Purchased+from+Alfa-Aesar+%28CAS+no.+188111-79-7%2C+catalog+no.+H26937%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Suzuki, A. J.</span><span> </span><span class="NLM_article-title">Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995–1998</span> <span class="citation_source-journal">J. Organomet. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">576</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="refDoi"> DOI: 10.1016/S0022-328X(98)01055-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0022-328X%2898%2901055-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK1MXivFOlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=576&publication_year=1999&pages=147&author=A.+J.+Suzuki&title=Recent+advances+in+the+cross-coupling+reactions+of+organoboron+derivatives+with+organic+electrophiles%2C+1995%E2%80%931998&doi=10.1016%2FS0022-328X%2898%2901055-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995-1998</span></div><div class="casAuthors">Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">576</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">147-168</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science S.A.</span>)
        </div><div class="casAbstract">The Pd-catalyzed cross-coupling reaction between organoboron compds. and org. halides or triflates provides a powerful and general methodol. for the formation of C-C bonds.  Recently, this reaction was called the Suzuki coupling, Suzuki reaction, or Suzuki-Miyaura coupling, although the authors never referred to it as such previously.  In this review, this name will be used with hesitation, simply to express the coupling reaction.  The availability of the reagents and the mild reaction conditions all contribute to the versatility of this reaction.  The coupling reaction offers several addnl. advantages, such as being largely unaffected by the presence of H2O, tolerating a broad range of functional groups, and proceeding generally regio- and stereoselectively.  Also, the inorg. byproduct of the reaction is nontoxic and easily removed from the reaction mixt. thereby making the Suzuki coupling suitable not only for labs. but also for industrial processes.  The authors published previously a comprehensive review of the reaction which covered mainly the refs. until the end of 1994.  Thereafter, a large no. of papers related to the coupling reaction are reported.  Consequently, such new results presented from 1995 to May 1998 are summarized in this review, with 139 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCbrdm1cvkLVg90H21EOLACvtfcHk0lg8CMC2NH-w9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFOlsr0%253D&md5=be2fdd114211afa4abdf106008dd9845</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0022-328X%2898%2901055-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-328X%252898%252901055-9%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520cross-coupling%2520reactions%2520of%2520organoboron%2520derivatives%2520with%2520organic%2520electrophiles%252C%25201995%25E2%2580%25931998%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D1999%26volume%3D576%26spage%3D147%26doi%3D10.1016%2FS0022-328X%2898%2901055-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Johnson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blom, T.</span><span> </span><span class="NLM_article-title">Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1016/j.ab.2008.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.ab.2008.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=19154726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFKjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=20-29&author=K.+A.+Johnsonauthor=Z.+B.+Simpsonauthor=T.+Blom&title=Global+Kinetic+Explorer%3A+A+new+computer+program+for+dynamic+simulation+and+fitting+of+kinetic+data&doi=10.1016%2Fj.ab.2008.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data</span></div><div class="casAuthors">Johnson, Kenneth A.; Simpson, Zachary B.; Blom, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe a new dynamic kinetic simulation program that allows multiple data sets to be fit simultaneously to a single model based on numerical integration of the rate equations describing the reaction mechanism.  Unlike other programs that allow fitting based on numerical integration of rate equations, in the dynamic simulation rate consts., output factors, and starting concns. of reactants can be scrolled while observing the change in the shape of the simulated reaction curves.  Fast dynamic simulation facilitates the exploration of initial parameters that serve as the starting point for nonlinear regression in fitting data and facilitates exploration of the relationships between individual consts. and observable reactions.  The exploration of parameter space by dynamic simulation provides a powerful tool for learning kinetics and for evaluating the extent to which parameters are constrained by the data.  This feature is crit. to avoid overly complex models that are not supported by the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFFZnhMRb-rVg90H21EOLACvtfcHk0lg8CMC2NH-w9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFKjt7c%253D&md5=1d0227c91a334f47edae70f5a89478ff</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2008.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2008.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DSimpson%26aufirst%3DZ.%2BB.%26aulast%3DBlom%26aufirst%3DT.%26atitle%3DGlobal%2520Kinetic%2520Explorer%253A%2520A%2520new%2520computer%2520program%2520for%2520dynamic%2520simulation%2520and%2520fitting%2520of%2520kinetic%2520data%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D387%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.ab.2008.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Johnson, K.</span><span> </span><span class="NLM_article-title">A Fitting enzyme kinetic data with KinTek Global Kinetic Explorer</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1016/S0076-6879(09)67023-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0076-6879%2809%2967023-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=601-626&author=K.+Johnson&title=A+Fitting+enzyme+kinetic+data+with+KinTek+Global+Kinetic+Explorer&doi=10.1016%2FS0076-6879%2809%2967023-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2809%2967023-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252809%252967023-3%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%26atitle%3DA%2520Fitting%2520enzyme%2520kinetic%2520data%2520with%2520KinTek%2520Global%2520Kinetic%2520Explorer%26jtitle%3DMethods%2520Enzymol.%26date%3D2009%26volume%3D467%26spage%3D601%26epage%3D626%26doi%3D10.1016%2FS0076-6879%2809%2967023-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Thompson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubbon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankshun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0960-894X%2802%2900106-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1219-1223&author=J.+E.+Thompsonauthor=R.+M.+Cubbonauthor=R.+T.+Cummingsauthor=L.+S.+Wickerauthor=R.+Frankshunauthor=B.+R.+Cunninghamauthor=P.+M.+Cameronauthor=P.+T.+Meinkeauthor=N.+Livertonauthor=Y.+Wengauthor=J.+A.+DeMartino&title=Photochemical+preparation+of+a+pyridone+containing+tetracycle%3A+A+Jak+protein+kinase+inhibitor&doi=10.1016%2FS0960-894X%2802%2900106-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900106-3%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26aulast%3DCubbon%26aufirst%3DR.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DFrankshun%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DPhotochemical%2520preparation%2520of%2520a%2520pyridone%2520containing%2520tetracycle%253A%2520A%2520Jak%2520protein%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1219%26epage%3D1223%26doi%3D10.1016%2FS0960-894X%2802%2900106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lg0yFOBZr9oRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissinel, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments. Acta Crystallographica Section D</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&issue=4&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments.+Acta+Crystallographica+Section+D&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments.%2520Acta%2520Crystallographica%2520Section%2520D%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the aximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&issue=3&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+aximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520aximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26issue%3D3%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Smart, O. S.; Vonrhein, C.; Womack, T. O.</span>BUSTER, version <span class="NLM_edition">2.8.0</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&issue=4&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lg0yFOBZr9oRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D4%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':[],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 58 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Vincent M. Crowley, Marvin Thielert, <span class="NLM_string-name hlFld-ContribAuthor">Benjamin F. Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2021,</strong> <em>7 </em>
                                    (4)
                                     , 613-623. <a href="https://doi.org/10.1021/acscentsci.0c01336" title="DOI URL">https://doi.org/10.1021/acscentsci.0c01336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.0c01336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.0c01336%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DFunctionalized%252BScout%252BFragments%252Bfor%252BSite-Specific%252BCovalent%252BLigand%252BDiscovery%252Band%252BOptimization%26aulast%3DCrowley%26aufirst%3DVincent%2BM.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D05102020%26date%3D05042021%26volume%3D7%26issue%3D4%26spage%3D613%26epage%3D623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eunsun Park, Sun Joo Lee, Heegyum Moon, Jongmi Park, Hyeonho Jeon, Ji Sun Hwang, Hayoung Hwang, Ki Bum Hong, Seung-Hee Han, Sun Choi, <span class="NLM_string-name hlFld-ContribAuthor">Soosung Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 958-979. <a href="https://doi.org/10.1021/acs.jmedchem.0c01026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252BEvaluation%252Bof%252BN-Methyl-pyrrolo%25255B2%25252C3-b%25255Dpyridine-5-carboxamide%252BDerivatives%252Bas%252BJAK1-Selective%252BInhibitors%26aulast%3DPark%26aufirst%3DEunsun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D16062020%26date%3D11012021%26volume%3D64%26issue%3D2%26spage%3D958%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Levente M. Mihalovits, György G. Ferenczy, <span class="NLM_string-name hlFld-ContribAuthor">György M. Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (12)
                                     , 6579-6594. <a href="https://doi.org/10.1021/acs.jcim.0c00834" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00834%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAffinity%252Band%252BSelectivity%252BAssessment%252Bof%252BCovalent%252BInhibitors%252Bby%252BFree%252BEnergy%252BCalculations%26aulast%3DMihalovits%26aufirst%3DLevente%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22072020%26date%3D09122020%26volume%3D60%26issue%3D12%26spage%3D6579%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Keisuke Tokunaga, Mami Sato, Keiko Kuwata, Chizuru Miura, Hirokazu Fuchida, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Naoya Shindo, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (43)
                                     , 18522-18531. <a href="https://doi.org/10.1021/jacs.0c07490" title="DOI URL">https://doi.org/10.1021/jacs.0c07490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c07490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c07490%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DBicyclobutane%252BCarboxylic%252BAmide%252Bas%252Ba%252BCysteine-Directed%252BStrained%252BElectrophile%252Bfor%252BSelective%252BTargeting%252Bof%252BProteins%26aulast%3DTokunaga%26aufirst%3DKeisuke%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12072020%26date%3D13102020%26volume%3D142%26issue%3D43%26spage%3D18522%26epage%3D18531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mami Sato, Hirokazu Fuchida, Naoya Shindo, Keiko Kuwata, Keisuke Tokunaga, Guo Xiao-Lin, Ryo Inamori, Keitaro Hosokawa, Kosuke Watari, Tomohiro Shibata, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Mayumi Ono, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1137-1144. <a href="https://doi.org/10.1021/acsmedchemlett.9b00574" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00574%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSelective%252BCovalent%252BTargeting%252Bof%252BMutated%252BEGFR%252528T790M%252529%252Bwith%252BChlorofluoroacetamide-Pyrimidines%26aulast%3DSato%26aufirst%3DMami%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04122019%26date%3D08042020%26date%3D10042020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1137%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Tao, J. Christopher McWilliams, Kristin E. Wiglesworth, Kevin P. Girard, Teresa M. Makowski, Neal W. Sach, Jason G. Mustakis, Ruchi Mehta, John I. Trujillo, Xiaofeng Chen, Tangqing Li, Feng Shi, Chengfu Xie, <span class="NLM_string-name hlFld-ContribAuthor">Qing Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Process Development and Scale Up of a Selective JAK3 Covalent Inhibitor PF-06651600. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1872-1880. <a href="https://doi.org/10.1021/acs.oprd.9b00198" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00198%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DProcess%252BDevelopment%252Band%252BScale%252BUp%252Bof%252Ba%252BSelective%252BJAK3%252BCovalent%252BInhibitor%252BPF-06651600%26aulast%3DTao%26aufirst%3DYong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D01052019%26date%3D31072019%26date%3D19072019%26volume%3D23%26issue%3D9%26spage%3D1872%26epage%3D1880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven H. Spergel, Michael E. Mertzman, James Kempson, Junqing Guo, Sylwia Stachura, Lauren Haque, Jonathan S. Lippy, Rosemary F. Zhang, Michael Galella, Sidney Pitt, Guoxiang Shen, Aberra Fura, Kathleen Gillooly, Kim W. McIntyre, Vicky Tang, John Tokarski, John S. Sack, Javed Khan, Percy H. Carter, Joel C. Barrish, Steven G. Nadler, Luisa M. Salter-Cid, Gary L. Schieven, Stephen T. Wrobleski, <span class="NLM_string-name hlFld-ContribAuthor">William J. Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 306-311. <a href="https://doi.org/10.1021/acsmedchemlett.8b00508" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BJAK1%25252F3%252BInhibitor%252Band%252BUse%252Bof%252Ba%252BProdrug%252BTo%252BDemonstrate%252BEfficacy%252Bin%252Ba%252BModel%252Bof%252BRheumatoid%252BArthritis%26aulast%3DSpergel%26aufirst%3DSteven%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D26102018%26date%3D07022019%26date%3D13022019%26volume%3D10%26issue%3D3%26spage%3D306%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liyang Shi, Zhenpeng Zhong, Xitao Li, Yiqing Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Zhengying Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 1054-1066. <a href="https://doi.org/10.1021/acs.jmedchem.8b01823" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ban%252BOrally%252BAvailable%252BJanus%252BKinase%252B3%252BSelective%252BCovalent%252BInhibitor%26aulast%3DShi%26aufirst%3DLiyang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D07012019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Agustin Casimiro-Garcia, John I. Trujillo, Felix Vajdos, Brian Juba, Mary Ellen Banker, Ann Aulabaugh, Paul Balbo, Jonathan Bauman, Jill Chrencik, Jotham W. Coe, Robert Czerwinski, Martin Dowty, John D. Knafels, Soojin Kwon, Louis Leung, Sidney Liang, Ralph P. Robinson, Jean-Baptiste Telliez, Ray Unwalla, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Atli Thorarensen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10665-10699. <a href="https://doi.org/10.1021/acs.jmedchem.8b01308" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01308%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BCyanamide-Based%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BCovalent%252BInhibitors%26aulast%3DCasimiro-Garcia%26aufirst%3DAgustin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18082018%26date%3D30112018%26date%3D13112018%26volume%3D61%26issue%3D23%26spage%3D10665%26epage%3D10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Forster, Apirat Chaikuad, Teodor Dimitrov, Eva Döring, Julia Holstein, Benedict-Tilman Berger, Matthias Gehringer, Kamran Ghoreschi, Susanne Müller, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Stefan A. Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5350-5366. <a href="https://doi.org/10.1021/acs.jmedchem.8b00571" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00571%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%25252C%252BOptimization%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BCovalent-Reversible%252BJAK3%252BInhibitors%252BBased%252Bon%252Ba%252BTricyclic%252BImidazo%25255B5%25252C4-d%25255Dpyrrolo%25255B2%25252C3-b%25255Dpyridine%252BScaffold%26aulast%3DForster%26aufirst%3DMichael%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11042018%26date%3D13062018%26date%3D31052018%26volume%3D61%26issue%3D12%26spage%3D5350%26epage%3D5366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel E.  Dalton</span>, <span class="hlFld-ContribAuthor ">Lars  Dittus</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Thomas</span>, <span class="hlFld-ContribAuthor ">Máire A.  Convery</span>, <span class="hlFld-ContribAuthor ">Joao  Nunes</span>, <span class="hlFld-ContribAuthor ">Jacob T.  Bush</span>, <span class="hlFld-ContribAuthor ">John P.  Evans</span>, <span class="hlFld-ContribAuthor ">Thilo  Werner</span>, <span class="hlFld-ContribAuthor ">Marcus  Bantscheff</span>, <span class="hlFld-ContribAuthor ">John A.  Murphy</span>, and <span class="hlFld-ContribAuthor ">Sebastien  Campos</span>  . </span><span class="cited-content_cbyCitation_article-title">Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (3)
                                     , 932-939. <a href="https://doi.org/10.1021/jacs.7b08979" title="DOI URL">https://doi.org/10.1021/jacs.7b08979</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b08979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b08979%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSelectively%252BTargeting%252Bthe%252BKinome-Conserved%252BLysine%252Bof%252BPI3K%2525CE%2525B4%252Bas%252Ba%252BGeneral%252BApproach%252Bto%252BCovalent%252BKinase%252BInhibition%26aulast%3DDalton%26aufirst%3DSamuel%2BE.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D22082017%26date%3D09012018%26date%3D24012018%26date%3D12122017%26volume%3D140%26issue%3D3%26spage%3D932%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Judit  Remenyi</span>, <span class="hlFld-ContribAuthor ">Rangeetha Jayaprakash  Naik</span>, <span class="hlFld-ContribAuthor ">Jinhua  Wang</span>, <span class="hlFld-ContribAuthor ">Momchil  Razsolkov</span>, <span class="hlFld-ContribAuthor ">Alyssa  Verano</span>, <span class="hlFld-ContribAuthor ">Quan  Cai</span>, <span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Rachel  Toth</span>, <span class="hlFld-ContribAuthor ">Samantha  Raggett</span>, <span class="hlFld-ContribAuthor ">Carla  Baillie</span>, <span class="hlFld-ContribAuthor ">Ryan  Traynor</span>, <span class="hlFld-ContribAuthor ">C. James  Hastie</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">J. Simon C.  Arthur</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of a chemical genetic model for JAK3. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-89356-4" title="DOI URL">https://doi.org/10.1038/s41598-021-89356-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-89356-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-89356-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DGeneration%252Bof%252Ba%252Bchemical%252Bgenetic%252Bmodel%252Bfor%252BJAK3%26aulast%3DRemenyi%26aufirst%3DJudit%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akachukwu  Ibezim</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Onah</span>, <span class="hlFld-ContribAuthor ">Ebubechukwu N.  Dim</span>, <span class="hlFld-ContribAuthor ">Fidele  Ntie-Kang</span>. </span><span class="cited-content_cbyCitation_article-title">A computational multi-targeting approach for drug repositioning for psoriasis treatment. </span><span class="cited-content_cbyCitation_journal-name">BMC Complementary Medicine and Therapies</span><span> <strong>2021,</strong> <em>21 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12906-021-03359-2" title="DOI URL">https://doi.org/10.1186/s12906-021-03359-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12906-021-03359-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12906-021-03359-2%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Complementary%2520Medicine%2520and%2520Therapies%26atitle%3DA%252Bcomputational%252Bmulti-targeting%252Bapproach%252Bfor%252Bdrug%252Brepositioning%252Bfor%252Bpsoriasis%252Btreatment%26aulast%3DIbezim%26aufirst%3DAkachukwu%26date%3D2021%26date%3D2021%26volume%3D21%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabiola  De Marchi</span>, <span class="hlFld-ContribAuthor ">Ivana  Munitic</span>, <span class="hlFld-ContribAuthor ">Amedeo  Amedei</span>, <span class="hlFld-ContribAuthor ">James D.  Berry</span>, <span class="hlFld-ContribAuthor ">Eva L.  Feldman</span>, <span class="hlFld-ContribAuthor ">Eleonora  Aronica</span>, <span class="hlFld-ContribAuthor ">Giovanni  Nardo</span>, <span class="hlFld-ContribAuthor ">Donatienne  Van Weehaeghe</span>, <span class="hlFld-ContribAuthor ">Elena  Niccolai</span>, <span class="hlFld-ContribAuthor ">Nikolina  Prtenjaca</span>, <span class="hlFld-ContribAuthor ">Stacey A.  Sakowski</span>, <span class="hlFld-ContribAuthor ">Caterina  Bendotti</span>, <span class="hlFld-ContribAuthor ">Letizia  Mazzini</span>. </span><span class="cited-content_cbyCitation_article-title">Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience & Biobehavioral Reviews</span><span> <strong>2021,</strong> <em>127 </em>, 958-978. <a href="https://doi.org/10.1016/j.neubiorev.2021.06.027" title="DOI URL">https://doi.org/10.1016/j.neubiorev.2021.06.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neubiorev.2021.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neubiorev.2021.06.027%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520%2526%2520Biobehavioral%2520Reviews%26atitle%3DInterplay%252Bbetween%252Bimmunity%252Band%252Bamyotrophic%252Blateral%252Bsclerosis%25253A%252BClinical%252Bimpact%26aulast%3DDe%2BMarchi%26aufirst%3DFabiola%26date%3D2021%26volume%3D127%26spage%3D958%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michela  Sperti</span>, <span class="hlFld-ContribAuthor ">Marta  Malavolta</span>, <span class="hlFld-ContribAuthor ">Gloria  Ciniero</span>, <span class="hlFld-ContribAuthor ">Simone  Borrelli</span>, <span class="hlFld-ContribAuthor ">Marco  Cavaglià</span>, <span class="hlFld-ContribAuthor ">Stefano  Muscat</span>, <span class="hlFld-ContribAuthor ">Jack Adam  Tuszynski</span>, <span class="hlFld-ContribAuthor ">Antonella  Afeltra</span>, <span class="hlFld-ContribAuthor ">Domenico Paolo Emanuele  Margiotta</span>, <span class="hlFld-ContribAuthor ">Luca  Navarini</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2021,</strong> <em>104 </em>, 107789. <a href="https://doi.org/10.1016/j.jmgm.2020.107789" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107789%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DJAK%252Binhibitors%252Bin%252Bimmune-mediated%252Brheumatic%252Bdiseases%25253A%252BFrom%252Ba%252Bmolecular%252Bperspective%252Bto%252Bclinical%252Bstudies%26aulast%3DSperti%26aufirst%3DMichela%26date%3D2021%26volume%3D104%26spage%3D107789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kishor D.  Mane</span>, <span class="hlFld-ContribAuthor ">Rohit B.  Kamble</span>, <span class="hlFld-ContribAuthor ">Gurunath  Suryavanshi</span>. </span><span class="cited-content_cbyCitation_article-title">Short enantioselective total synthesis of (+)-tofacitinib. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>67 </em>, 152838. <a href="https://doi.org/10.1016/j.tetlet.2021.152838" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.152838</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.152838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.152838%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DShort%252Benantioselective%252Btotal%252Bsynthesis%252Bof%252B%252528%25252B%252529-tofacitinib%26aulast%3DMane%26aufirst%3DKishor%2BD.%26date%3D2021%26volume%3D67%26spage%3D152838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin  Litwin</span>, <span class="hlFld-ContribAuthor ">Vincent M.  Crowley</span>, <span class="hlFld-ContribAuthor ">Radu M.  Suciu</span>, <span class="hlFld-ContribAuthor ">Dale L.  Boger</span>, <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical proteomic identification of functional cysteines with atypical electrophile reactivities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>67 </em>, 152861. <a href="https://doi.org/10.1016/j.tetlet.2021.152861" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.152861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.152861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.152861%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DChemical%252Bproteomic%252Bidentification%252Bof%252Bfunctional%252Bcysteines%252Bwith%252Batypical%252Belectrophile%252Breactivities%26aulast%3DLitwin%26aufirst%3DKevin%26date%3D2021%26volume%3D67%26spage%3D152861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">László  Petri</span>, <span class="hlFld-ContribAuthor ">Attila  Egyed</span>, <span class="hlFld-ContribAuthor ">Dávid  Bajusz</span>, <span class="hlFld-ContribAuthor ">Tímea  Imre</span>, <span class="hlFld-ContribAuthor ">Anasztázia  Hetényi</span>, <span class="hlFld-ContribAuthor ">Tamás  Martinek</span>, <span class="hlFld-ContribAuthor ">Péter  Ábrányi-Balogh</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112836. <a href="https://doi.org/10.1016/j.ejmech.2020.112836" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112836</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112836%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Belectrophilic%252Bwarhead%252Blibrary%252Bfor%252Bmapping%252Bthe%252Breactivity%252Band%252Baccessibility%252Bof%252Btractable%252Bcysteines%252Bin%252Bprotein%252Bkinases%26aulast%3DPetri%26aufirst%3DL%25C3%25A1szl%25C3%25B3%26date%3D2020%26volume%3D207%26spage%3D112836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Roda</span>, <span class="hlFld-ContribAuthor ">Arianna  Dal Buono</span>, <span class="hlFld-ContribAuthor ">Marjorie  Argollo</span>, <span class="hlFld-ContribAuthor ">Silvio  Danese</span>. </span><span class="cited-content_cbyCitation_article-title">JAK selectivity: more precision less troubles. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Gastroenterology & Hepatology</span><span> <strong>2020,</strong> <em>14 </em>
                                    (9)
                                     , 789-796. <a href="https://doi.org/10.1080/17474124.2020.1780120" title="DOI URL">https://doi.org/10.1080/17474124.2020.1780120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474124.2020.1780120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474124.2020.1780120%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DJAK%252Bselectivity%25253A%252Bmore%252Bprecision%252Bless%252Btroubles%26aulast%3DRoda%26aufirst%3DGiulia%26date%3D2020%26date%3D2020%26volume%3D14%26issue%3D9%26spage%3D789%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Rogler</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of JAK inhibitors in Crohn’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2020,</strong> <em>14 </em>
                                    (Supplement_2)
                                     , S746-S754. <a href="https://doi.org/10.1093/ecco-jcc/jjz186" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjz186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjz186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjz186%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DEfficacy%252Bof%252BJAK%252Binhibitors%252Bin%252BCrohn%2525E2%252580%252599s%252BDisease%26aulast%3DRogler%26aufirst%3DGerhard%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3DSupplement_2%26spage%3DS746%26epage%3DS754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajesh  Bahekar</span>, <span class="hlFld-ContribAuthor ">Nandini  Panchal</span>, <span class="hlFld-ContribAuthor ">Shubhangi  Soman</span>, <span class="hlFld-ContribAuthor ">Jigar  Desai</span>, <span class="hlFld-ContribAuthor ">Dipam  Patel</span>, <span class="hlFld-ContribAuthor ">Anil  Argade</span>, <span class="hlFld-ContribAuthor ">Archana  Gite</span>, <span class="hlFld-ContribAuthor ">Sanjay  Gite</span>, <span class="hlFld-ContribAuthor ">Bhaumin  Patel</span>, <span class="hlFld-ContribAuthor ">Jeevan  Kumar</span>, <span class="hlFld-ContribAuthor ">Sachchidanand  S</span>, <span class="hlFld-ContribAuthor ">Harilal  Patel</span>, <span class="hlFld-ContribAuthor ">Rajesh  Sundar</span>, <span class="hlFld-ContribAuthor ">Abhijit  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Jogeswar  Mahapatra</span>, <span class="hlFld-ContribAuthor ">Hoshang  Patel</span>, <span class="hlFld-ContribAuthor ">Krishnarup  Ghoshdastidar</span>, <span class="hlFld-ContribAuthor ">Debdutta  Bandyopadhyay</span>, <span class="hlFld-ContribAuthor ">Ranjit C.  Desai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103851. <a href="https://doi.org/10.1016/j.bioorg.2020.103851" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103851%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bdiaminopyrimidine-carboxamide%252Bderivatives%252Bas%252BJAK3%252Binhibitors%26aulast%3DBahekar%26aufirst%3DRajesh%26date%3D2020%26volume%3D99%26spage%3D103851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Danielle A.  Chisolm</span>, <span class="hlFld-ContribAuthor ">Rachael L.  Philips</span>, <span class="hlFld-ContribAuthor ">Iain B.  McInness</span>, <span class="hlFld-ContribAuthor ">Paul S.  Changelian</span>, <span class="hlFld-ContribAuthor ">John J.  O’Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Translating JAKs to Jakinibs. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2020,</strong> <em>204 </em>
                                    (8)
                                     , 2011-2020. <a href="https://doi.org/10.4049/jimmunol.1901477" title="DOI URL">https://doi.org/10.4049/jimmunol.1901477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1901477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1901477%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DTranslating%252BJAKs%252Bto%252BJakinibs%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2020%26date%3D2020%26volume%3D204%26issue%3D8%26spage%3D2011%26epage%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Shu</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Xueting  Huan</span>, <span class="hlFld-ContribAuthor ">Hao  Huang</span>, <span class="hlFld-ContribAuthor ">Manman  Wang</span>, <span class="hlFld-ContribAuthor ">Jianqiu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yile  Yan</span>, <span class="hlFld-ContribAuthor ">Jianming  Liu</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>, <span class="hlFld-ContribAuthor ">Dayong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>191 </em>, 112148. <a href="https://doi.org/10.1016/j.ejmech.2020.112148" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112148%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bpharmacological%252Bevaluation%252Bof%252B4-%252Bor%252B6-phenyl-pyrimidine%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252BJanus%252Bkinase%252B3%252Binhibitors%26aulast%3DShu%26aufirst%3DLei%26date%3D2020%26volume%3D191%26spage%3D112148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Janus Kinase 3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 225-256. <a href="https://doi.org/10.1007/7355_2020_96" title="DOI URL">https://doi.org/10.1007/7355_2020_96</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_96%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BJanus%252BKinase%252B3%252BInhibitors%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D225%26epage%3D256%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fuyun  Chi</span>, <span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Youjun  Xu</span>, <span class="hlFld-ContribAuthor ">Tengyue  Ma</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>. </span><span class="cited-content_cbyCitation_article-title">JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>95 </em>, 103542. <a href="https://doi.org/10.1016/j.bioorg.2019.103542" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103542%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DJAK3%252Binhibitors%252Bbased%252Bon%252Bthieno%25255B3%25252C2-d%25255Dpyrimidine%252Bscaffold%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Bbioactivity%252Bevaluation%252Bfor%252Bthe%252Btreatment%252Bof%252BB-cell%252Blymphoma%26aulast%3DChi%26aufirst%3DFuyun%26date%3D2020%26volume%3D95%26spage%3D103542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Hu</span>, <span class="hlFld-ContribAuthor ">Chengbo  Xu</span>, <span class="hlFld-ContribAuthor ">Chao  Yang</span>, <span class="hlFld-ContribAuthor ">Hongli  Zuo</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaona  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjie  Wang</span>, <span class="hlFld-ContribAuthor ">Jiangong  Shi</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-019-1062-x" title="DOI URL">https://doi.org/10.1186/s13046-019-1062-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-019-1062-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-019-1062-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DDiscovery%252Band%252Bevaluation%252Bof%252BZT55%25252C%252Ba%252Bnovel%252Bhighly-selective%252Btyrosine%252Bkinase%252Binhibitor%252Bof%252BJAK2V617F%252Bagainst%252Bmyeloproliferative%252Bneoplasms%26aulast%3DHu%26aufirst%3DMin%26date%3D2019%26date%3D2019%26volume%3D38%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Dai</span>, <span class="hlFld-ContribAuthor ">LiXi  Yang</span>, <span class="hlFld-ContribAuthor ">Glynn  Addison</span>. </span><span class="cited-content_cbyCitation_article-title">Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (18)
                                     , 1531-1543. <a href="https://doi.org/10.2174/1389557519666190617152011" title="DOI URL">https://doi.org/10.2174/1389557519666190617152011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557519666190617152011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557519666190617152011%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BStatus%252Bin%252Bthe%252BDiscovery%252Bof%252BCovalent%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BInhibitors%26aulast%3DDai%26aufirst%3DJun%26date%3D2019%26volume%3D19%26issue%3D18%26spage%3D1531%26epage%3D1543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Marjorie  Argollo</span>, <span class="hlFld-ContribAuthor ">Catherine  Le Berre</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. </span><span class="cited-content_cbyCitation_journal-name">Gut</span><span> <strong>2019,</strong> <em>68 </em>
                                    (10)
                                     , 1893-1899. <a href="https://doi.org/10.1136/gutjnl-2019-318448" title="DOI URL">https://doi.org/10.1136/gutjnl-2019-318448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/gutjnl-2019-318448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fgutjnl-2019-318448%26sid%3Dliteratum%253Aachs%26jtitle%3DGut%26atitle%3DJAK%252Bselectivity%252Bfor%252Binflammatory%252Bbowel%252Bdisease%252Btreatment%25253A%252Bdoes%252Bit%252Bclinically%252Bmatter%25253F%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2019%26date%3D2019%26volume%3D68%26issue%3D10%26spage%3D1893%26epage%3D1899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katie  Bechman</span>, <span class="hlFld-ContribAuthor ">Mark  Yates</span>, <span class="hlFld-ContribAuthor ">James B.  Galloway</span>. </span><span class="cited-content_cbyCitation_article-title">The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>147 </em>, 104392. <a href="https://doi.org/10.1016/j.phrs.2019.104392" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104392%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Bnew%252Bentries%252Bin%252Bthe%252Btherapeutic%252Barmamentarium%25253A%252BThe%252Bsmall%252Bmolecule%252BJAK%252Binhibitors%26aulast%3DBechman%26aufirst%3DKatie%26date%3D2019%26volume%3D147%26spage%3D104392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, <span class="hlFld-ContribAuthor ">Leena  Patel</span>, <span class="hlFld-ContribAuthor ">Kassandra F.  Sedillo</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule agents for the treatment of inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2034-2041. <a href="https://doi.org/10.1016/j.bmcl.2019.06.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall-molecule%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DCurrie%26aufirst%3DKevin%2BS.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2034%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Chiara  Greco</span>, <span class="hlFld-ContribAuthor ">Ilaria  Giacchello</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Munjed M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Giancarlo  Grossi</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>. </span><span class="cited-content_cbyCitation_article-title">An Update on JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (10)
                                     , 1806-1832. <a href="https://doi.org/10.2174/0929867325666180327093502" title="DOI URL">https://doi.org/10.2174/0929867325666180327093502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180327093502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180327093502%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BJAK%252BInhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2019%26volume%3D26%26issue%3D10%26spage%3D1806%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anja  Dullius</span>, <span class="hlFld-ContribAuthor ">Claudia Monfroni  Rocha</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Claucia Fernanda Volken  de Souza</span>, <span class="hlFld-ContribAuthor ">Márcia Inês  Goettert</span>. </span><span class="cited-content_cbyCitation_article-title">Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. </span><span class="cited-content_cbyCitation_journal-name">Inflammopharmacology</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 433-452. <a href="https://doi.org/10.1007/s10787-019-00589-2" title="DOI URL">https://doi.org/10.1007/s10787-019-00589-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10787-019-00589-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10787-019-00589-2%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammopharmacology%26atitle%3DAre%252Bpeptides%252Ba%252Bsolution%252Bfor%252Bthe%252Btreatment%252Bof%252Bhyperactivated%252BJAK3%252Bpathways%25253F%26aulast%3DDullius%26aufirst%3DAnja%26date%3D2019%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D433%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanislav  Andreev</span>, <span class="hlFld-ContribAuthor ">Tatu  Pantsar</span>, <span class="hlFld-ContribAuthor ">Francesco  Ansideri</span>, <span class="hlFld-ContribAuthor ">Mark  Kudolo</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3β Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2331. <a href="https://doi.org/10.3390/molecules24122331" title="DOI URL">https://doi.org/10.3390/molecules24122331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122331%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B7-Chloro-9H-pyrimido%25255B4%25252C5-b%25255Dindole-based%252BGlycogen%252BSynthase%252BKinase-3%2525CE%2525B2%252BInhibitors%26aulast%3DAndreev%26aufirst%3DStanislav%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian-Xin  Lin</span>, <span class="hlFld-ContribAuthor ">Warren J.  Leonard</span>. </span><span class="cited-content_cbyCitation_article-title">Fine-Tuning Cytokine Signals. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Immunology</span><span> <strong>2019,</strong> <em>37 </em>
                                    (1)
                                     , 295-324. <a href="https://doi.org/10.1146/annurev-immunol-042718-041447" title="DOI URL">https://doi.org/10.1146/annurev-immunol-042718-041447</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-immunol-042718-041447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-immunol-042718-041447%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Immunology%26atitle%3DFine-Tuning%252BCytokine%252BSignals%26aulast%3DLin%26aufirst%3DJian-Xin%26date%3D2019%26volume%3D37%26issue%3D1%26spage%3D295%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Warren J.  Leonard</span>, <span class="hlFld-ContribAuthor ">Jian-Xin  Lin</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications. </span><span class="cited-content_cbyCitation_journal-name">Immunity</span><span> <strong>2019,</strong> <em>50 </em>
                                    (4)
                                     , 832-850. <a href="https://doi.org/10.1016/j.immuni.2019.03.028" title="DOI URL">https://doi.org/10.1016/j.immuni.2019.03.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.immuni.2019.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.immuni.2019.03.028%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunity%26atitle%3DThe%252B%2525CE%2525B3c%252BFamily%252Bof%252BCytokines%25253A%252BBasic%252BBiology%252Bto%252BTherapeutic%252BRamifications%26aulast%3DLeonard%26aufirst%3DWarren%2BJ.%26date%3D2019%26volume%3D50%26issue%3D4%26spage%3D832%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anniina  T. Virtanen</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Juuli  Raivola</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">BioDrugs</span><span> <strong>2019,</strong> <em>33 </em>
                                    (1)
                                     , 15-32. <a href="https://doi.org/10.1007/s40259-019-00333-w" title="DOI URL">https://doi.org/10.1007/s40259-019-00333-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40259-019-00333-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40259-019-00333-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBioDrugs%26atitle%3DSelective%252BJAKinibs%25253A%252BProspects%252Bin%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DT.%2BVirtanen%26aufirst%3DAnniina%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D1%26spage%3D15%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Mimi T  Le</span>, <span class="hlFld-ContribAuthor ">Daniella M  Schwartz</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>, <span class="hlFld-ContribAuthor ">Shingo  Nakayamada</span>, <span class="hlFld-ContribAuthor ">Kunihiro  Yamaoka</span>, <span class="hlFld-ContribAuthor ">John J  O’Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases to jakinibs: from basic insights to clinical practice. </span><span class="cited-content_cbyCitation_journal-name">Rheumatology</span><span> <strong>2019,</strong> <em>58 </em>
                                    (Supplement_1)
                                     , i4-i16. <a href="https://doi.org/10.1093/rheumatology/key432" title="DOI URL">https://doi.org/10.1093/rheumatology/key432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/rheumatology/key432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Frheumatology%2Fkey432%26sid%3Dliteratum%253Aachs%26jtitle%3DRheumatology%26atitle%3DJanus%252Bkinases%252Bto%252Bjakinibs%25253A%252Bfrom%252Bbasic%252Binsights%252Bto%252Bclinical%252Bpractice%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3DSupplement_1%26spage%3Di4%26epage%3Di16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Ran</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Yanqiu  Gong</span>, <span class="hlFld-ContribAuthor ">Xiaoxin  Chen</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-23569-y" title="DOI URL">https://doi.org/10.1038/s41598-018-23569-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-23569-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-23569-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bselective%252BJAK3%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DPei%26aufirst%3DHeying%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosanne  Spolski</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Warren J.  Leonard</span>. </span><span class="cited-content_cbyCitation_article-title">Biology and regulation of IL-2: from molecular mechanisms to human therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Immunology</span><span> <strong>2018,</strong> <em>18 </em>
                                    (10)
                                     , 648-659. <a href="https://doi.org/10.1038/s41577-018-0046-y" title="DOI URL">https://doi.org/10.1038/s41577-018-0046-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41577-018-0046-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41577-018-0046-y%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Immunology%26atitle%3DBiology%252Band%252Bregulation%252Bof%252BIL-2%25253A%252Bfrom%252Bmolecular%252Bmechanisms%252Bto%252Bhuman%252Btherapy%26aulast%3DSpolski%26aufirst%3DRosanne%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D10%26spage%3D648%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Catrina  Johnson</span>, <span class="hlFld-ContribAuthor ">Daniella  Schwartz</span>, <span class="hlFld-ContribAuthor ">Michael  Bonelli</span>, <span class="hlFld-ContribAuthor ">Sarfaraz  Hasni</span>, <span class="hlFld-ContribAuthor ">Yuka  Kanno</span>, <span class="hlFld-ContribAuthor ">Paul  Changelian</span>, <span class="hlFld-ContribAuthor ">Arian  Laurence</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Leukocyte Biology</span><span> <strong>2018,</strong> <em>104 </em>
                                    (3)
                                     , 499-514. <a href="https://doi.org/10.1002/JLB.5RI0218-084R" title="DOI URL">https://doi.org/10.1002/JLB.5RI0218-084R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/JLB.5RI0218-084R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2FJLB.5RI0218-084R%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Leukocyte%2520Biology%26atitle%3DTranslational%252Band%252Bclinical%252Badvances%252Bin%252BJAK-STAT%252Bbiology%25253A%252BThe%252Bpresent%252Band%252Bfuture%252Bof%252Bjakinibs%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2018%26date%3D2018%26volume%3D104%26issue%3D3%26spage%3D499%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Yin</span>, <span class="hlFld-ContribAuthor ">Cheng-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Ru-Nan  Yu</span>, <span class="hlFld-ContribAuthor ">Zhi-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tian-Tai  Zhang</span>, <span class="hlFld-ContribAuthor ">Da-Yong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (17)
                                     , 4774-4786. <a href="https://doi.org/10.1016/j.bmc.2018.04.005" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amino%252Bderivatives%252Bas%252BJanus%252Bkinase%252B3%252Binhibitors%26aulast%3DYin%26aufirst%3DYuan%26date%3D2018%26volume%3D26%26issue%3D17%26spage%3D4774%26epage%3D4786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (2)
                                     , 343-358. <a href="https://doi.org/10.1007/s11030-017-9803-2" title="DOI URL">https://doi.org/10.1007/s11030-017-9803-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9803-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9803-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252BSAR%252Bstudy%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Birreversible%252Bcovalent%252BJAK3%252Binhibitors%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D2%26spage%3D343%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Zifei  Han</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Li</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 836-848. <a href="https://doi.org/10.1016/j.ejmech.2018.03.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C6-disubstituted-9H-purine%25252C%252B2%25252C4-disubstitued-thieno%25255B3%25252C2-d%25255Dpyrimidine%252Band%252B-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Banalogues%252Bas%252Bnovel%252BCHK1%252Binhibitors%26aulast%3DTian%26aufirst%3DChao%26date%3D2018%26volume%3D151%26spage%3D836%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (16)
                                     , 4456-4470. <a href="https://doi.org/10.1002/ange.201707875" title="DOI URL">https://doi.org/10.1002/ange.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDas%252BCysteinom%252Bder%252BProteinkinasen%252Bals%252BZielstruktur%252Bin%252Bder%252BArzneistoffentwicklung%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D16%26spage%3D4456%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">The Cysteinome of Protein Kinases as a Target in Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (16)
                                     , 4372-4385. <a href="https://doi.org/10.1002/anie.201707875" title="DOI URL">https://doi.org/10.1002/anie.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DThe%252BCysteinome%252Bof%252BProtein%252BKinases%252Bas%252Ba%252BTarget%252Bin%252BDrug%252BDevelopment%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D16%26spage%3D4372%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shijie  Song</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Huang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Yongming  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jihong  Yao</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1847-1857. <a href="https://doi.org/10.1016/j.ejmech.2017.10.080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bhighly%252Bpotent%252BBTK%252Band%252BJAK3%252Bdual%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Bfor%252Bthe%252Btreatment%252Bof%252BB-cell%252Blymphoma%26aulast%3DGe%26aufirst%3DYang%26date%3D2018%26volume%3D143%26spage%3D1847%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M L  Robinette</span>, <span class="hlFld-ContribAuthor ">M  Cella</span>, <span class="hlFld-ContribAuthor ">J B  Telliez</span>, <span class="hlFld-ContribAuthor ">T K  Ulland</span>, <span class="hlFld-ContribAuthor ">A D  Barrow</span>, <span class="hlFld-ContribAuthor ">K  Capuder</span>, <span class="hlFld-ContribAuthor ">S  Gilfillan</span>, <span class="hlFld-ContribAuthor ">L-L  Lin</span>, <span class="hlFld-ContribAuthor ">L D  Notarangelo</span>, <span class="hlFld-ContribAuthor ">M  Colonna</span>. </span><span class="cited-content_cbyCitation_article-title">Jak3 deficiency blocks innate lymphoid cell development. </span><span class="cited-content_cbyCitation_journal-name">Mucosal Immunology</span><span> <strong>2018,</strong> <em>11 </em>
                                    (1)
                                     , 50-60. <a href="https://doi.org/10.1038/mi.2017.38" title="DOI URL">https://doi.org/10.1038/mi.2017.38</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/mi.2017.38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fmi.2017.38%26sid%3Dliteratum%253Aachs%26jtitle%3DMucosal%2520Immunology%26atitle%3DJak3%252Bdeficiency%252Bblocks%252Binnate%252Blymphoid%252Bcell%252Bdevelopment%26aulast%3DRobinette%26aufirst%3DM%2BL%26date%3D2018%26date%3D2017%26volume%3D11%26issue%3D1%26spage%3D50%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yao  Yao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 493-505. <a href="https://doi.org/10.1016/j.ejmech.2017.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bbinding%252Bdesign%252Bstrategy%25253A%252BA%252Bprospective%252Bmethod%252Bfor%252Bdiscovery%252Bof%252Bpotent%252Btargeted%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2017%26volume%3D142%26spage%3D493%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (11)
                                     , 1700194. <a href="https://doi.org/10.1002/ardp.201700194" title="DOI URL">https://doi.org/10.1002/ardp.201700194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700194%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252Ba%252BHighly%252BSelective%252BJAK3%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D11%26spage%3D1700194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James  Kempson</span>, <span class="hlFld-ContribAuthor ">Damaso  Ovalle</span>, <span class="hlFld-ContribAuthor ">Junqing  Guo</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>, <span class="hlFld-ContribAuthor ">Shuqun  Lin</span>, <span class="hlFld-ContribAuthor ">Steven H.  Spergel</span>, <span class="hlFld-ContribAuthor ">James J.-W.  Duan</span>, <span class="hlFld-ContribAuthor ">Bin  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhonghui  Lu</span>, <span class="hlFld-ContribAuthor ">Jagabandhu  Das</span>, <span class="hlFld-ContribAuthor ">Bingwei V.  Yang</span>, <span class="hlFld-ContribAuthor ">John  Hynes</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">John  Tokarski</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Javed  Khan</span>, <span class="hlFld-ContribAuthor ">Gary  Schieven</span>, <span class="hlFld-ContribAuthor ">Yuval  Blatt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of highly potent, selective, covalent inhibitors of JAK3. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (20)
                                     , 4622-4625. <a href="https://doi.org/10.1016/j.bmcl.2017.09.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Bcovalent%252Binhibitors%252Bof%252BJAK3%26aulast%3DKempson%26aufirst%3DJames%26date%3D2017%26volume%3D27%26issue%3D20%26spage%3D4622%26epage%3D4625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liron  Bar-Peled</span>, <span class="hlFld-ContribAuthor ">Esther K.  Kemper</span>, <span class="hlFld-ContribAuthor ">Radu M.  Suciu</span>, <span class="hlFld-ContribAuthor ">Ekaterina V.  Vinogradova</span>, <span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>, <span class="hlFld-ContribAuthor ">Benjamin D.  Horning</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Paul</span>, <span class="hlFld-ContribAuthor ">Taka-Aki  Ichu</span>, <span class="hlFld-ContribAuthor ">Robert U.  Svensson</span>, <span class="hlFld-ContribAuthor ">Jose  Olucha</span>, <span class="hlFld-ContribAuthor ">Max W.  Chang</span>, <span class="hlFld-ContribAuthor ">Bernard P.  Kok</span>, <span class="hlFld-ContribAuthor ">Zhou  Zhu</span>, <span class="hlFld-ContribAuthor ">Nathan T.  Ihle</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Ping  Jiang</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">Enrique  Saez</span>, <span class="hlFld-ContribAuthor ">Reuben J.  Shaw</span>, <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2017,</strong> <em>171 </em>
                                    (3)
                                     , 696-709.e23. <a href="https://doi.org/10.1016/j.cell.2017.08.051" title="DOI URL">https://doi.org/10.1016/j.cell.2017.08.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2017.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2017.08.051%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DChemical%252BProteomics%252BIdentifies%252BDruggable%252BVulnerabilities%252Bin%252Ba%252BGenetically%252BDefined%252BCancer%26aulast%3DBar-Peled%26aufirst%3DLiron%26date%3D2017%26volume%3D171%26issue%3D3%26spage%3D696%26epage%3D709.e23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (18)
                                     , 4229-4237. <a href="https://doi.org/10.1016/j.bmcl.2017.07.079" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.07.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.07.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.07.079%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Badvances%252Bin%252BJAK3%252Binhibition%25253A%252BIsoform%252Bselectivity%252Bby%252Bcovalent%252Bcysteine%252Btargeting%26aulast%3DForster%26aufirst%3DMichael%26date%3D2017%26volume%3D27%26issue%3D18%26spage%3D4229%26epage%3D4237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FDA approved JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Crystal structure of tofacitinib in JAK3 illustrating key movement around the N–C axis that would place the amide in close proximity to Cys-909. (b) Dependency of the NMe group on conformational energetics with conformer A being favored by 70:30 for <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Correlation between our IL-15 PBMC assay and the corresponding HWB assay. Anilinoacrylamide = blue, aliphaticacrylamide = green. (b) Stability of the compounds in HWB: <i>T</i><sub>1/2</sub>, <100 min, magenta; 100–200 min, tan; 200–300 min, yellow; >300 min, green (<i>n</i> = 107).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Illustration of individual binding and reactive events required for covalent modification of Cys-909 in JAK3: E = enzyme, S = substrate, I = inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of compounds bound to JAK3 with a covalent bond to Cys-909: (a) <b>4</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTS">5TTS</a>; (b) <b>6</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTV">5TTV</a>; (c) <b>7</b> PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTU">5TTU</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of <b>7</b>. Eight-week-old female BALB/c mice (Taconic) were sensitized with 2 × 10<sup>7</sup> sheep red blood cells (sRBCs) subcutaneously on day 0. Oral dosing began on day 0 prior to the sensitization and continuing through day 6. The mice were challenged with 1 × 10<sup>8</sup> sRBCs in the right hind foot pad, and the left hind footpad received an injection of sterile PBS. Paw thickness was measured prior to the injection for a baseline measurement and then again at 24 h via caliper. Paw thickness was significantly reduced in a dose-dependent manner compared to the mice that were dosed with the vehicle. All compounds were dosed twice daily except where otherwise noted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Kinome selectivity of <b>11</b> determined at 1 μM for 305 kinases determined at Invitrogen. The percent inhibition is color coded and ranges from 0% inhibition (darker green) to 100% inhibition (darker red) with 50% inhibition displayed in yellow. The selectivity determined by Gini coefficient is 0.88. (b) Kinases tested that contained CYS in the ATP site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Acrylamides <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of acryloyl chloride, 1.3 equiv of TEA, DCM, 0 °C, 1 h, 32%; (b) 1.2 equiv of <b>23</b>, 1.2 of equiv DIPEA, <i>n</i>-BuOH, 70 °C, 14 h, 42%; (c) 2 equiv of LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (1:1:1), 60 °C, 1 h, 70%; (d) 4 N HCl/dioxane, rt, 92%; (e) 1.0 equiv of acryloyl chloride, DCM/EtOH (10:1), 4.4 equiv of TEA, 0 °C, 2 h, 33%; (f) 1.0 equiv of (<i>E</i>)-but-2-enoyl chloride, DCM/EtOH (10:1), 4.4 equiv of TEA, 0 °C, 2 h, 38%; (g) 1.0 equiv of <b>28</b>, 5.0 equiv of DIPEA, <i>n</i>-BuOH, 130 °C, 60%; (h) 10% Pd/C, MeOH/THF (∼2:1), 50 psi, H<sub>2</sub>, 48 h, 100%; (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 76%; (j) 0.86 equiv of acrylogyl chloride, THF/H<sub>2</sub>O, NaHCO<sub>3</sub>, 5 °C, 1 h, 14%; (k) 1.2 equiv of <b>32</b>, 3.0 equiv of K<sub>2</sub>CO<sub>3</sub> dioxane/H<sub>2</sub>O (5:1), 0.1 equiv of Pd(PPh<sub>3</sub>)<sub>4</sub>, 110 °C, 16 h, 50%; (l) 1.0 equiv of acryloyl chloride, THF, 4.0 equiv of TEA, 0 °C, 2 h, 20%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>7</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2.2 equiv of DIPEA, 1.2 equiv of CbzCI, DCM, 45 min, 90%; (b) 4 N HCl/dioxane, rt, 15 h, 85%; (c) SFC purification, AS 250 mm × 50 mm, 10 μm, CO<sub>2</sub>/EtOH (0.05%DEA); (d) 1.1 equiv of <b>38a</b>, 4.5 equiv of DIPEA, <i>n</i>-BuOH, 80 °C, 3 h, 80%; (e) 10 mol % 10%Pd/C, EtOH, 50 psi H<sub>2</sub>, 65 °C, 48 h, 90%; (f) 1.1 equiv of acryloyl chloride, 3.3 equiv of NaHCO<sub>3</sub>, H<sub>2</sub>O, CH<sub>3</sub>CN, 0 °C, 81%; (g) 1.1 equiv of AcCl, 5.1 equiv of DIPEA, DCM, 0 °C, 74%.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of <b>42</b>, 4.0 equiv of DIPEA, <i>n</i>-BuOH, 85 °C, 18 h, 36%; (b) 3.0 equiv of LiOH·H<sub>2</sub>O, MeOH/H<sub>2</sub>O (3:1), 60 °C, 1.5 h, 91%; (c) 1.0 equiv of Pd(OH)<sub>2</sub>, MeOH, 40 equiv of cyclohexadiene, 14 h, 52%; (d) 1.1 equiv of acryloyl chloride, DCM, 5.0 equiv of DIPEA, DCM, 0 °C, 2 h, 71%.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>11</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.3 equiv of Boc<sub>2</sub>O, EtOH, 0 °C, 14 h, 67%; (b) 10 mol % PtO<sub>2</sub>, HOAc, 55 psi H<sub>2</sub>, 50 °C, 100%, ∼2:1 cis/trans; (c) 1.5 equiv of CbzCl, 7.0 equiv of NaHCO<sub>3</sub>, THF/H<sub>2</sub>O (1:1), 100%; (d) chiral SFC, ChiralCel OD 300 mm × 50 mm, 10 μm, CO<sub>2</sub>/IPA (0.1% NH<sub>3</sub>); (e) 4 N HCl/dioxane, DCM, rt; (f) 1.1 equiv of <b>51b</b> or <b>51a</b>, 5.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 14 h, 86%; (g) 10 mol % 10%Pd/C, MeOH/THF (6:1), 45 psi H<sub>2</sub>, 25 °C, 48 h, 95%; (h) 1.2 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 38%; (i) chiral SFC, ChiralPak IC 300 mm × 50 μm, 10 μm, CO<sub>2</sub>/EtOH (0.05% NH3), 45%.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of Boc<sub>2</sub>O, THF, rt, 5 h, 69%; (b) 10 mol % PtO<sub>2</sub>, HOAc, 5 d, 55 psi H<sub>2</sub>, 50 °C, 100%, mixture cis/trans; (c) 1.2 equiv of CbzCl, 3.8 equiv of NaHCO<sub>3</sub>, rt, THF/H<sub>2</sub>O (2:1), 8 h, 45%; (d) 4 N HCl/dioxane, DCM, rt, 43%; (e) 1.1 equiv of <b>62a</b>,<b>b</b>, 4.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 30 h, 34% (cis) and 10% (trans); (f) 10 mol % 10% Pd/C, MeOH/THF (3:1), 50 psi H<sub>2</sub>, 40 °C, 3 d, 100%; (g) 1.1 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 2 h, 71% (for <b>64</b>); 50% (for <b>66</b>); (h) chiral SFC, AD 250 mm × 30 mm, 20 μm, CO<sub>2</sub>/MeOH (0.05% NH<sub>3</sub>), 45% (for <b>15</b> and <b>17</b>); 40% (for <b>18</b> and <b>16</b>).</p></p></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/medium/jm-2016-01694j_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01694/20170303/images/large/jm-2016-01694j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01694&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of <b>69</b>, 3.0 equiv of DIPEA, <i>n</i>-BuOH, 140 °C, 24 h, 66%; (b) 10 mol % 10% Pd/C, MeOH/THF (3:1), 50 psi H<sub>2</sub>, 40 °C, 2 d, 93%; (c) 4 N HCl/dioxane, 0 °C, 100%; (d) 1.1 equiv of acryloyl chloride, sat. NaHCO<sub>3</sub>, THF, 0 °C, 2 h, 34%; (e) chiral SFC, AD 250 mm × 30 mm, 5 μm, CO<sub>2</sub>/EtOH (0.05% NH<sub>3</sub>), 45% (for <b>19</b> and <b>20</b>).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J.</span><span> </span><span class="NLM_article-title">JAK kinases in health and disease: An update</span> <span class="citation_source-journal">Open Rheumatol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+An+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lgL7b6dZ4HGOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520An%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective TYK2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1517/13543776.2012.723693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+TYK2+inhibitor+patents&doi=10.1517%2F13543776.2012.723693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0lgL7b6dZ4HGOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520TYK2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249%26doi%3D10.1517%2F13543776.2012.723693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Wilson, L. J.</span><span> </span><span class="NLM_article-title">Recent patents in the discovery of small molecule inhibitors of JAK3</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1517/13543771003709767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1517%2F13543771003709767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20402545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=609-623&author=L.+J.+Wilson&title=Recent+patents+in+the+discovery+of+small+molecule+inhibitors+of+JAK3&doi=10.1517%2F13543771003709767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent patents in the discovery of small molecule inhibitors of JAK3</span></div><div class="casAuthors">Wilson, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Protein kinase enzymes have become increasingly important as the target of many disease modification drug discovery programs.  Disruption of JAK3 function results in quant. and qual. deficiencies in both B- and T-cell compartments of the immune system of JAK3 deficient mice and development of severe combined immunodeficiency in humans with the JAK3 genetic aberration.  JAK3 plays a specific role in immune function and lymphoid development and it only resides in the hematopoietic system, thus the rationale for selective targeting.  Inhibitors of JAK3 have shown utility in many different autoimmune disorders, including allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergic and asthmatic diseases.  These inhibitors are making their way into clin. trials with profound effects, thus, validating the target and strategy.  Areas covered in this review: A review that covers around 90 patents and patent applications made in the last 10 years in the area involving JAK3 inhibitors is provided.  Specifically, what this content will provide is the genus, highlighted compds. of particular interest, filing organization and some biol. measure of these compds. as inhibitors of this protein kinase or none if it is not provided.  Some information from original research articles appearing in peer reviewed literature is provided, but this article is not a review of the literature.  Furthermore, an overview of the current clin. status and future outcomes of this field is provided as summary.  What the reader will gain: A strong understanding for the current state of the art in patents dealing with inhibitors of JAK3 including genus and species designations, potential com. interest of this target in the pharmaceutical community, depth of coverage by nos. of examples and selected proof of action against the target.  Also, a brief understanding of the biol. and pharmacol. involved in the processes involving the research, discovery, characterization and clin. status of JAK3 inhibitors.  Take home message: This review is intended for medicinal chemists and patent agents who want to get a quick understanding of the state of the art in the field of JAK3 inhibitors.  It further serves as a ref. point to go into more depth on any series reported and to be able to evaluate any original research ideas in this area in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro9U4cmf9rH7Vg90H21EOLACvtfcHk0liU2OXNDMKMew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWhtrY%253D&md5=ddc7a801bc9fd439ac204f3bc6f106e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F13543771003709767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003709767%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DL.%2BJ.%26atitle%3DRecent%2520patents%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520JAK3%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D609%26epage%3D623%26doi%3D10.1517%2F13543771003709767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0liU2OXNDMKMew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x"> (</span><span class="NLM_issue">5237</span><span class="NLM_x">) </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&issue=5237&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5237%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drückes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the Janus kinase Jak3-Are they effective?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4617</span><span class="NLM_x">–</span> <span class="NLM_lpage">4621</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2014.08.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4617-4621&author=G.+Thomaauthor=P.+Dr%C3%BCckesauthor=H.+G.+Zerwes&title=Selective+inhibitors+of+the+Janus+kinase+Jak3-Are+they+effective%3F&doi=10.1016%2Fj.bmcl.2014.08.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DDr%25C3%25BCckes%26aufirst%3DP.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520Janus%2520kinase%2520Jak3-Are%2520they%2520effective%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4617%26epage%3D4621%26doi%3D10.1016%2Fj.bmcl.2014.08.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.+B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+Kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0liU2OXNDMKMew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520Kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Alicea-Vela̅zquez, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">The use of structural biology in Janus kinase targeted drug discovery</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Vela%CC%85zquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+Janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0ljyCpdCj9Jrdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Vela%25CC%2585zquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520Janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Goedken, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argiriadi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banach, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiamengo, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, J. W.</span><span> </span><span class="NLM_article-title">Tricyclic covalent inhibitors selectively target Jak3 through an active-site thiol</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">4573</span><span class="NLM_x">–</span> <span class="NLM_lpage">4589</span><span class="refDoi"> DOI: 10.1074/jbc.M114.595181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1074%2Fjbc.M114.595181" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=4573-4589&author=E.+R.+Goedkenauthor=M.+A.+Argiriadiauthor=D.+L.+Banachauthor=B.+A.+Fiamengoauthor=S.+E.+Foleyauthor=K.+E.+Frankauthor=J.+S.+Georgeauthor=C.+M.+Harrisauthor=A.+D.+Hobsonauthor=D.+C.+Ihleauthor=D.+Marcotteauthor=P.+J.+Mertaauthor=M.+E.+Michalakauthor=S.+E.+Murdockauthor=M.+J.+Tomlinsonauthor=J.+W.+Voss&title=Tricyclic+covalent+inhibitors+selectively+target+Jak3+through+an+active-site+thiol&doi=10.1074%2Fjbc.M114.595181"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.595181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.595181%26sid%3Dliteratum%253Aachs%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DArgiriadi%26aufirst%3DM.%2BA.%26aulast%3DBanach%26aufirst%3DD.%2BL.%26aulast%3DFiamengo%26aufirst%3DB.%2BA.%26aulast%3DFoley%26aufirst%3DS.%2BE.%26aulast%3DFrank%26aufirst%3DK.%2BE.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHobson%26aufirst%3DA.%2BD.%26aulast%3DIhle%26aufirst%3DD.%2BC.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DMerta%26aufirst%3DP.%2BJ.%26aulast%3DMichalak%26aufirst%3DM.%2BE.%26aulast%3DMurdock%26aufirst%3DS.%2BE.%26aulast%3DTomlinson%26aufirst%3DM.%2BJ.%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26atitle%3DTricyclic%2520covalent%2520inhibitors%2520selectively%2520target%2520Jak3%2520through%2520an%2520active-site%2520thiol%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D4573%26epage%3D4589%26doi%3D10.1074%2Fjbc.M114.595181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyskens, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herter-Sprie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannessen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akbay, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Development of selective covalent JAK3 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6589</span><span class="NLM_x">–</span> <span class="NLM_lpage">6606</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00710</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00710" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6589-6606&author=L.+Tanauthor=K.+Akahaneauthor=R.+McNallyauthor=K.+M.+Reyskensauthor=S.+B.+Ficarroauthor=S.+Liuauthor=G.+S.+Herter-Sprieauthor=S.+Koyamaauthor=M.+J.+Pattisonauthor=K.+M.+Labellaauthor=L.+Johannessenauthor=E.+A.+Akbayauthor=K.+K.+Wongauthor=D.+A.+Frankauthor=J.+A.+Martoauthor=A.+T.+Lookauthor=S.+Arthurauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Development+of+selective+covalent+JAK3+inhibitors&doi=10.1021%2Facs.jmedchem.5b00710"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00710%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAkahane%26aufirst%3DK.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DReyskens%26aufirst%3DK.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DPattison%26aufirst%3DM.%2BJ.%26aulast%3DLabella%26aufirst%3DK.%2BM.%26aulast%3DJohannessen%26aufirst%3DL.%26aulast%3DAkbay%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DArthur%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520selective%2520covalent%2520JAK3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6589%26epage%3D6606%26doi%3D10.1021%2Facs.jmedchem.5b00710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lgB525NZWn3sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">We evaluated the conformational preference of compounds <b>4</b> and <b>5</b> with high-level DFT calculations (ref) using the M06-2X method and 6-31G* basis set. These calculations suggest that conformer A where the N–H group is oriented toward the pyrrole ring is energetically favored over the alternative rotational isomer in the gas phase by ∼0.6 kcal/mol and resulting in a 70:30 distribution for the two conformers. In contrast for the N-Me group both conformers are almost equally populated in the gas phase with the conformational energy difference being only 0.02 kcal/mol.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi-Fard, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, H. L.</span><span> </span><span class="NLM_article-title">Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1002/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=1404-1414&author=T.+S.+Maurerauthor=M.+A.+Tabrizi-Fardauthor=H.+L.+Fung&title=Impact+of+mechanism-based+enzyme+inactivation+on+inhibitor+potency%3A+implications+for+rational+drug+discovery&doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1520-6017%2528200011%252989%253A11%253C1404%253A%253AAID-JPS4%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DTabrizi-Fard%26aufirst%3DM.%2BA.%26aulast%3DFung%26aufirst%3DH.%2BL.%26atitle%3DImpact%2520of%2520mechanism-based%2520enzyme%2520inactivation%2520on%2520inhibitor%2520potency%253A%2520implications%2520for%2520rational%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D89%26spage%3D1404%26epage%3D1414%26doi%3D10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Thorarensen, A.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thorarensen%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+computational+methods+for+the+characterization+of+covalent+reactive+groups+for+the+prospective+design+of+irreversible+inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lgB525NZWn3sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520computational%2520methods%2520for%2520the%2520characterization%2520of%2520covalent%2520reactive%2520groups%2520for%2520the%2520prospective%2520design%2520of%2520irreversible%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0li5XBvjKVGt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5112</span><span class="NLM_x">–</span> <span class="NLM_lpage">5128</span><span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+Liauthor=Y.+Zuoauthor=G.+Tangauthor=Y.+Wangauthor=Y.+Zhouauthor=X.+Wangauthor=T.+Guoauthor=M.+Xiaauthor=N.+Dingauthor=Z.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0li5XBvjKVGt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0li5XBvjKVGt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Siewert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Esterl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, F.</span><span> </span><span class="NLM_article-title">Different protein turnover of interleukin-6-type cytokine signaling components</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1046/j.1432-1327.1999.00719.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1046%2Fj.1432-1327.1999.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10491180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1999&pages=251-257&author=E.+Siewertauthor=W.+M%C3%BCller-Esterlauthor=R.+Starrauthor=P.+C.+Heinrichauthor=F.+Schaper&title=Different+protein+turnover+of+interleukin-6-type+cytokine+signaling+components&doi=10.1046%2Fj.1432-1327.1999.00719.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Different protein turnover of interleukin-6-type cytokine signalling components</span></div><div class="casAuthors">Siewert, Elmar; Muller-Esterl, Werner; Starr, Robin; Heinrich, Peter C.; Schaper, Fred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Interleukin (IL)-6 and IL-6-type cytokines signal through the gp130/Jak/STAT signal transduction pathway.  The key components involved are the signal transducing receptor subunit gp130, the Janus kinases Jak1, Jak2 and Tyk2, STAT1 and STAT3 of the family of signal transducers and activators of transcription, the protein tyrosine phosphatase SHP2 and the suppressors of cytokine signalling SOCS1, SOCS2 and SOCS3.  Whereas considerable information has been accumulated concerning the time-course of activation for the individual signalling mols., data on the availability of the proteins involved in IL-6-type cytokine signal transduction are scarce.  Nevertheless, availability of these mols., detd. by the balance of protein synthesis and degrdn., also influences IL-6-type cytokine signal transduction.  Here, we present a comprehensive set of data on the half-lives of the key mols. involved in the IL-6 signal transduction pathway.  The turnover rates for the various proteins differ substantially.  Three groups of signalling proteins can be discriminated: whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3 and SHP2 have an extremely slow turnover rate.  Interestingly, the half-life of STAT3β, a splice variant of STAT3α, is reduced to almost 50% of the half-life of STAT3α.  The Janus kinases Jak1, Jak2, Tyk2 and gp130 show intermediate half-lives.  The data imply that signalling components activated by post-translational modifications are long-lived whereas the activity of very short-lived proteins is regulated mainly at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykEOWrPY1qrVg90H21EOLACvtfcHk0lhS08zJxOnPMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D&md5=9a92232aa03148d1a70e5a9c2cd89733</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DSiewert%26aufirst%3DE.%26aulast%3DM%25C3%25BCller-Esterl%26aufirst%3DW.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DSchaper%26aufirst%3DF.%26atitle%3DDifferent%2520protein%2520turnover%2520of%2520interleukin-6-type%2520cytokine%2520signaling%2520components%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D265%26spage%3D251%26epage%3D257%26doi%3D10.1046%2Fj.1432-1327.1999.00719.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Telliez, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jussif, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unwalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajdos, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoghegan, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel JAK3-selective inhibitor: Functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3442</span><span class="NLM_x">–</span> <span class="NLM_lpage">3451</span><span class="refDoi"> DOI: 10.1021/acschembio.6b00677</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00677" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3442-3451&author=J.+B.+Telliezauthor=M.+E.+Dowtyauthor=L.+Wangauthor=J.+Jussifauthor=T.+Linauthor=L.+Liauthor=E.+Moyauthor=P.+Balboauthor=W.+Liauthor=Y.+Zhaoauthor=K.+Crouseauthor=C.+Dickinsonauthor=P.+Symanowiczauthor=M.+Hegenauthor=M.+E.+Bankerauthor=F.+Vincentauthor=R.+Unwallaauthor=S.+Liangauthor=A.+M.+Gilbertauthor=M.+F.+Brownauthor=M.+Haywardauthor=J.+Montgomeryauthor=X.+Yangauthor=J.+Baumanauthor=J.+I.+Trujilloauthor=A.+Casimiro-Garciaauthor=F.+F.+Vajdosauthor=L.+Leungauthor=K.+F.+Geogheganauthor=A.+Quaziauthor=D.+Xuanauthor=L.+H.+Jonesauthor=E.+Hettauthor=K.+Wrightauthor=J.+D.+Clarkauthor=A.+Thorarensen&title=Discovery+of+a+novel+JAK3-selective+inhibitor%3A+Functional+differentiation+of+JAK3-selective+inhibition+over+pan-JAK+or+JAK1-selective+inhibition&doi=10.1021%2Facschembio.6b00677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DBalbo%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCrouse%26aufirst%3DK.%26aulast%3DDickinson%26aufirst%3DC.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DQuazi%26aufirst%3DA.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DHett%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520JAK3-selective%2520inhibitor%253A%2520Functional%2520differentiation%2520of%2520JAK3-selective%2520inhibition%2520over%2520pan-JAK%2520or%2520JAK1-selective%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D3442%26epage%3D3451%26doi%3D10.1021%2Facschembio.6b00677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foltin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beidler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6545</span><span class="NLM_x">–</span> <span class="NLM_lpage">6553</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2011.08.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6545-6553&author=M.+J.+Meyersauthor=S.+A.+Longauthor=M.+J.+Pelcauthor=J.+L.+Wangauthor=S.+J.+Bowenauthor=B.+A.+Schweitzerauthor=M.+V.+Wilcoxauthor=J.+McDonaldauthor=S.+E.+Smithauthor=S.+Foltinauthor=J.+Rumseyauthor=Y.+S.+Yangauthor=M.+C.+Walkerauthor=S.+Kamtekarauthor=D.+Beidlerauthor=A.+Thorarensen&title=Discovery+of+novel+spirocyclic+inhibitors+of+fatty+acid+amide+hydrolase+%28FAAH%29.+Part+2.+Discovery+of+7-azaspiro%5B3.5%5Dnonane+urea+PF-04862853%2C+an+orally+efficacious+inhibitor+of+fatty+acid+amide+hydrolase+%28FAAH%29+for+pain&doi=10.1016%2Fj.bmcl.2011.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DLong%26aufirst%3DS.%2BA.%26aulast%3DPelc%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DBowen%26aufirst%3DS.%2BJ.%26aulast%3DSchweitzer%26aufirst%3DB.%2BA.%26aulast%3DWilcox%26aufirst%3DM.%2BV.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DFoltin%26aufirst%3DS.%26aulast%3DRumsey%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DWalker%26aufirst%3DM.%2BC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%2520spirocyclic%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529.%2520Part%25202.%2520Discovery%2520of%25207-azaspiro%255B3.5%255Dnonane%2520urea%2520PF-04862853%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%2520for%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6545%26epage%3D6553%26doi%3D10.1016%2Fj.bmcl.2011.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.bmcl.2011.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=21958547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12jsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.+H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.bmcl.2011.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Kim, Kyung-Hee; Maderna, Andreas; Schnute, Mark E.; Hegen, Martin; Mohan, Shashi; Miyashiro, Joy; Lin, Laura; Li, Evelyn; Keegan, Sean; Lussier, Jennifer; Wrocklage, Christopher; Nickerson-Nutter, Cheryl L.; Wittwer, Arthur J.; Soutter, Holly; Caspers, Nicole; Han, Seung-Il; Kurumbail, Ravi; Dunussi-Joannopoulos, Kyri; Douhan, John, III; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6258-6263</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors.  The syntheses and SAR of this series of compds. are presented as well as the X-ray crystal structure of the lead compd. I in complex with a gate-keeper variant of ITK enzyme.  The lead compd. showed good in vivo efficacy in preclin. RA models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfyHkAnJXNpLVg90H21EOLACvtfcHk0likynIZRoKadw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12jsbfO&md5=500482f7b4005a5c343da07c0e7d2319</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263%26doi%3D10.1016%2Fj.bmcl.2011.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shibata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0likynIZRoKadw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span> </span><span class="NLM_article-title">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1124/dmd.116.072983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1124%2Fdmd.116.072983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=27784718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1-7&author=L.+Leungauthor=X.+Yangauthor=T.+J.+Strelevitzauthor=J.+Montgomeryauthor=M.+F.+Brownauthor=M.+A.+Zientekauthor=C.+Banfieldauthor=A.+M.+Gilbertauthor=A.+Thorarensenauthor=E.+Martinauthor=M.+E.+Dowty&title=Clearance+prediction+of+targeted+covalent+inhibitors+by+in+vitro-in+vivo+extrapolation+of+hepatic+and+extrahepatic+clearance+mechanisms&doi=10.1124%2Fdmd.116.072983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span></div><div class="casAuthors">Leung, Louis; Yang, Xin; Strelevitz, Timothy J.; Montgomery, Justin; Brown, Matthew F.; Zientek, Michael A.; Banfield, Christopher; Gilbert, Adam M.; Thorarensen, Atli; Dowty, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of target-specific covalent enzyme inhibitors appears attractive from both an efficacy and a selectivity viewpoint considering the potential for enhanced biochem. efficiency assocd. with an irreversible mechanism.  Aside from potential safety concerns, clearance prediction of covalent inhibitors represents a unique challenge due to the inclusion of nontraditional metabolic pathways of direct conjugation with glutathione (GSH) or via GSH S-transferase-mediated processes.  In this article, a novel pharmacokinetic algorithm was developed using a series of Pfizer kinase selective acrylamide covalent inhibitors based on their in vitro-in vivo extrapolation of systemic clearance in rats.  The algorithmencompasses the use of hepatocytes as an in vitro model for hepatic clearance due to oxidative metab. and GSH conjugation, and the use of whole blood as an in vitro surrogate for GSH conjugation in extrahepatic tissues.  Initial evaluations with clin. covalent inhibitors suggested that the scaling algorithm developed from rats may also be useful for human clearance prediction when species-specific parameters, such as hepatocyte and blood stability and blood binding, were considered.  With careful consideration of clearance mechanisms, the described in vitro-in vivo extrapolation approach may be useful to facilitate candidate optimization, selection, and prediction of human pharmacokinetic clearance during the discovery and development of targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvIMBCrCxzNLVg90H21EOLACvtfcHk0likynIZRoKadw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D&md5=8c8b918b087278b2025e0ae56a7abe37</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072983%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26atitle%3DClearance%2520prediction%2520of%2520targeted%2520covalent%2520inhibitors%2520by%2520in%2520vitro-in%2520vivo%2520extrapolation%2520of%2520hepatic%2520and%2520extrahepatic%2520clearance%2520mechanisms%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1%26epage%3D7%26doi%3D10.1124%2Fdmd.116.072983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamper, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrer, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilworth, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmeier, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radabaugh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zutshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Discovery of an oral potent selective inhibitor of hematopoietic prostaglandin D synthase (HPGDS)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/ml900025z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900025z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=59-63&author=C.+P.+Carronauthor=J.+I.+Trujilloauthor=K.+L.+Olsonauthor=W.+Huangauthor=B.+C.+Hamperauthor=T.+Diceauthor=B.+E.+Nealauthor=M.+J.+Pelcauthor=J.+E.+Dayauthor=D.+C.+Rohrerauthor=J.+R.+Kieferauthor=J.+B.+Moonauthor=B.+A.+Schweitzerauthor=T.+D.+Blakeauthor=S.+R.+Turnerauthor=R.+Woerndleauthor=B.+L.+Caseauthor=C.+P.+Bonoauthor=V.+M.+Dilworthauthor=C.+L.+Funckes-Shippyauthor=B.+L.+Hoodauthor=G.+M.+Jeromeauthor=C.+M.+Kornmeierauthor=M.+R.+Radabaughauthor=M.+L.+Williamsauthor=M.+S.+Daviesauthor=C.+D.+Wegnerauthor=D.+J.+Welschauthor=W.+M.+Abrahamauthor=C.+J.+Warrenauthor=M.+E.+Dowtyauthor=F.+Huaauthor=A.+Zutshiauthor=J.+Z.+Yangauthor=A.+Thorarensen&title=Discovery+of+an+oral+potent+selective+inhibitor+of+hematopoietic+prostaglandin+D+synthase+%28HPGDS%29&doi=10.1021%2Fml900025z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml900025z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900025z%26sid%3Dliteratum%253Aachs%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DHamper%26aufirst%3DB.%2BC.%26aulast%3DDice%26aufirst%3DT.%26aulast%3DNeal%26aufirst%3DB.%2BE.%26aulast%3DPelc%26aufirst%3DM.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DRohrer%26aufirst%3DD.%2BC.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DMoon%26aufirst%3DJ.%2BB.%26aulast%3DSchweitzer%26aufirst%3DB.%2BA.%26aulast%3DBlake%26aufirst%3DT.%2BD.%26aulast%3DTurner%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DBono%26aufirst%3DC.%2BP.%26aulast%3DDilworth%26aufirst%3DV.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DB.%2BL.%26aulast%3DJerome%26aufirst%3DG.%2BM.%26aulast%3DKornmeier%26aufirst%3DC.%2BM.%26aulast%3DRadabaugh%26aufirst%3DM.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DM.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DWelsch%26aufirst%3DD.%2BJ.%26aulast%3DAbraham%26aufirst%3DW.%2BM.%26aulast%3DWarren%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHua%26aufirst%3DF.%26aulast%3DZutshi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%2BZ.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520an%2520oral%2520potent%2520selective%2520inhibitor%2520of%2520hematopoietic%2520prostaglandin%2520D%2520synthase%2520%2528HPGDS%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D59%26epage%3D63%26doi%3D10.1021%2Fml900025z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Casimiro-Garcia%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">Compound <b>11</b> is commercially available via Sigma Aldrich (catalog no. PZ0316).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Hett, E.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hett%2C+E.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHett%26aufirst%3DE." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lgDNCRv5CHQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Wilcox, G. E.; Koecher, C.; Vries, T.; Flanagan, M. E.; Munchof, M. J.</span><span> </span><span class="NLM_article-title">Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3-d]pyrimidines as protein kinase inhibitors</span>. PCT Int. Appl. WO2002096909,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=G.+E.+Wilcox&author=C.+Koecher&author=T.+Vries&author=M.+E.+Flanagan&author=M.+J.+Munchof&title=Optical+resolution+of+%281-benzyl-4-methylpiperidin-3-yl%29-methylamine+and+the+use+thereof+for+the+preparation+of+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DG.%2BE.%26atitle%3DOptical%2520resolution%2520of%2520%25281-benzyl-4-methylpiperidin-3-yl%2529-methylamine%2520and%2520the%2520use%2520thereof%2520for%2520the%2520preparation%2520of%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cox, P. J.; Majaid, T. N.; Amendola, S.; Deprets, S. D.; Edlin, C.; Pedgrift, B. L.; Halley, F.; Edwards, M.; Baudoin, B.; McIay, L. M.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidines as protein kinase inhibitors</span>. PCT Int. Appl. WO 2003000695,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=P.+J.+Cox&author=T.+N.+Majaid&author=S.+Amendola&author=S.+D.+Deprets&author=C.+Edlin&author=B.+L.+Pedgrift&author=F.+Halley&author=M.+Edwards&author=B.+Baudoin&author=L.+M.+McIay&title=Preparation+of+pyrrolopyrimidines+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DP.%2BJ.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidines%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Patil, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonde, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kekan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span> </span><span class="NLM_article-title">An improved and efficient process for the preparation of tofacitinib citrate</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="refDoi"> DOI: 10.1021/op500274j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500274j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1714&author=Y.+S.+Patilauthor=N.+L.+Bondeauthor=A.+S.+Kekanauthor=D.+G.+Satheauthor=A.+Das&title=An+improved+and+efficient+process+for+the+preparation+of+tofacitinib+citrate&doi=10.1021%2Fop500274j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fop500274j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500274j%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%2BS.%26aulast%3DBonde%26aufirst%3DN.%2BL.%26aulast%3DKekan%26aufirst%3DA.%2BS.%26aulast%3DSathe%26aufirst%3DD.%2BG.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DAn%2520improved%2520and%2520efficient%2520process%2520for%2520the%2520preparation%2520of%2520tofacitinib%2520citrate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1714%26doi%3D10.1021%2Fop500274j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span>Purchased from Alfa-Aesar (CAS no. 188111-79-7, catalog no. H26937).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Purchased+from+Alfa-Aesar+%28CAS+no.+188111-79-7%2C+catalog+no.+H26937%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Suzuki, A. J.</span><span> </span><span class="NLM_article-title">Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995–1998</span> <span class="citation_source-journal">J. Organomet. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">576</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="refDoi"> DOI: 10.1016/S0022-328X(98)01055-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0022-328X%2898%2901055-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK1MXivFOlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=576&publication_year=1999&pages=147&author=A.+J.+Suzuki&title=Recent+advances+in+the+cross-coupling+reactions+of+organoboron+derivatives+with+organic+electrophiles%2C+1995%E2%80%931998&doi=10.1016%2FS0022-328X%2898%2901055-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995-1998</span></div><div class="casAuthors">Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">576</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">147-168</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science S.A.</span>)
        </div><div class="casAbstract">The Pd-catalyzed cross-coupling reaction between organoboron compds. and org. halides or triflates provides a powerful and general methodol. for the formation of C-C bonds.  Recently, this reaction was called the Suzuki coupling, Suzuki reaction, or Suzuki-Miyaura coupling, although the authors never referred to it as such previously.  In this review, this name will be used with hesitation, simply to express the coupling reaction.  The availability of the reagents and the mild reaction conditions all contribute to the versatility of this reaction.  The coupling reaction offers several addnl. advantages, such as being largely unaffected by the presence of H2O, tolerating a broad range of functional groups, and proceeding generally regio- and stereoselectively.  Also, the inorg. byproduct of the reaction is nontoxic and easily removed from the reaction mixt. thereby making the Suzuki coupling suitable not only for labs. but also for industrial processes.  The authors published previously a comprehensive review of the reaction which covered mainly the refs. until the end of 1994.  Thereafter, a large no. of papers related to the coupling reaction are reported.  Consequently, such new results presented from 1995 to May 1998 are summarized in this review, with 139 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCbrdm1cvkLVg90H21EOLACvtfcHk0lgDNCRv5CHQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFOlsr0%253D&md5=be2fdd114211afa4abdf106008dd9845</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0022-328X%2898%2901055-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-328X%252898%252901055-9%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520cross-coupling%2520reactions%2520of%2520organoboron%2520derivatives%2520with%2520organic%2520electrophiles%252C%25201995%25E2%2580%25931998%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D1999%26volume%3D576%26spage%3D147%26doi%3D10.1016%2FS0022-328X%2898%2901055-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Johnson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blom, T.</span><span> </span><span class="NLM_article-title">Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1016/j.ab.2008.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2Fj.ab.2008.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=19154726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFKjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=20-29&author=K.+A.+Johnsonauthor=Z.+B.+Simpsonauthor=T.+Blom&title=Global+Kinetic+Explorer%3A+A+new+computer+program+for+dynamic+simulation+and+fitting+of+kinetic+data&doi=10.1016%2Fj.ab.2008.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data</span></div><div class="casAuthors">Johnson, Kenneth A.; Simpson, Zachary B.; Blom, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe a new dynamic kinetic simulation program that allows multiple data sets to be fit simultaneously to a single model based on numerical integration of the rate equations describing the reaction mechanism.  Unlike other programs that allow fitting based on numerical integration of rate equations, in the dynamic simulation rate consts., output factors, and starting concns. of reactants can be scrolled while observing the change in the shape of the simulated reaction curves.  Fast dynamic simulation facilitates the exploration of initial parameters that serve as the starting point for nonlinear regression in fitting data and facilitates exploration of the relationships between individual consts. and observable reactions.  The exploration of parameter space by dynamic simulation provides a powerful tool for learning kinetics and for evaluating the extent to which parameters are constrained by the data.  This feature is crit. to avoid overly complex models that are not supported by the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFFZnhMRb-rVg90H21EOLACvtfcHk0lje352jLk7mXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFKjt7c%253D&md5=1d0227c91a334f47edae70f5a89478ff</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2008.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2008.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DSimpson%26aufirst%3DZ.%2BB.%26aulast%3DBlom%26aufirst%3DT.%26atitle%3DGlobal%2520Kinetic%2520Explorer%253A%2520A%2520new%2520computer%2520program%2520for%2520dynamic%2520simulation%2520and%2520fitting%2520of%2520kinetic%2520data%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D387%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.ab.2008.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Johnson, K.</span><span> </span><span class="NLM_article-title">A Fitting enzyme kinetic data with KinTek Global Kinetic Explorer</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1016/S0076-6879(09)67023-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0076-6879%2809%2967023-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=601-626&author=K.+Johnson&title=A+Fitting+enzyme+kinetic+data+with+KinTek+Global+Kinetic+Explorer&doi=10.1016%2FS0076-6879%2809%2967023-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2809%2967023-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252809%252967023-3%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%26atitle%3DA%2520Fitting%2520enzyme%2520kinetic%2520data%2520with%2520KinTek%2520Global%2520Kinetic%2520Explorer%26jtitle%3DMethods%2520Enzymol.%26date%3D2009%26volume%3D467%26spage%3D601%26epage%3D626%26doi%3D10.1016%2FS0076-6879%2809%2967023-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Thompson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubbon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankshun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0960-894X%2802%2900106-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1219-1223&author=J.+E.+Thompsonauthor=R.+M.+Cubbonauthor=R.+T.+Cummingsauthor=L.+S.+Wickerauthor=R.+Frankshunauthor=B.+R.+Cunninghamauthor=P.+M.+Cameronauthor=P.+T.+Meinkeauthor=N.+Livertonauthor=Y.+Wengauthor=J.+A.+DeMartino&title=Photochemical+preparation+of+a+pyridone+containing+tetracycle%3A+A+Jak+protein+kinase+inhibitor&doi=10.1016%2FS0960-894X%2802%2900106-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900106-3%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26aulast%3DCubbon%26aufirst%3DR.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DFrankshun%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DPhotochemical%2520preparation%2520of%2520a%2520pyridone%2520containing%2520tetracycle%253A%2520A%2520Jak%2520protein%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1219%26epage%3D1223%26doi%3D10.1016%2FS0960-894X%2802%2900106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lje352jLk7mXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissinel, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments. Acta Crystallographica Section D</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&issue=4&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments.+Acta+Crystallographica+Section+D&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments.%2520Acta%2520Crystallographica%2520Section%2520D%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the aximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&issue=3&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+aximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520aximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26issue%3D3%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Smart, O. S.; Vonrhein, C.; Womack, T. O.</span>BUSTER, version <span class="NLM_edition">2.8.0</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&issue=4&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0ljRFQE69lh-DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D4%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTS','PDB','5TTS'); return false;">PDB: 5TTS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTV','PDB','5TTV'); return false;">PDB: 5TTV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TTU','PDB','5TTU'); return false;">PDB: 5TTU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i96"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01694">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46824"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01694">10.1021/acs.jmedchem.6b01694</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_001.csv">CSV</a>)</p></li><li><p class="inline">Single molecule X-ray crystallography data for <b>38b</b> and kinetics of covalent modification of on-target and off-target kinases by <b>11</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_001.csv">jm6b01694_si_001.csv (1.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01694/suppl_file/jm6b01694_si_002.pdf">jm6b01694_si_002.pdf (968.86 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01694&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01694%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01694" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799682848123291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
